

Targeting the phosphoinositide 3-kinase pathway in cancer

Nature Reviews Drug Discovery

8, 627-644

DOI: [10.1038/nrd2926](https://doi.org/10.1038/nrd2926)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tumor Suppression by PTEN Requires the Activation of the PKR-eIF2 $\hat{\pm}$ Phosphorylation Pathway. <i>Science Signaling</i> , 2009, 2, ra85.	1.6	72
2	Resistance to Trastuzumab in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7479-7491.	3.2	397
3	Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 305-316.	2.7	148
4	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6830-6835.	1.0	43
5	mTOR mediated anti-cancer drug discovery. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2009, 6, 47-55.	0.5	146
6	Cellular and Molecular Pathology of Adrenocortical Carcinoma. , 2009, , 127-150.		0
7	S-Adenosylhomocysteine Promotes the Invasion of C6 Glioma Cells via Increased Secretion of Matrix Metalloproteinase-2 in Murine Microglial BV2 Cells. <i>Toxicological Sciences</i> , 2009, 112, 322-330.	1.4	15
8	Novel Agents in the Treatment of Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 273-282.	1.0	6
9	TOR Signaling and Cell Death. <i>The Enzymes</i> , 2010, 28, 217-244.	0.7	2
10	Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. <i>Blood</i> , 2010, 115, 2127-2135.	0.6	84
11	Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 2486-2493.	0.7	60
12	Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1375-1378.	0.6	4
13	Chronotherapy and the molecular clock: Clinical implications in oncology $\hat{\text{t}}$. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 979-1001.	6.6	139
14	Cherry silver berry (<i>Elaeagnus multiflora</i>) extracts exert antiinflammatory effects by inhibiting COX-2 and Akt signals in HT-29 colon cancer cells. <i>Food Science and Biotechnology</i> , 2010, 19, 1673-1677.	1.2	16
15	Management Strategies for Patients with KRAS Mutations. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 199-205.	1.0	0
16	Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer. <i>Current Oncology Reports</i> , 2010, 12, 87-94.	1.8	54
17	Phosphatidylinositol-3-Kinase-AKT Pathway, Phospho-JUN and Phospho-JNK Expression in Spontaneously Arising Bovine Urinary Bladder Tumours. <i>Journal of Comparative Pathology</i> , 2010, 143, 173-178.	0.1	16
18	Glutamine addiction: a new therapeutic target in cancer. <i>Trends in Biochemical Sciences</i> , 2010, 35, 427-433.	3.7	1,422

#	ARTICLE	IF	CITATIONS
19	Angiogenesis Inhibitors: Current Strategies and Future Prospects. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 222-243.	157.7	413
20	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 991-1002.	1.9	106
21	Emerging roles of PDGF-D signaling pathway in tumor development and progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 122-130.	3.3	99
22	BRAF as therapeutic target in melanoma. <i>Biochemical Pharmacology</i> , 2010, 80, 561-567.	2.0	151
23	Modulation of cell sensitivity to antitumor agents by targeting survival pathways. <i>Biochemical Pharmacology</i> , 2010, 80, 1459-1465.	2.0	17
24	Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. <i>Experimental Cell Research</i> , 2010, 316, 3197-3206.	1.2	35
25	Assaying multiple biochemical variables from the same tissue sample. <i>Journal of Neuroscience Methods</i> , 2010, 191, 234-238.	1.3	11
26	Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase- $\hat{\pm}$: Hit to lead studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 636-639.	1.0	35
27	Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 653-656.	1.0	28
28	Dissecting the role of mTOR: Lessons from mTOR inhibitors. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010, 1804, 433-439.	1.1	389
29	Novel benzofuran-3-one indole inhibitors of PI3 kinase- $\hat{\pm}$ and the mammalian target of rapamycin: Hit to lead studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2586-2590.	1.0	27
30	5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3 kinase- $\hat{\pm}$ and mTOR for the treatment of breast cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3526-3529.	1.0	27
31	Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6895-6898.	1.0	23
32	The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells. <i>Phytotherapy Research</i> , 2010, 24, 1317-1321.	2.8	25
33	The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. <i>Journal of Pathology</i> , 2010, 220, 263-280.	2.1	369
34	Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1329-1337.	0.8	43
35	CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy. <i>Cancer Science</i> , 2010, 101, 2644-2651.	1.7	15
36	Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. <i>Oncogene</i> , 2010, 29, 3733-3744.	2.6	283

#	ARTICLE	IF	CITATIONS
37	Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. <i>Oncogene</i> , 2010, 29, 4493-4503.	2.6	76
38	A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. <i>British Journal of Cancer</i> , 2010, 102, 104-114.	2.9	54
39	The IL-23/IL-17 axis may be important in obesity-associated cancer by way of the activation of multiple signal pathways. <i>International Journal of Obesity</i> , 2010, 34, 1227-1228.	1.6	9
40	Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. <i>Laboratory Investigation</i> , 2010, 90, 1406-1414.	1.7	136
41	Revealing the delta lady. <i>Nature Chemical Biology</i> , 2010, 6, 82-83.	3.9	10
42	Phosphoinositide signalling in cancer: beyond PI3K and PTEN. <i>Nature Reviews Cancer</i> , 2010, 10, 342-352.	12.8	369
44	The nuts and bolts of AGC protein kinases. <i>Nature Reviews Molecular Cell Biology</i> , 2010, 11, 9-22.	16.1	1,137
45	Rene policistico autosomico dominante: nuovi aspetti terapeutici. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2010, 22, 59-64.	0.1	0
46	microRNA Expression Patterns Reveal Differential Expression of Target Genes with Age. <i>PLoS ONE</i> , 2010, 5, e10724.	1.1	304
47	Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition. <i>PLoS ONE</i> , 2010, 5, e12913.	1.1	247
48	Prospects for the Use of ATR Inhibitors to Treat Cancer. <i>Pharmaceuticals</i> , 2010, 3, 1311-1334.	1.7	50
49	Identification of Common Predictive Markers of <i>in vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1985-1994.	1.9	59
50	Interactome Mapping of the Phosphatidylinositol 3-Kinase-Mammalian Target of Rapamycin Pathway Identifies Deformed Epidermal Autoregulatory Factor-1 as a New Glycogen Synthase Kinase-3 Interactor. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1578-1593.	2.5	51
51	Novel targets for prostate cancer chemoprevention. <i>Endocrine-Related Cancer</i> , 2010, 17, R195-R212.	1.6	42
52	New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways. <i>Clinical Cancer Research</i> , 2010, 16, 3811-3818.	3.2	41
53	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5424-5435.	3.2	146
54	Taking PI3K β and PI3K δ One Step Ahead: Dual Active PI3K β/δ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 279-299.	0.7	24
55	mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling. <i>Molecular and Cellular Biology</i> , 2010, 30, 908-921.	1.1	365

#	ARTICLE	IF	CITATIONS
56	Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPK β 1. <i>Carcinogenesis</i> , 2010, 31, 1092-1099.	1.3	52
57	Mammalian Target of Rapamycin β -Dependent Acinar Cell Neoplasia after Inactivation of <i>Apc</i> and <i>Pten</i> in the Mouse Salivary Gland: Implications for Human Acinic Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 9143-9152.	0.4	44
58	Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis. <i>Endocrine-Related Cancer</i> , 2010, 17, R287-R304.	1.6	62
59	Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. <i>Cancer Research</i> , 2010, 70, 2146-2157.	0.4	254
60	Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: <i>In silico</i> and Biological Evaluations. <i>Cancer Research</i> , 2010, 70, 4982-4994.	0.4	108
61	Inhibition of the PI3K Pathway: Hope We Can Believe in?. <i>Clinical Cancer Research</i> , 2010, 16, 3094-3099.	3.2	37
62	Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 976-984.	1.9	60
63	Temsirolimus Has Activity in Non β -Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	0.8	181
64	The Akt isoforms, their unique functions and potential as anticancer therapeutic targets. <i>Biomolecular Concepts</i> , 2010, 1, 389-401.	1.0	10
65	Lipid Signaling in T-Cell Development and Function. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a002428-a002428.	2.3	55
66	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 22231-22236.	3.3	249
67	Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?. <i>Future Oncology</i> , 2010, 6, 619-634.	1.1	52
68	Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer. <i>Thyroid</i> , 2010, 20, 697-706.	2.4	258
69	Distinct Biological Roles for the Akt Family in Mammary Tumor Progression. <i>Cancer Research</i> , 2010, 70, 4260-4264.	0.4	138
70	The molecular pathogenesis of small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 1-10.	1.5	65
71	A biochemical mechanism for the oncogenic potential of the p110 β catalytic subunit of phosphoinositide 3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19897-19902.	3.3	51
72	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20780-20785.	3.3	84
73	Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1436-1442.	1.7	78

#	ARTICLE	IF	CITATIONS
74	Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2592-2597.	3.3	69
75	Integrative platform to translate gene sets to networks. Bioinformatics, 2010, 26, 1802-1803.	1.8	22
76	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. Cancers, 2010, 2, 1576-1596.	1.7	40
77	Inhibition of voltage-gated K ⁺ channels in dendritic cells by rapamycin. American Journal of Physiology - Cell Physiology, 2010, 299, C1379-C1385.	2.1	18
78	Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Therapeutic Advances in Respiratory Disease, 2010, 4, 19-34.	1.0	43
79	Translating Gene Expression Into Clinical Care: Sarcomas As a Paradigm. Journal of Clinical Oncology, 2010, 28, 1796-1805.	0.8	42
80	Rapamycin-induced phosphaturia. Nephrology Dialysis Transplantation, 2010, 25, 2938-2944.	0.4	38
81	PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress. Current Medicinal Chemistry, 2010, 17, 4326-4341.	1.2	89
82	Regulation of Akt signaling activation by ubiquitination. Cell Cycle, 2010, 9, 486-497.	1.3	130
83	Role of the mTOR Pathway in Normal and Tumoral Adrenal Cells. Neuroendocrinology, 2010, 92, 28-34.	1.2	36
84	The Regulation of Class IA PI 3-Kinases by Inter-Subunit Interactions. Current Topics in Microbiology and Immunology, 2010, 346, 87-114.	0.7	73
85	Epidermal Growth Factor Receptor Is an Obligatory Intermediate for Oxytocin-Induced Cyclooxygenase 2 Expression and Prostaglandin F ₂ ± Production in Bovine Endometrial Epithelial Cells. Endocrinology, 2010, 151, 1367-1374.	1.4	13
86	PI3K/AKT/mTOR Inhibitors In Ovarian Cancer. Current Medicinal Chemistry, 2010, 17, 4433-4447.	1.2	41
87	Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 152-156.	0.9	2
88	Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results. Current Cancer Drug Targets, 2010, 10, 737-757.	0.8	10
89	Genetic inactivation of <i>AKT1</i> , <i>AKT2</i> , and <i>PDPK1</i> in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2598-2603.	3.3	113
90	Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leukemia and Lymphoma, 2010, 51, 1968-2005.	0.6	53
91	The Role of Phosphoinositide 3-Kinase in Breast Cancer: An Overview. Clinical Breast Cancer, 2010, 10, S56-S58.	1.1	1

#	ARTICLE	IF	CITATIONS
92	Caught in the Akt: Regulation of Wnt Signaling in the Intestine. <i>Gastroenterology</i> , 2010, 139, 718-722.	0.6	44
93	Recent advances in the discovery of small molecule mTOR inhibitors. <i>Future Medicinal Chemistry</i> , 2010, 2, 1577-1589.	1.1	13
94	Targeting Multiple Kinase Pathways: A Change In Paradigm. <i>Clinical Cancer Research</i> , 2010, 16, 1973-1978.	3.2	99
95	Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. <i>Molecular Aspects of Medicine</i> , 2010, 31, 135-144.	2.7	35
96	Scaffold-based design of kinase inhibitors for cancer therapy. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 79-86.	1.5	16
97	Molecular networks in respiratory epithelium carcinomas. <i>Cancer Letters</i> , 2010, 295, 1-6.	3.2	0
98	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. <i>Cancer Letters</i> , 2010, 298, 195-203.	3.2	20
99	Forkhead box M1 transcription factor: A novel target for cancer therapy. <i>Cancer Treatment Reviews</i> , 2010, 36, 151-156.	3.4	139
100	The long road to colorectal cancer therapy: Searching for the right signals. <i>Drug Resistance Updates</i> , 2010, 13, 44-56.	6.5	25
101	A Pivotal Role for CXCL12 Signaling in HPV-Mediated Transformation of Keratinocytes: Clues to Understanding HPV-Pathogenesis in WHIM Syndrome. <i>Cell Host and Microbe</i> , 2010, 8, 523-533.	5.1	64
102	Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1887-1898.	2.5	59
103	Caloric restriction: From soup to nuts. <i>Ageing Research Reviews</i> , 2010, 9, 324-353.	5.0	139
104	The molecular pathology of cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 251-265.	12.5	224
105	Tirucallic Acids Are Novel Pleckstrin Homology Domain-Dependent Akt Inhibitors Inducing Apoptosis in Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2010, 77, 378-387.	1.0	65
106	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 819-828.	1.7	240
107	Second AKT: The rise of SGK in cancer signalling. <i>Growth Factors</i> , 2010, 28, 394-408.	0.5	127
108	The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 3272-3281.	3.2	90
109	Structure-Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5174-5184.	2.9	40

#	ARTICLE	IF	CITATIONS
110	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. <i>Nature Chemical Biology</i> , 2011, 7, 787-793.	3.9	156
111	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. <i>Nature Medicine</i> , 2011, 17, 1116-1120.	15.2	231
112	Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells. <i>Translational Oncology</i> , 2011, 4, 241-248.	1.7	21
113	AKT Signaling Pathway in the Nucleus Accumbens Mediates Excessive Alcohol Drinking Behaviors. <i>Biological Psychiatry</i> , 2011, 70, 575-582.	0.7	104
114	Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. <i>Xenobiotica</i> , 2011, 41, 1088-1099.	0.5	22
115	Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010). <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 131-146.	2.4	39
116	Synergistic Induction of Apoptosis in Brain Cancer Cells by Targeted Codelivery of siRNA and Anticancer Drugs. <i>Molecular Pharmaceutics</i> , 2011, 8, 1955-1961.	2.3	76
117	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 34-38.	1.3	27
118	Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines. <i>Advances in Medical Sciences</i> , 2011, 56, 275-284.	0.9	82
119	Hepatitis B x-interacting protein induces HepG2 cell proliferation through activation of the phosphatidylinositol 3-kinase/Akt pathway. <i>Experimental Biology and Medicine</i> , 2011, 236, 62-69.	1.1	33
120	Selective PI3K β inhibitors, a review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 1773-1790.	2.4	52
121	Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. <i>Neuroscientist</i> , 2011, 17, 54-78.	2.6	131
122	Rational Design of Phosphoinositide 3-Kinase β Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase δ Isoform. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7815-7833.	2.9	60
123	Targeting Cell Signaling and Apoptotic Pathways by Dietary Agents: Role in the Prevention and Treatment of Cancer. <i>Nutrition and Cancer</i> , 2011, 63, 161-173.	0.9	195
124	Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 266-278.	1.0	6
125	FKBP51 regulation of AKT/protein kinase B phosphorylation. <i>Current Opinion in Pharmacology</i> , 2011, 11, 360-364.	1.7	41
126	Ubiquitin networks in cancer. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 21-28.	1.5	85
127	GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. <i>Cancer Letters</i> , 2011, 309, 27-36.	3.2	37

#	ARTICLE	IF	CITATIONS
128	Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer. <i>Cancer Letters</i> , 2011, 310, 207-215.	3.2	70
129	Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. <i>European Journal of Cancer</i> , 2011, 47, 2654-2664.	1.3	38
130	Ouabain-induced modifications of prostate cancer cell lipidome investigated with mass spectrometry and FTIR spectroscopy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011, 1808, 597-605.	1.4	24
131	Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 194-199.	1.0	144
132	Autophagy as a target for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 528-539.	12.5	709
133	Insulin and the Physiology of Carbohydrate Metabolism. <i>Energy Balance and Cancer</i> , 2011, , 1-52.	0.2	1
134	Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1789-1811.	2.9	103
135	<i>DAXX</i> / <i>ATRX</i> , <i>MEN1</i> , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. <i>Science</i> , 2011, 331, 1199-1203.	6.0	1,504
136	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R21.	2.2	162
137	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	1.1	191
138	Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4735-4751.	2.9	54
139	Molecular Targeted Approaches in Mantle Cell Lymphoma. <i>Seminars in Hematology</i> , 2011, 48, 214-226.	1.8	19
140	Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2011, 185, 2376-2381.	0.2	51
141	Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 101, 165-170.	0.3	24
142	Novel Library of Selenocompounds as Kinase Modulators. <i>Molecules</i> , 2011, 16, 6349-6364.	1.7	17
143	Ablation of Akt2 Induces Autophagy through Cell Cycle Arrest, the Downregulation of p70S6K, and the Dereglulation of Mitochondria in MDA-MB231 Cells. <i>PLoS ONE</i> , 2011, 6, e14614.	1.1	60
144	Identification of a Novel TGF β 2/PKA Signaling Transduceome in Mediating Control of Cell Survival and Metastasis in Colon Cancer. <i>PLoS ONE</i> , 2011, 6, e19335.	1.1	43
145	Temporal Regulation of Rapamycin on Memory CTL Programming by IL-12. <i>PLoS ONE</i> , 2011, 6, e25177.	1.1	17

#	ARTICLE	IF	CITATIONS
146	A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors. PLoS ONE, 2011, 6, e26343.	1.1	50
147	Molecular Predictors of Response to Antiangiogenesis Therapies. Cancer Journal (Sudbury, Mass), 2011, 17, 134-141.	1.0	53
148	The Phosphoinositide-3-Kinase/Akt Signaling Pathway Is Important for Staphylococcus aureus Internalization by Endothelial Cells. Infection and Immunity, 2011, 79, 4569-4577.	1.0	47
149	The Next Step: Innovative Molecular Targeted Therapies for Treatment of Intracranial Chordoma Patients. Neurosurgery, 2011, 68, 231-241.	0.6	26
150	A drug targeting only p110 α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochemical Journal, 2011, 438, 53-62.	1.7	137
151	Multiple signal pathways in obesity-associated cancer. Obesity Reviews, 2011, 12, 1063-1070.	3.1	133
152	Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science, 2011, 102, 1-8.	1.7	102
153	Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. British Journal of Haematology, 2011, 153, 545-556.	1.2	19
154	An anticancer strategic dilemma: to kill or to contain. The choice of the pharmaceutical industry in 2009. Fundamental and Clinical Pharmacology, 2011, 25, 283-295.	1.0	5
155	Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor γ coactivator-1 β expression. British Journal of Pharmacology, 2011, 162, 1000-1008.	2.7	19
156	Neutral not a loss: phosphoinositides beyond the head group. Nature Methods, 2011, 8, 219-220.	9.0	3
157	Parkinson's disease and cancer: two wars, one front. Nature Reviews Cancer, 2011, 11, 813-823.	12.8	146
158	Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nature Reviews Drug Discovery, 2011, 10, 111-126.	21.5	302
159	Blocking phospholipid-protein interactions. Nature Reviews Drug Discovery, 2011, 10, 19-19.	21.5	6
160	PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene, 2011, 30, 494-503.	2.6	90
161	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011, 30, 3222-3233.	2.6	170
162	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene, 2011, 30, 3489-3501.	2.6	91
163	New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology, 2011, 21, 335-346.	4.3	35

#	ARTICLE	IF	CITATIONS
164	Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. , 2011, 130, 310-324.		139
165	Beyond trastuzumab: New treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011, 20, S20-S27.	0.9	53
166	The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. <i>Gynecologic Oncology</i> , 2011, 123, 411-420.	0.6	23
167	Targeting phosphoinositide 3-kinase signalling in lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 278-290.	2.0	33
168	Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl)quinoxalines as PI3K inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5540-5548.	2.6	31
169	Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer. <i>Biochemical Pharmacology</i> , 2011, 82, 1320-1334.	2.0	33
170	Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4773-4778.	1.0	33
171	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 575-586.	7.7	1,026
172	Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. <i>Cellular Signalling</i> , 2011, 23, 201-212.	1.7	95
173	The PI3K-Akt pathway regulates calpain 6 expression, proliferation, and apoptosis. <i>Cellular Signalling</i> , 2011, 23, 827-836.	1.7	26
174	GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2426-2436.	1.9	210
175	The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling. <i>Annual Review of Biochemistry</i> , 2011, 80, 769-795.	5.0	316
176	Histamine H ₃ Receptor as a Drug Discovery Target. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 26-53.	2.9	130
177	Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7105-7126.	2.9	97
178	PI3K Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic. <i>Cancer Discovery</i> , 2011, 1, 562-572.	7.7	126
179	Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 774-779.	1.3	223
180	Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. <i>Investigational New Drugs</i> , 2011, 29, 1303-1313.	1.2	42
181	Systemic administration of antisense oligonucleotides simultaneously targeting CK2 and β subunits reduces orthotopic xenograft prostate tumors in mice. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 21-35.	1.4	40

#	ARTICLE	IF	CITATIONS
182	Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1881-1888.	1.9	21
183	Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. <i>Applied Microbiology and Biotechnology</i> , 2011, 89, 1423-1433.	1.7	71
184	Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. <i>Molecular Cancer</i> , 2011, 10, 138.	7.9	54
185	The secret life of kinases: functions beyond catalysis. <i>Cell Communication and Signaling</i> , 2011, 9, 23.	2.7	154
186	Functional characterization of Trip10 in cancer cell growth and survival. <i>Journal of Biomedical Science</i> , 2011, 18, 12.	2.6	25
187	Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer. <i>Prostate</i> , 2011, 71, 1510-1517.	1.2	14
188	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2011, 226, 822-831.	2.0	59
189	Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. <i>NMR in Biomedicine</i> , 2011, 24, 734-749.	1.6	81
190	Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. <i>International Journal of Cancer</i> , 2011, 129, 1006-1017.	2.3	21
191	Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1767-1772.	1.0	62
192	Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2335-2340.	1.0	11
193	Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4036-4040.	1.0	10
194	16-Hydroxycyclohexa-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis. <i>Toxicology</i> , 2011, 285, 72-80.	2.0	21
195	Small-molecule inhibitors of the PI3K signaling network. <i>Future Medicinal Chemistry</i> , 2011, 3, 549-565.	1.1	96
196	Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6052-6060.	3.2	113
197	Role of Sp Transcription Factors in the Regulation of Cancer Cell Metabolism. <i>Genes and Cancer</i> , 2011, 2, 712-719.	0.6	46
198	Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?. <i>Current Medicinal Chemistry</i> , 2011, 18, 5528-5544.	1.2	51
199	Rethinking Pediatric Gliomas as Developmental Brain Abnormalities. <i>Current Topics in Developmental Biology</i> , 2011, 94, 283-308.	1.0	5

#	ARTICLE	IF	CITATIONS
200	Faulty Epithelial Polarity Genes and Cancer. <i>Advances in Cancer Research</i> , 2011, 111, 97-161.	1.9	18
201	Akt Determines Cell Fate Through Inhibition of the PERK-eIF2 γ Phosphorylation Pathway. <i>Science Signaling</i> , 2011, 4, ra62.	1.6	102
202	The Phosphoinositide 3-Kinase Signaling Pathway as a Therapeutic Target in Grade IV Brain Tumors. <i>Current Cancer Drug Targets</i> , 2011, 11, 894-918.	0.8	30
203	Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. <i>Proceedings of SPIE</i> , 2011, , .	0.8	0
204	ATP-Competitive Inhibitors of mTOR: An Update. <i>Current Medicinal Chemistry</i> , 2011, 18, 2995-3014.	1.2	122
205	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1535-1546.	1.5	7
206	EGFR Mutant Lung Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2011, 355, 59-81.	0.7	8
207	Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor. <i>Clinical Cancer Research</i> , 2011, 17, 3193-3203.	3.2	146
208	<i>In Vivo</i> Activity of Combined PI3K/mTOR and MEK Inhibition in a <i>Kras</i> G12D; <i>Pten</i> Deletion Mouse Model of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1440-1449.	1.9	70
209	Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. <i>Human Molecular Genetics</i> , 2011, 20, 1324-1338.	1.4	52
210	A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells. <i>Clinical Cancer Research</i> , 2011, 17, 3686-3696.	3.2	73
211	Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates. <i>Cancer Research</i> , 2011, 71, 4573-4584.	0.4	68
212	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 155-161.	1.3	270
213	Serine/threonine protein kinase SGK1 in glucocorticoid-dependent transdifferentiation of pancreatic acinar cells to hepatocytes. <i>Journal of Cell Science</i> , 2011, 124, 405-413.	1.2	14
214	Herpes Simplex Virus Requires VP11/12 To Activate Src Family Kinase-Phosphoinositide 3-Kinase-Akt Signaling. <i>Journal of Virology</i> , 2011, 85, 2803-2812.	1.5	43
215	Aberrant AKT activation drives well-differentiated liposarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16386-16391.	3.3	50
216	Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1752-1762.	0.4	56
217	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <i>EGFR</i> Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2260-2269.	3.2	101

#	ARTICLE	IF	CITATIONS
218	Emergence of the Phosphoinositide 3-Kinase-Akt- Mammalian Target of Rapamycin Axis in Transforming Growth Factor- β -Induced Epithelial-Mesenchymal Transition. <i>Cells Tissues Organs</i> , 2011, 193, 8-22.	1.3	85
219	Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells. <i>Urologia Internationalis</i> , 2011, 87, 105-113.	0.6	16
220	Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells. <i>Urologia Internationalis</i> , 2011, 86, 346-354.	0.6	11
221	Epithelial cell extrusion requires the sphingosine-1-phosphate receptor 2 pathway. <i>Journal of Cell Biology</i> , 2011, 193, 667-676.	2.3	140
222	p73 as a Pharmaceutical Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 578-590.	0.9	33
223	How moderate changes in Akt T-loop phosphorylation impact on tumorigenesis and insulin resistance. <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 95-103.	1.2	14
224	Phosphoinositide-3-Kinase Inhibition Enhances Radiosensitization of Cervical Cancer In Vivo. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 100-105.	1.2	24
225	Critical role of PI3K signaling for NF- κ B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 272-277.	3.3	127
226	Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3342-3347.	3.3	175
227	Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 3233-3247.	3.2	56
228	Epithelial Phosphatidylinositol-3-Kinase Signaling Is Required for β -Catenin Activation and Host Defense against <i>Citrobacter rodentium</i> Infection. <i>Infection and Immunity</i> , 2011, 79, 1863-1872.	1.0	41
229	Frontier of Epilepsy Research - mTOR signaling pathway. <i>Experimental and Molecular Medicine</i> , 2011, 43, 231.	3.2	74
230	EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 63-74.	1.5	134
231	Glomerular endothelial PI3 kinase couples to VEGFR2, but is not required for eNOS activation. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F1242-F1250.	1.3	8
232	Phosphatidylinositide-3-Kinase Inhibitors: Addressing Questions of Isoform Selectivity and Pharmacodynamic/Predictive Biomarkers in Early Clinical Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 331-333.	0.8	37
233	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 109.	1.3	72
234	Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKC Invasive Signaling Axis. <i>Science Signaling</i> , 2012, 5, ra66.	1.6	69
235	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. <i>Cancer Research</i> , 2012, 72, 210-219.	0.4	228

#	ARTICLE	IF	CITATIONS
236	Akt and mTOR in B Cell Activation and Differentiation. <i>Frontiers in Immunology</i> , 2012, 3, 228.	2.2	165
237	Molecular Mechanism of Arenavirus Assembly and Budding. <i>Viruses</i> , 2012, 4, 2049-2079.	1.5	36
238	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. <i>OncoTargets and Therapy</i> , 2012, 5, 409.	1.0	14
239	Roles of Cell Signaling Pathways in Cell-to-Cell Contact-Mediated Epstein-Barr Virus Transmission. <i>Journal of Virology</i> , 2012, 86, 9285-9296.	1.5	29
240	Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1315-1326.	0.5	175
241	Targeting eNOS in Pancreatic Cancer. <i>Cancer Research</i> , 2012, 72, 4472-4482.	0.4	54
242	Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism <i>in vivo</i> . <i>Biochemical Journal</i> , 2012, 442, 161-169.	1.7	42
243	Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 873-887.	1.9	348
244	A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4173-4182.	3.2	153
245	An Introduction to Phosphoinositides. <i>Current Topics in Microbiology and Immunology</i> , 2012, 362, 1-42.	0.7	17
246	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , 2012, 9, 065004.	0.8	8
247	The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. <i>Endocrine-Related Cancer</i> , 2012, 19, 351-364.	1.6	46
248	Signal Transduction Pathways of the Epidermal Growth Factor Receptor in Colorectal Cancer and their Inhibition by Small Molecules. <i>Current Medicinal Chemistry</i> , 2012, 19, 5735-5744.	1.2	49
249	NVP-BE2235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1597-1606.	1.9	14
250	Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110 β as a Potential Anticancer Agent. <i>Cancer Discovery</i> , 2012, 2, 425-433.	7.7	152
251	Dual PI3K/mTOR inhibitor NVP-BE2235 suppresses hypoxia-inducible factor (HIF)-1 α expression by blocking protein translation and increases cell death under hypoxia. <i>Cancer Biology and Therapy</i> , 2012, 13, 1102-1111.	1.5	33
252	p85 β increases phosphoinositide 3-kinase activity and accelerates tumor progression.	1.3	2
253	A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle. <i>Biochemical Journal</i> , 2012, 447, 137-147.	1.7	47

#	ARTICLE	IF	CITATIONS
254	Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e41.	2.3	24
255	The IgA1 immune complexâ€‘mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. <i>Kidney International</i> , 2012, 82, 1284-1296.	2.6	75
256	Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 453-466.	2.5	62
257	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. <i>Journal of Biological Chemistry</i> , 2012, 287, 9742-9752.	1.6	89
258	Threonine-120 Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like Kinase 1. <i>Journal of Biological Chemistry</i> , 2012, 287, 23698-23709.	1.6	51
259	The PI3K/Akt Pathway Contributes to Arenavirus Budding. <i>Journal of Virology</i> , 2012, 86, 4578-4585.	1.5	53
260	Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. <i>Carcinogenesis</i> , 2012, 33, 1814-1821.	1.3	17
261	Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. <i>Autophagy</i> , 2012, 8, 200-212.	4.3	340
262	Rapamycin Sensitive ROS Formation and Na ⁺ /H ⁺ Exchanger Activity in Dendritic Cells. <i>Cellular Physiology and Biochemistry</i> , 2012, 29, 543-550.	1.1	24
263	PI3Ksâ€‘Drug Targets in Inflammation and Cancer. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 111-181.	1.0	9
264	Targeting the PI3K Pathway in the Brainâ€‘Efficacy of a PI3K Inhibitor Optimized to Cross the Bloodâ€‘Brain Barrier. <i>Clinical Cancer Research</i> , 2012, 18, 6239-6248.	3.2	59
265	Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome. <i>Cancers</i> , 2012, 4, 1180-1211.	1.7	270
266	NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. <i>Journal of Signal Transduction</i> , 2012, 2012, 1-14.	2.0	28
267	Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2012, 2012, 1-6.	0.4	24
268	New Challenges for Cancer Systems Biomedicine. <i>SIMA Springer Series</i> , 2012, , .	0.4	8
269	p85 ^{Î²} phosphoinositide 3-kinase subunit regulates tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11318-11323.	3.3	56
270	The p110 ^{Î±} and p110 ^{Î²} isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. <i>Genes and Development</i> , 2012, 26, 1573-1586.	2.7	116
271	New Therapeutic Targets in Soft Tissue Sarcoma. <i>Advances in Anatomic Pathology</i> , 2012, 19, 170-180.	2.4	45

#	ARTICLE	IF	CITATIONS
272	TP-58, a Novel Thienopyridine Derivative, Protects Mice from ConcanavalinA-Induced Hepatitis by Suppressing Inflammation. Cellular Physiology and Biochemistry, 2012, 29, 31-40.	1.1	12
273	Anti-Tumor Effect of AlkB Homolog 3 Knockdown in Hormone- Independent Prostate Cancer Cells. Current Cancer Drug Targets, 2012, 12, 847-856.	0.8	37
274	TGF- β 1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis. Current Pharmaceutical Design, 2012, 18, 3874-3888.	0.9	30
275	Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin Pathway in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, S379-S382.	0.5	4
276	Phosphoinositide 3-kinase β 2 regulates chromosome segregation in mitosis. Molecular Biology of the Cell, 2012, 23, 4526-4542.	0.9	19
277	Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell Cycle, 2012, 11, 3997-4008.	1.3	34
278	PI3K keeps the balance between metabolism and cancer. Advances in Biological Regulation, 2012, 52, 389-405.	1.4	37
279	PTEN: An Intercellular Peacekeeper?. Science Signaling, 2012, 5, pe50.	1.6	11
280	Antithrombotic phosphoinositide 3-kinase β 2 inhibitors in humans: a "shear" delight!. Journal of Thrombosis and Haemostasis, 2012, 10, 2123-2126.	1.9	24
281	Natural products as kinase inhibitors. Natural Product Reports, 2012, 29, 392.	5.2	47
282	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Annals of Oncology, 2012, 23, 2399-2408.	0.6	125
283	Revisiting CB1 Receptor as Drug Target in Human Melanoma. Pathology and Oncology Research, 2012, 18, 857-866.	0.9	21
284	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death and Disease, 2012, 3, e440-e440.	2.7	10
285	Binding Selectivity Studies of Phosphoinositide 3-Kinases Using Free Energy Calculations. Journal of Chemical Information and Modeling, 2012, 52, 3213-3224.	2.5	28
286	AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Clinical Cancer Research, 2012, 18, 3912-3923.	3.2	86
287	Oncogenes in Cell Survival and Cell Death. Cold Spring Harbor Perspectives in Biology, 2012, 4, a009829-a009829.	2.3	99
288	Initiating breast cancer by PIK3CA mutation. Breast Cancer Research, 2012, 14, 301.	2.2	18
289	Anti-cancer potential of selenium- and tellurium-containing species: opportunities abound!. Applied Organometallic Chemistry, 2012, 26, 655-662.	1.7	54

#	ARTICLE	IF	CITATIONS
290	Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose- and 3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer. <i>Molecular Imaging and Biology</i> , 2012, 14, 753-761.	1.3	23
291	Redox control of cytosolic Akt phosphorylation in PTEN null cells. <i>Free Radical Biology and Medicine</i> , 2012, 53, 1697-1707.	1.3	16
292	Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies. <i>Pharmacological Reviews</i> , 2012, 64, 1027-1054.	7.1	107
293	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 319-337.	1.4	24
294	Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7796-7816.	2.9	42
295	Activation of PI3K Signaling in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 1227-1236.	3.2	97
296	Evaluation of WO2012032067 and WO2012055846: two selective PI3K inhibitors, which is GSK-2269557?. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 965-970.	2.4	2
297	Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. <i>British Journal of Cancer</i> , 2012, 107, 1093-1099.	2.9	116
298	Autophagy and polyglutamine diseases. <i>Progress in Neurobiology</i> , 2012, 97, 67-82.	2.8	74
299	Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. <i>Leukemia</i> , 2012, 26, 1761-1770.	3.3	20
300	Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2625-2631.	3.2	184
301	Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16190-16195.	3.3	21
302	Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1261-1273.	2.9	48
303	Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1785-1796.	1.7	36
304	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	21.5	591
305	Î2-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. <i>Nature Medicine</i> , 2012, 18, 892-901.	15.2	336
306	Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. <i>Advances in Biological Regulation</i> , 2012, 52, 205-213.	1.4	30
307	Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms. <i>FEBS Letters</i> , 2012, 586, 2662-2673.	1.3	115

#	ARTICLE	IF	CITATIONS
308	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4613-4618.	1.0	24
309	Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5714-5720.	1.0	24
310	The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. <i>Cell</i> , 2012, 149, 1098-1111.	13.5	332
311	From drug discovery to biomarker-driven clinical trials in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 643-653.	12.5	25
312	Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. <i>BMC Biochemistry</i> , 2012, 13, 30.	4.4	9
313	Dichotomy effects of Akt signaling in breast cancer. <i>Molecular Cancer</i> , 2012, 11, 61.	7.9	6
314	Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. <i>Journal of Inflammation</i> , 2012, 9, 23.	1.5	75
315	Enhancing the effectiveness of virtual screening by using the ChemBioServer: Application to the discovery of PI3K inhibitors. , 2012, , .		2
316	Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling. <i>Clinical Cancer Research</i> , 2012, 18, 4104-4113.	3.2	193
317	Obesity and cancer risk: evidence, mechanisms, and recommendations. <i>Annals of the New York Academy of Sciences</i> , 2012, 1271, 37-43.	1.8	468
318	Multiple roles for the p85 β isoform in the regulation and function of PI3K signalling and receptor trafficking. <i>Biochemical Journal</i> , 2012, 441, 23-37.	1.7	83
319	The Design and Identification of Brain Penetrant Inhibitors of Phosphoinositide 3-Kinase β . <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8007-8020.	2.9	47
320	Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3K β Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4788-4805.	2.9	50
321	Chemokine receptors in the pathogenesis and therapy of psoriasis. <i>Journal of Dermatological Science</i> , 2012, 65, 4-11.	1.0	81
322	N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3K β). <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 7175-7183.	1.4	25
323	A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer. <i>Cancer Letters</i> , 2012, 324, 210-220.	3.2	21
324	Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 243-251.	2.0	51
325	Pathophysiology of chemokines and chemokine receptors in dermatological science: A focus on psoriasis and cutaneous T-cell lymphoma. <i>Dermatologica Sinica</i> , 2012, 30, 128-135.	0.2	17

#	ARTICLE	IF	CITATIONS
326	Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. <i>European Journal of Cancer</i> , 2012, 48, 3319-3327.	1.3	115
327	Visceral obesity, metabolic syndrome, insulin resistance and cancer. <i>Proceedings of the Nutrition Society</i> , 2012, 71, 181-189.	0.4	214
328	Testing the Promiscuity of Commercial Kinase Inhibitors Against the AGC Kinase Group Using a Split-luciferase Screen. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1526-1537.	2.9	35
329	Profiling mTOR pathway in neuroendocrine tumors. <i>Targeted Oncology</i> , 2012, 7, 183-188.	1.7	33
330	The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses. <i>Neoplasia</i> , 2012, 14, 34-IN8.	2.3	157
331	Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. <i>Experimental Hematology and Oncology</i> , 2012, 1, 5.	2.0	21
332	EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2012, 32, 834-838.	1.0	26
333	A signal transduction score flow algorithm for cyclic cellular pathway analysis, which combines transcriptome and ChIP-seq data. <i>Molecular BioSystems</i> , 2012, 8, 3224.	2.9	11
334	The Akt-associated microRNAs. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3601-3612.	2.4	58
335	Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e31255.	1.1	74
336	The Natural Anticancer Agent Plumbagin Induces Potent Cytotoxicity in MCF-7 Human Breast Cancer Cells by Inhibiting a PI-5 Kinase for ROS Generation. <i>PLoS ONE</i> , 2012, 7, e45023.	1.1	63
337	Plasma Membrane Phosphatidylinositol 4,5 Bisphosphate Is Required for Internalization of Foot-and-Mouth Disease Virus and Vesicular Stomatitis Virus. <i>PLoS ONE</i> , 2012, 7, e45172.	1.1	9
338	Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 851-855.	0.7	33
339	Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart. <i>Frontiers in Pharmacology</i> , 2012, 3, 113.	1.6	21
340	Synergistic effect of a combination of nanoparticulate Fe ₃ O ₄ and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 4109.	3.3	19
341	Cell Death and Cancer, Novel Therapeutic Strategies. , 0, , .		8
342	Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2012, 2012, 1-12.	0.6	29
343	Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. <i>World Journal of Virology</i> , 2012, 1, 154.	1.3	66

#	ARTICLE	IF	CITATIONS
344	Molecular biomarkers of glioblastoma: current targets and clinical implications. <i>Current Biomarker Findings</i> , 0, , 63.	0.4	4
345	Maximizing Human Epidermal Growth Factor Receptor 2 Inhibition: A New Oncologic Paradigm in the Era of Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1712-1714.	0.8	23
346	Targeting the PI3K signaling pathway in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 121-130.	1.5	176
347	Distinct perturbation of the transcriptome by the antidiabetic drug metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8977-8982.	3.3	169
348	Acquired resistance to drugs targeting receptor tyrosine kinases. <i>Biochemical Pharmacology</i> , 2012, 83, 1041-1048.	2.0	104
349	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S27.	1.5	580
350	Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 317-328.	1.9	480
351	Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells. <i>Clinical Cancer Research</i> , 2012, 18, 184-195.	3.2	148
352	Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 518-524.	0.8	36
353	Discovery and Optimization of a Series of 3-(3-Phenyl-3 <i>H</i> -imidazo[4,5- <i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5291-5310.	2.9	70
354	Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3K \hat{r} inhibitors; the basis of a US\$251 million deal. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 971-976.	2.4	2
355	Selectivity Enhancement Arising from Interactions at the PI3K Unique Pocket. <i>ChemMedChem</i> , 2012, 7, 1379-1383.	1.6	4
356	Apigenin Attenuates Insulin-Like Growth Factor-I Signaling in an Autochthonous Mouse Prostate Cancer Model. <i>Pharmaceutical Research</i> , 2012, 29, 1506-1517.	1.7	45
357	PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies. <i>Current Oncology Reports</i> , 2012, 14, 129-138.	1.8	175
358	Characterization of molecular recognition of Phosphoinositide-3-kinase \hat{r} inhibitor through molecular dynamics simulation. <i>Journal of Molecular Modeling</i> , 2012, 18, 1907-1916.	0.8	9
359	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	1.2	65
360	Sp1 is involved in regulation of cystathionine \hat{r} -lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. <i>Cellular Signalling</i> , 2012, 24, 1229-1240.	1.7	100
361	Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases. <i>European Journal of Medicinal Chemistry</i> , 2012, 48, 143-152.	2.6	65

#	ARTICLE	IF	CITATIONS
362	Novel pyrazolo[1,5-a]pyridines as p110 α -selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 58-68.	1.4	34
363	Discovery and bioactivity of 4-(2-arylpyrido[3,2-b:4,5-b']pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 339-342.	1.0	18
364	Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 876-880.	1.0	23
365	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1874-1878.	1.0	29
366	Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2283-2286.	1.0	22
367	Pyrazolopyrimidines as dual Akt/p70S6K inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2693-2697.	1.0	22
368	Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. <i>Gynecologic Oncology</i> , 2012, 125, 734-741.	0.6	44
369	Studies on the Expression Patterns of Class I PI3K Catalytic Subunits and Its Prognostic Significance in Colorectal Cancer. <i>Cell Biochemistry and Biophysics</i> , 2012, 62, 47-54.	0.9	16
370	A selectivity study on mTOR/PI3K α inhibitors by homology modeling and 3D-QSAR. <i>Journal of Molecular Modeling</i> , 2012, 18, 171-186.	0.8	13
371	Colorectal cancer and RASSF family: A special emphasis on RASSF1A. <i>International Journal of Cancer</i> , 2013, 132, 251-258.	2.3	54
372	The activity of the androgen receptor variant AR α 7 is regulated by FOXO1 in a PTEN α PI3K α AKT α dependent way. <i>Prostate</i> , 2013, 73, 267-277.	1.2	48
373	Molecular mechanisms of the PRL phosphatases. <i>FEBS Journal</i> , 2013, 280, 505-524.	2.2	109
374	Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non α -Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 322-332.	1.1	93
375	Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer. <i>Future Oncology</i> , 2013, 9, 1171-1194.	1.1	19
376	Control of oncogenesis by eIF2 α phosphorylation: implications in PTEN and PI3K α Akt signaling and tumor treatment. <i>Future Oncology</i> , 2013, 9, 1005-1015.	1.1	26
377	Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. <i>Molecular and Cellular Biochemistry</i> , 2013, 383, 39-48.	1.4	57
378	PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine. <i>Journal of Cardiac Failure</i> , 2013, 19, 268-282.	0.7	24
379	Medicinal Chemistry of Dihydropyran-Based Medium Ring Macrolides Related to Aspergillides: Selective Inhibition of PI3K α . <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6122-6135.	2.9	30

#	ARTICLE	IF	CITATIONS
380	Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines inÂvitro and inÂvivo. <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 243-251.	2.6	44
381	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1395-1409.	1.1	190
382	SnapShot: Class I PI3K Isoform Signaling. <i>Cell</i> , 2013, 154, 940-940.e1.	13.5	32
383	Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1561-1573.	2.2	16
384	Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2013, 991, 105-139.	0.8	36
385	Role of the mTOR signaling pathway in epilepsy. <i>Journal of the Neurological Sciences</i> , 2013, 332, 4-15.	0.3	101
386	FOXM1 (Forkhead box M1) in Tumorigenesis. <i>Advances in Cancer Research</i> , 2013, 119, 191-419.	1.9	146
387	Targeted Therapy and New Anticancer Drugs in Advanced Disease. <i>Thoracic Surgery Clinics</i> , 2013, 23, 411-419.	0.4	7
388	Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response. <i>Neoplasia</i> , 2013, 15, 694-IN4.	2.3	27
389	Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway. <i>Breast Care</i> , 2013, 8, 248-255.	0.8	40
390	PDK1 Signaling Toward PLK1â€MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy. <i>Cancer Discovery</i> , 2013, 3, 1156-1171.	7.7	119
391	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 228-235.	5.1	147
392	Can Cancer Drugs Treat Immunodeficiency?. <i>Science</i> , 2013, 342, 814-815.	6.0	7
393	The Key Regulatory Roles of the PI3K/Akt Signaling Pathway in the Functionalities of Mesenchymal Stem Cells and Applications in Tissue Regeneration. <i>Tissue Engineering - Part B: Reviews</i> , 2013, 19, 516-528.	2.5	193
394	Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19426-19431.	3.3	51
395	3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors. <i>Journal of Molecular Structure</i> , 2013, 1054-1055, 107-116.	1.8	8
396	Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2013, 3, 2859.	1.6	118
397	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. <i>Journal of Hematology and Oncology</i> , 2013, 6, 88.	6.9	211

#	ARTICLE	IF	CITATIONS
398	Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 412-419.	1.4	16
399	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
400	Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. <i>Breast Cancer Research</i> , 2013, 15, R55.	2.2	79
401	Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. <i>BMC Complementary and Alternative Medicine</i> , 2013, 13, 185.	3.7	72
402	Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2013, 1, 30.	2.8	11
403	PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. <i>Cancer Letters</i> , 2013, 335, 1-8.	3.2	65
404	Novel self-assembled lithocholic acid nanoparticles for drug delivery in cancer. <i>RSC Advances</i> , 2013, 3, 19760.	1.7	16
405	Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 313-320.	3.4	81
406	Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences. <i>Kidney International</i> , 2013, 84, 667-681.	2.6	28
407	Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110 ^Δ /PIK3CA but not by HER2 or mutant AKT1. <i>Oncogene</i> , 2013, 32, 4417-4426.	2.6	27
408	Differential activation of myocardial ER stress response: A possible role in hypoxic tolerance. <i>International Journal of Cardiology</i> , 2013, 168, 4667-4677.	0.8	19
409	Noncanonical control of <i>C. elegans</i> germline apoptosis by the insulin/IGF-1 and Ras/MAPK signaling pathways. <i>Cell Death and Differentiation</i> , 2013, 20, 97-107.	5.0	43
410	High Expression of Proline-Rich Tyrosine Kinase2 is Associated with Poor Survival of Hepatocellular Carcinoma via Regulating Phosphatidylinositol 3-Kinase/AKT Pathway. <i>Annals of Surgical Oncology</i> , 2013, 20, 312-323.	0.7	13
411	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. <i>Scandinavian Journal of Urology</i> , 2013, 47, 423-432.	0.6	69
412	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. <i>Cancer Research</i> , 2013, 73, 2574-2586.	0.4	170
413	Phosphoinositide 3-kinase and INPP4B in human breast cancer. <i>Annals of the New York Academy of Sciences</i> , 2013, 1280, 1-5.	1.8	43
414	The novel phosphoinositide 3-kinase mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. <i>International Journal of Cancer</i> , 2013, 133, 505-513.	2.3	28
415	mTOR regulates DNA damage response through NF- κ B-mediated FANCD2 pathway in hematopoietic cells. <i>Leukemia</i> , 2013, 27, 2040-2046.	3.3	68

#	ARTICLE	IF	CITATIONS
416	Combination of TNF- α and graphene oxide-loaded BEZ235 to enhance apoptosis of PIK3CA mutant colorectal cancer cells. <i>Journal of Materials Chemistry B</i> , 2013, 1, 5602.	2.9	14
417	<i>PIK3CA</i> Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. <i>Cancer Research</i> , 2013, 73, 276-284.	0.4	262
418	Forkhead Box(O) in Control of Reactive Oxygen Species and Genomic Stability to Ensure Healthy Lifespan. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1400-1419.	2.5	12
419	VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 151-161.	1.9	59
420	Enhanced recovery from ischemia-reperfusion injury in PI3K dominant negative hearts: Investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 54, 9-18.	0.9	15
421	Targeting the Phosphoinositide 3-Kinase p110 Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 96-105.	3.2	30
422	The phosphatidylinositol 3-kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells <i>in vitro</i> . <i>International Journal of Cancer</i> , 2013, 133, 247-252.	2.3	36
423	A Practical Synthesis of a PI3K Inhibitor under Noncryogenic Conditions via Functionalization of a Lithium Triarylmagnesiato Intermediate. <i>Organic Process Research and Development</i> , 2013, 17, 97-107.	1.3	22
424	The transcription factor NF- κ B-related Factor 2 (Nrf2): a protooncogene?. <i>FASEB Journal</i> , 2013, 27, 414-423.	0.2	166
425	QSAR and pharmacophore modeling of N-acetyl-2-aminobenzothiazole class of phosphoinositide-3-kinase inhibitors. <i>Medicinal Chemistry Research</i> , 2013, 22, 890-899.	1.1	7
426	Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 143-147.	1.1	17
427	MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance. <i>Molecular Cell</i> , 2013, 50, 43-55.	4.5	86
428	Signaling interplay between transforming growth factor- β receptor and PI3K/AKT pathways in cancer. <i>Trends in Biochemical Sciences</i> , 2013, 38, 612-620.	3.7	207
429	Hydrogen sulfide augments the proliferation and survival of human induced pluripotent stem cell-derived mesenchymal stromal cells through inhibition of BKCa. <i>Cytotherapy</i> , 2013, 15, 1395-1405.	0.3	33
430	miR-128 and its target genes in tumorigenesis and metastasis. <i>Experimental Cell Research</i> , 2013, 319, 3059-3064.	1.2	97
431	GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. <i>Cancer Letters</i> , 2013, 329, 27-36.	3.2	29
432	Lead optimization of a dihydropyrrlopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 673-678.	1.0	16
433	Discovery of 4-Amino-N-[(1-(4-chlorophenyl)-3-hydroxypropyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2059-2073.	2.9	135

#	ARTICLE	IF	CITATIONS
434	An efficient synthesis of (R)- and (S)-8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene. <i>Tetrahedron: Asymmetry</i> , 2013, 24, 320-323.	1.8	2
435	Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer. <i>Cancer Cell</i> , 2013, 23, 406-420.	7.7	291
436	Personalized therapy on the horizon for squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2013, 80, 249-255.	0.9	60
437	Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3K β . <i>Journal of Medicinal Chemistry</i> , 2013, 56, 712-721.	2.9	70
438	Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 829-842.	1.1	367
439	Role of Phospholipids in Endocytosis, Phagocytosis, and Macropinocytosis. <i>Physiological Reviews</i> , 2013, 93, 69-106.	13.1	250
440	Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2013, 14, 3874-3900.	1.8	40
441	Emerging targeted agents in metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 191-210.	12.5	158
442	Targeted Therapy of Multiple Myeloma. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 197-221.	0.8	20
443	Molecular Machinery and Genetics of the Autophagy Pathway. , 2013, , 11-30.		1
444	Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. <i>Current Oncology Reports</i> , 2013, 15, 386-395.	1.8	54
445	Cell survival and metastasis regulation by Akt signaling in colorectal cancer. <i>Cellular Signalling</i> , 2013, 25, 1711-1719.	1.7	137
446	RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 313-319.	2.5	39
447	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
448	The anti-cancer activities of jasmonates. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 275-285.	1.1	48
449	Targeting apoptosis pathways in pancreatic cancer. <i>Cancer Letters</i> , 2013, 332, 346-358.	3.2	116
450	Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 802-805.	1.0	13
451	MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. <i>Oncogene</i> , 2013, 32, 1073-1081.	2.6	334

#	ARTICLE	IF	CITATIONS
452	Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1023-1040.	1.9	32
453	Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. <i>Biochemical Journal</i> , 2013, 452, 499-508.	1.7	141
454	Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4652-4656.	1.0	7
455	The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial lysosomal cross-talk. <i>International Journal of Cancer</i> , 2013, 132, 2682-2693.	2.3	72
456	The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 838-847.	0.4	5
457	Strategies for optimizing the response of cancer and normal tissues to radiation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 526-542.	21.5	335
458	A systems biology analysis of autophagy in cancer therapy. <i>Cancer Letters</i> , 2013, 337, 149-160.	3.2	26
459	Gain of Interaction with IRS1 by p110 ^H -Helical Domain Mutants Is Crucial for Their Oncogenic Functions. <i>Cancer Cell</i> , 2013, 23, 583-593.	7.7	85
460	Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 137-147.	2.6	17
461	Inhibition of constitutive Akt (PKB) phosphorylation by docosahexaenoic acid in the human breast cancer cell line MDA-MB-453. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 306-313.	1.2	14
462	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R83-R99.	1.6	272
463	Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress. <i>Science</i> , 2013, 341, 395-399.	6.0	351
464	Control of AMP-activated protein kinase, Akt, and mTOR in EGCG-treated HT-29 colon cancer cells. <i>Food Science and Biotechnology</i> , 2013, 22, 147-151.	1.2	1
465	Targeted inhibition of phosphatidylinositol-3-kinase p110 ^B , but not p110 ^H , enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 509-520.	2.2	25
466	Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. <i>Investigational New Drugs</i> , 2013, 31, 293-303.	1.2	16
467	TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer. <i>Cancer Research</i> , 2013, 73, 6938-6950.	0.4	89
468	E-TALEN: a web tool to design TALENs for genome engineering. <i>Nucleic Acids Research</i> , 2013, 41, e190-e190.	6.5	60
469	Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer. <i>Cell Cycle</i> , 2013, 12, 1999-2010.	1.3	82

#	ARTICLE	IF	CITATIONS
470	The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. <i>Cell Cycle</i> , 2013, 12, 3589-3593.	1.3	3
471	Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 888-896.	1.5	23
472	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.4	10
473	Targeting PI3K in Cancer: Any Good News?. <i>Frontiers in Oncology</i> , 2013, 3, 108.	1.3	87
474	MicroRNA-17-492 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. <i>EMBO Journal</i> , 2013, 32, 2377-2391.	3.5	123
475	Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice. <i>Current Opinion in Oncology</i> , 2013, 25, 609-614.	1.1	23
476	PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas. <i>Clinical Cancer Research</i> , 2013, 19, 1106-1115.	3.2	47
477	Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc. <i>Journal of Virology</i> , 2013, 87, 11276-11286.	1.5	21
478	Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks. <i>Cancer Research</i> , 2013, 73, 3393-3401.	0.4	78
479	PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival. <i>Clinical Cancer Research</i> , 2013, 19, 6450-6460.	3.2	17
480	Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 714-723.	1.5	52
481	ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18824-18849.	1.8	129
482	Antiproliferative effects of Î³-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action. <i>Journal of International Medical Research</i> , 2013, 41, 1017-1026.	0.4	8
483	Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 3796-3807.	3.2	77
484	Major Signaling Pathways Involved in Breast Cancer. , 2013, , 47-64.		3
485	Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation. <i>Physiological Reviews</i> , 2013, 93, 1019-1137.	13.1	1,281
486	Regulation of mRNA export by the PI3 kinase/AKT signal transduction pathway. <i>Molecular Biology of the Cell</i> , 2013, 24, 1208-1221.	0.9	14
487	Phosphatidylinositol Phosphate 5-Kinase Î³i2 in Association with Src Controls Anchorage-independent Growth of Tumor Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 34707-34718.	1.6	13

#	ARTICLE	IF	CITATIONS
488	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF</i> -Mutant Melanoma. <i>Science Translational Medicine</i> , 2013, 5, 196ra98.	5.8	124
489	Pertuzumab: new hope for patients with HER2-positive breast cancer. <i>Annals of Oncology</i> , 2013, 24, 273-282.	0.6	128
490	Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. <i>Journal of Pineal Research</i> , 2013, 55, 174-183.	3.4	59
491	Inhibiting the RAS-PI3K Pathway in Cancer Therapy. <i>The Enzymes</i> , 2013, 34 Pt. B, 107-136.	0.7	20
492	Perifosine – a new option in treatment of acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1315-1327.	1.9	13
493	Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts. <i>Journal of Biological Chemistry</i> , 2013, 288, 35346-35357.	1.6	35
494	Selective anti-cancer agents as anti-aging drugs. <i>Cancer Biology and Therapy</i> , 2013, 14, 1092-1097.	1.5	41
495	Pharmacologic Profiling of Phosphoinositide 3-Kinase Inhibitors as Mitigators of Ionizing Radiation-Induced Cell Death. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 669-680.	1.3	13
496	Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 33-46.	3.0	85
497	Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. <i>Cell Death and Disease</i> , 2013, 4, e486-e486.	2.7	44
498	Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 826-830.	2.9	110
499	Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2013, 27, 586-594.	3.3	92
500	PPAR γ Induces Estrogen Receptor-Positive Mammary Neoplasia through an Inflammatory and Metabolic Phenotype Linked to mTOR Activation. <i>Cancer Research</i> , 2013, 73, 4349-4361.	0.4	52
501	Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. <i>Genes and Development</i> , 2013, 27, 1568-1580.	2.7	19
502	Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. <i>Oncology Reports</i> , 2013, 30, 773-782.	1.2	59
503	Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1. <i>Oncology Letters</i> , 2013, 5, 43-48.	0.8	52
504	Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis. <i>Anti-Cancer Drugs</i> , 2013, 24, 14-19.	0.7	31
505	Anti-cancer Therapies in High Grade Gliomas. <i>Current Proteomics</i> , 2013, 10, 246-260.	0.1	28

#	ARTICLE	IF	CITATIONS
506	Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. , 2013, , .		0
507	Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly (lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway. International Journal of Nanomedicine, 2013, 8, 2689.	3.3	16
508	Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662	0.8	14
509	The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism. PLoS ONE, 2013, 8, e62399.	1.1	36
510	Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS ONE, 2013, 8, e67258.	1.1	31
511	Cancer Cells Resistant to Therapy Promote Cell Surface Relocalization of GRP78 Which Complexes with PI3K and Enhances PI(3,4,5)P3 Production. PLoS ONE, 2013, 8, e80071.	1.1	120
512	PI3K/Akt Signal Pathway Involved in the Cognitive Impairment Caused by Chronic Cerebral Hypoperfusion in Rats. PLoS ONE, 2013, 8, e81901.	1.1	64
513	Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer. Current Cancer Drug Targets, 2013, 13, 175-187.	0.8	36
514	Target Cancer Therapy. , 0, , .		0
515	Molecular Pathways in Head and Neck Cancer: EGFR, PI3K, and More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 246-255.	1.8	46
516	Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. Journal of Gynecologic Oncology, 2014, 25, 249.	1.0	31
517	Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches. PLoS ONE, 2014, 9, e87309.	1.1	56
518	p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. PLoS ONE, 2014, 9, e90171.	1.1	26
519	AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake. PLoS ONE, 2014, 9, e92948.	1.1	68
520	Rhinovirus-16 Induced Release of IP-10 and IL-8 Is Augmented by Th2 Cytokines in a Pediatric Bronchial Epithelial Cell Model. PLoS ONE, 2014, 9, e94010.	1.1	34
521	Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function. PLoS ONE, 2014, 9, e99486.	1.1	11
522	A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic. Journal of Cancer Research, 2014, 2014, 1-12.	0.7	25
523	Knockdown of <i>AKT3</i> (<i>PKBβ</i>) and <i>PI3KCA</i> Suppresses Cell Viability and Proliferation and Induces the Apoptosis of Glioblastoma Multiforme T98G Cells. BioMed Research International, 2014, 2014, 1-12.	0.9	20

#	ARTICLE	IF	CITATIONS
524	Neoadjuvant Strategies for Triple Negative Breast Cancer: â€˜State-of-the-artâ€™™ and Future Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 15, 15-25.	0.9	7
525	PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Theranostics</i> , 2014, 4, 336-365.	4.6	78
526	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.4	63
527	Panitumumab: leading to better overall survival in metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 535-548.	1.4	1
528	FOXC1 is a Critical Mediator of EGFR Function in Human Basal-like Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 758-766.	0.7	34
529	Bowel perforation associated with temsirolimus use in a recently irradiated patient. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 919-923.	0.5	5
530	High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 299.	1.8	41
531	Ciliary neurotrophic factor (CNTF) promotes skeletal muscle progenitor cell (MPC) viability via the phosphatidylinositol 3-kinase-Akt pathway. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2014, 8, 963-968.	1.3	9
532	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	1.6	25
533	Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways. <i>Amino Acids</i> , 2014, 46, 2393-2401.	1.2	69
534	Targeting Small Cell Lung Cancer Harboring <i>PIK3CA</i> Mutation with a Selective Oral PI3K Inhibitor PF-4989216. <i>Clinical Cancer Research</i> , 2014, 20, 631-643.	3.2	34
535	Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. <i>Lung Cancer Management</i> , 2014, 3, 67-75.	1.5	104
536	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 233-245.	3.2	142
537	Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. <i>Cell Death and Disease</i> , 2014, 5, e1134-e1134.	2.7	21
538	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1223-e1223.	2.7	57
539	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 847-858.	1.3	17
540	Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells. <i>Bioscience Reports</i> , 2014, 34, .	1.1	1
541	mTOR pathway: A current, up-to-date mini-review (Review). <i>Oncology Letters</i> , 2014, 8, 2367-2370.	0.8	87

#	ARTICLE	IF	CITATIONS
542	Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. <i>Experimental Biology and Medicine</i> , 2014, 239, 805-812.	1.1	2
543	Effects of carbonic anhydrase-related protein VIII on human cells harbouring an A8344C mitochondrial DNA mutation. <i>Biochemical Journal</i> , 2014, 459, 149-160.	1.7	18
544	Cell Death and Deubiquitinases: Perspectives in Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-19.	0.9	36
545	Emerging therapy for adrenocortical carcinoma. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 173-182.	0.4	12
546	Targeting the PI3K/Akt/mTOR Pathway in Ocular Neovascularization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 801, 805-811.	0.8	35
547	Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. <i>Prostate</i> , 2014, 74, 1411-1422.	1.2	14
548	The Phosphoinositide 3-Kinase Isoform PI3K β Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice. <i>Arthritis and Rheumatology</i> , 2014, 66, 2210-2221.	2.9	29
549	Smarter drugs emerging in pancreatic cancer therapy. <i>Annals of Oncology</i> , 2014, 25, 1260-1270.	0.6	72
550	Carbohydrate metabolism during vertebrate appendage regeneration: What is its role? How is it regulated?. <i>BioEssays</i> , 2014, 36, 27-33.	1.2	43
551	Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 543-555.	1.1	27
552	Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2014, 105, 347-353.	1.7	81
553	A phase I trial of MK2206 in children with refractory malignancies: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1246-1251.	0.8	35
554	Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells. <i>Cancer Gene Therapy</i> , 2014, 21, 275-282.	2.2	8
555	The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. <i>International Journal of Cancer</i> , 2014, 134, 2560-2571.	2.3	50
556	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 2445-2456.	3.2	88
557	Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. <i>Frontiers in Physiology</i> , 2014, 5, 478.	1.3	40
558	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1227-1234.	1.1	11
559	PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 1067-1078.	0.8	189

#	ARTICLE	IF	CITATIONS
560	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 52.	3.5	43
561	Posttranslational regulation of Akt in human cancer. <i>Cell and Bioscience</i> , 2014, 4, 59.	2.1	111
562	Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, 316-323.	0.5	44
563	Identification of a Subset of Human Non-Small Cell Lung Cancer Patients with High PI3K ² and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 595-603.	3.2	27
564	Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 52-68.	1.4	54
565	A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 15-23.	0.4	57
566	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	3.2	38
567	The role of obesity in gastrointestinal cancer: evidence and opinion. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 38-50.	1.4	38
568	Targeting the Protein-Protein Interaction between IRS1 and Mutant p110 β for Cancer Therapy. <i>Toxicologic Pathology</i> , 2014, 42, 140-147.	0.9	11
569	Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1306-1312.	3.2	19
570	Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers. <i>Cancer Discovery</i> , 2014, 4, 1062-1073.	7.7	55
572	Signaling mechanisms of the epithelial-mesenchymal transition. <i>Science Signaling</i> , 2014, 7, re8.	1.6	1,257
573	Molecularly Targeted Therapies in Multiple Myeloma. <i>Leukemia Research and Treatment</i> , 2014, 2014, 1-8.	2.0	43
574	Translating the molecular analysis of cancer biology into therapeutic concepts. <i>Cancer Biomarkers</i> , 2014, 14, 87-91.	0.8	0
575	The Adherens Junction Protein Afadin Is an AKT Substrate that Regulates Breast Cancer Cell Migration. <i>Molecular Cancer Research</i> , 2014, 12, 464-476.	1.5	44
576	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6395-6400.	3.3	66
577	Using molecular profiles to tailor treatment in breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 21-26.	0.9	1
578	The Phosphatidylinositol 3-Kinase (PI3K) Isoform Dependence of Tumor Formation Is Determined by the Genetic Mode of PI3K Pathway Activation Rather than by Tissue Type. <i>Journal of Virology</i> , 2014, 88, 10673-10679.	1.5	10

#	ARTICLE	IF	CITATIONS
579	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2014, 191, 227-234.	0.2	60
580	Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 3739-3748.	1.4	26
581	Summary Report From the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. <i>Clinical Lung Cancer</i> , 2014, 15, 16-20.	1.1	1
582	NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 179-190.	2.2	20
583	Discovery and Development of Small Molecule SHIP Phosphatase Modulators. <i>Medicinal Research Reviews</i> , 2014, 34, 795-824.	5.0	44
584	The rationale for targeted therapies in medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 9-20.	0.6	54
585	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. <i>Journal of Neuro-Oncology</i> , 2014, 117, 7-13.	1.4	15
586	Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening. <i>Computational Biology and Chemistry</i> , 2014, 48, 1-13.	1.1	12
587	Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. <i>European Journal of Medicinal Chemistry</i> , 2014, 75, 96-105.	2.6	34
588	Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 790-793.	1.0	7
589	Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 750-759.	3.4	151
590	Molecular profiling of small cell lung cancer in a Japanese cohort. <i>Lung Cancer</i> , 2014, 84, 139-144.	0.9	32
591	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 862-871.	3.4	257
592	Cancer biomarker discovery: Current status and future perspectives. <i>International Journal of Radiation Biology</i> , 2014, 90, 659-677.	1.0	98
593	Biologically Driven Synthesis of Pyrazolo[3,4- <i>d</i>]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies. <i>Chemical Reviews</i> , 2014, 114, 7189-7238.	23.0	116
594	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175.		648
595	Regulation of matrix metalloproteinase-1, -3, and -9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI3K/p70 S6K cascade. <i>FASEB Journal</i> , 2014, 28, 85-93.	0.2	27
596	PIP ₃ Induces the Recycling of Receptor Tyrosine Kinases. <i>Science Signaling</i> , 2014, 7, ra5.	1.6	39

#	ARTICLE	IF	CITATIONS
597	PINK1 signalling in cancer biology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 590-598.	3.3	35
598	Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. <i>International Journal of Cancer</i> , 2014, 135, 2558-2568.	2.3	84
599	Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3K β : 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9157-9165.	1.5	14
600	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 353-365.	3.3	30
601	Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1078-1091.	1.9	68
602	Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group. <i>MedChemComm</i> , 2014, 5, 41-46.	3.5	12
603	PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival. <i>Cancer Discovery</i> , 2014, 4, 942-955.	7.7	75
604	Phosphatidylinositol 3-Phosphate Mimics Based on a Sulfoquinovose Scaffold: Synthesis and Evaluation as Protein Kinase B Inhibitors. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 5962-5967.	1.2	7
605	MAPK pathway inhibition in melanoma: resistance three ways. <i>Biochemical Society Transactions</i> , 2014, 42, 727-732.	1.6	21
606	Novel Targeted Agents in the Treatment of Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 903-925.	0.9	15
607	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1935-1945.	3.2	121
608	Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 613-631.	2.9	71
609	Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. <i>Food and Chemical Toxicology</i> , 2014, 73, 7-16.	1.8	38
610	A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apatolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 150-156.	1.4	6
611	Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 980-989.	3.4	95
612	Mammalian Target of Rapamycin Complex 1 and Cyclooxygenase 2 Pathways Cooperatively Exacerbate Endometrial Cancer. <i>American Journal of Pathology</i> , 2014, 184, 2390-2402.	1.9	17
613	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	1.9	72
614	GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 453, 533-538.	1.0	19

#	ARTICLE	IF	CITATIONS
615	<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3212-3220.	0.8	231
616	A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. <i>Genome Biology</i> , 2014, 15, R71.	13.9	30
617	miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. <i>Cell Communication and Signaling</i> , 2014, 12, 45.	2.7	39
618	A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma. <i>Journal of Neuro-Oncology</i> , 2014, 119, 285-295.	1.4	29
619	Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. <i>Cancer Letters</i> , 2014, 354, 355-364.	3.2	31
620	Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1835-1848.	1.2	41
621	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 670-681.	1.2	165
622	DRR regulates AKT activation to drive brain cancer invasion. <i>Oncogene</i> , 2014, 33, 4952-4960.	2.6	25
623	An update on molecular biology of thyroid cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 233-252.	2.0	83
624	Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in <i>PIK3CA</i> wild-type, <i>KRAS</i> mutant colorectal cancer. <i>Cancer Letters</i> , 2014, 347, 204-211.	3.2	36
625	Therapeutic targeting of the mTOR signalling pathway in cancer: benefits and limitations. <i>British Journal of Pharmacology</i> , 2014, 171, 3801-3813.	2.7	92
626	Inhibition of human lung cancer cell proliferation and survival by wine. <i>Cancer Cell International</i> , 2014, 14, 6.	1.8	27
627	Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. <i>Molecular Cancer</i> , 2014, 13, 65.	7.9	172
628	PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. <i>British Journal of Haematology</i> , 2014, 167, 69-79.	1.2	49
629	Presence and utility of intrinsically disordered regions in kinases. <i>Molecular BioSystems</i> , 2014, 10, 2876-2888.	2.9	26
630	Herpes Simplex Virus Protein Kinases US3 and UL13 Modulate VP11/12 Phosphorylation, Virion Packaging, and Phosphatidylinositol 3-Kinase/Akt Signaling Activity. <i>Journal of Virology</i> , 2014, 88, 7379-7388.	1.5	38
631	Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4538-4541.	1.0	17
632	Structural Basis for Phosphoinositide Substrate Recognition, Catalysis, and Membrane Interactions in Human Inositol Polyphosphate 5-Phosphatases. <i>Structure</i> , 2014, 22, 744-755.	1.6	46

#	ARTICLE	IF	CITATIONS
633	Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 320-326.	3.4	21
634	PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[1±]indene Derivative in Lung Cancer Cells. <i>Translational Oncology</i> , 2014, 7, 256-266.e5.	1.7	1
635	Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , 2014, 347, 196-203.	3.2	25
636	Activation of Akt involves resistance to NF- κ B inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells. <i>Lung Cancer</i> , 2014, 83, 139-145.	0.9	2
637	Personalized medicine for breast cancer: it is a new day!. <i>American Journal of Surgery</i> , 2014, 207, 321-325.	0.9	7
638	Genetics and epigenetics of adrenocortical tumors. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 67-84.	1.6	88
639	The Role of Src in Colon Cancer and Its Therapeutic Implications. <i>Clinical Colorectal Cancer</i> , 2014, 13, 5-13.	1.0	106
640	Targeting homologous recombination-mediated DNA repair in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 427-458.	1.5	43
641	Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1196-1206.	3.3	56
642	MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. <i>Journal of Surgical Research</i> , 2014, 191, 280-285.	0.8	21
643	Signals Controlling Unâ€Differentiated States in Embryonic Stem and Cancer Cells: Role of the Phosphatidylinositol 3â€ Kinase Pathway. <i>Journal of Cellular Physiology</i> , 2014, 229, 1312-1322.	2.0	18
644	Arachidonic acid promotes migration and invasion through a PI3K/Akt-dependent pathway in MDA-MB-231 breast cancer cells. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2014, 90, 169-177.	1.0	30
645	Inactivation of TGF- β 2 signaling and loss of PTEN cooperate to induce colon cancer in vivo. <i>Oncogene</i> , 2014, 33, 1538-1547.	2.6	66
646	A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway. <i>International Journal of Oncology</i> , 2014, 45, 771-781.	1.4	12
647	Significance of AKT in gastric cancer (Review). <i>International Journal of Oncology</i> , 2014, 45, 2187-2192.	1.4	48
648	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). <i>International Journal of Oncology</i> , 2014, 45, 929-949.	1.4	34
649	Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. <i>Oncology Reports</i> , 2014, 31, 1175-1182.	1.2	31
650	Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. <i>Oncology Reports</i> , 2014, 32, 1465-1472.	1.2	33

#	ARTICLE	IF	CITATIONS
652	TRAF4 promotes tumorigenesis of breast cancer through activation of Akt. <i>Oncology Reports</i> , 2014, 32, 1312-1318.	1.2	14
653	Emerging targeted therapies for melanoma treatment (Review). <i>International Journal of Oncology</i> , 2014, 45, 516-524.	1.4	39
654	Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review). <i>Oncology Reports</i> , 2014, 32, 3-15.	1.2	135
655	TRAF4 Enhances Osteosarcoma Cell Proliferation and Invasion by Akt Signaling Pathway. <i>Oncology Research</i> , 2014, 22, 21-28.	0.6	24
656	Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β -TrCP and GSK-3. <i>Biochemical Society Transactions</i> , 2015, 43, 611-620.	1.6	143
657	C6-ceramide nanoliposome suppresses tumor metastasis by eliciting PI3K and PKC δ tumor-suppressive activities and regulating integrin affinity modulation. <i>Scientific Reports</i> , 2015, 5, 9275.	1.6	21
658	Harnessing the apoptotic programs in cancer stem-like cells. <i>EMBO Reports</i> , 2015, 16, 1084-1098.	2.0	53
659	Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells. <i>International Journal of Molecular Medicine</i> , 2015, 36, 1556-1562.	1.8	25
660	Activin and TGF β 2 use diverging mitogenic signaling in advanced colon cancer. <i>Molecular Cancer</i> , 2015, 14, 182.	7.9	52
661	PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. <i>Cancer Cell International</i> , 2015, 15, 91.	1.8	21
662	The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 125.	3.5	18
663	Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases. <i>Neuropathology</i> , 2015, 35, 312-323.	0.7	9
664	Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 201-215.	0.4	1
665	Flavonoids of Korean <i>Citrus aurantium</i> L. Induce Apoptosis via Intrinsic Pathway in Human Hepatoblastoma HepG2 Cells. <i>Phytotherapy Research</i> , 2015, 29, 1940-1949.	2.8	17
666	Resveratrol in the treatment of pancreatic cancer. <i>Annals of the New York Academy of Sciences</i> , 2015, 1348, 10-19.	1.8	53
667	A Systematic Review on Antitumor Agents with 1, 3, 5-triazines. , 2015, 5, .		27
668	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 63.	0.4	24
669	Design, Synthesis and Biological Evaluation of Novel 1,3,5-triazines Derivatives as Potent Antitumor Agents. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
670	The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after		

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

#	ARTICLE	IF	CITATIONS
688	Current medical treatment of estrogen receptor-positive breast cancer. <i>World Journal of Biological Chemistry</i> , 2015, 6, 231.	1.7	144
689	Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo. <i>Tumor Biology</i> , 2015, 36, 5699-5706.	0.8	19
690	Synthesis and biological evaluation of 3-(piperidin-4-yl)isoxazolo[4,5-d]pyrimidine derivatives as novel PI3K γ inhibitors. <i>Chinese Chemical Letters</i> , 2015, 26, 1283-1288.	4.8	7
691	Hsp27 Inhibition with OGX-427 Sensitizes Non-small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1107-1116.	1.9	43
692	Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4365-4372.	3.2	31
693	Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation. <i>Cell Cycle</i> , 2015, 14, 2667-2676.	1.3	73
694	Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. <i>European Journal of Cancer</i> , 2015, 51, 1212-1220.	1.3	43
695	Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. <i>Autophagy</i> , 2015, 11, 1711-1728.	4.3	143
696	A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 62, 226-234.	1.3	20
697	Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. <i>Genome Medicine</i> , 2015, 7, 93.	3.6	199
698	Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7650-7660.	1.4	9
699	Sedanolid induces autophagy through the PI3K, p53 and NF- κ B signaling pathways in human liver cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 2240-2246.	1.4	22
700	Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. <i>International Journal of Oncology</i> , 2015, 47, 122-132.	1.4	34
701	Adenovirus-mediated ING4/PTEN double tumor suppressor gene co-transfer modified by RGD enhances antitumor activity in human nasopharyngeal carcinoma cells. <i>International Journal of Oncology</i> , 2015, 46, 1295-1303.	1.4	12
702	Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways. <i>Molecular Medicine Reports</i> , 2015, 12, 1050-1058.	1.1	22
703	Ochratoxin A activates opposing c-MET/PI3K/Akt and MAPK/ERK 1-2 pathways in human proximal tubule HK-2 cells. <i>Archives of Toxicology</i> , 2015, 89, 1313-1327.	1.9	42
704	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298.	0.8	136
705	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 77-86.	3.2	265

#	ARTICLE	IF	CITATIONS
706	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431.	1.9	29
707	Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor Growth. <i>Molecular Cell</i> , 2015, 57, 537-551.	4.5	509
708	Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 795-805.	1.5	82
709	Emerging drugs for squamous cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 149-160.	1.0	18
710	Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products. <i>Studies in Natural Products Chemistry</i> , 2015, 44, 251-307.	0.8	11
711	The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 173-179.	0.6	336
712	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	3.2	67
713	<i>In vitro</i> and <i>in vivo</i> regulation of synaptogenesis by the novel antidepressant spadin. <i>British Journal of Pharmacology</i> , 2015, 172, 2604-2617.	2.7	29
714	Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer. <i>Journal of Biological Chemistry</i> , 2015, 290, 2024-2033.	1.6	34
715	Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. <i>Journal of Molecular Histology</i> , 2015, 46, 157-171.	1.0	16
716	<i>Cell Growth.</i> , 2015, , 179-190.e1.		4
717	PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 51-68.	1.1	41
718	Synergy in activating class I PI3Ks. <i>Trends in Biochemical Sciences</i> , 2015, 40, 88-100.	3.7	164
719	6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3K β . <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1231-1240.	1.4	26
720	Formation of Disulfide Bridges Drives Oligomerization, Membrane Pore Formation, and Translocation of Fibroblast Growth Factor 2 to Cell Surfaces. <i>Journal of Biological Chemistry</i> , 2015, 290, 8925-8937.	1.6	51
721	Targeting PI3K/AKT/mTOR network for treatment of leukemia. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2337-2347.	2.4	199
722	Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 42.	1.8	50
723	SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. <i>Molecular Cancer</i> , 2015, 14, 12.	7.9	102

#	ARTICLE	IF	CITATIONS
724	Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 434-438.	1.3	34
725	Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Investigational New Drugs, 2015, 33, 310-320.	1.2	34
726	Phosphatidylinositol 3-Kinase Pathway. , 2015, , 43-54.		0
727	Modification of N -(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5-a] Tj ETQq1 1 0.784314 rgBT /Overlo Bioorganic and Medicinal Chemistry, 2015, 23, 5662-5671.	1.4	12
728	Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies. Critical Reviews in Oncology/Hematology, 2015, 95, 114-124.	2.0	15
729	Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1270-4.	0.6	77
730	Phosphatidylinositol Phosphate 5-Kinase Î³ and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth. Journal of Biological Chemistry, 2015, 290, 18843-18854.	1.6	36
731	Allosteric therapies for lung cancer. Cancer and Metastasis Reviews, 2015, 34, 303-312.	2.7	10
732	MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine. Medical Oncology, 2015, 32, 206.	1.2	18
733	PI3KÎ± is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovascular Research, 2015, 105, 292-303.	1.8	16
734	Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Seminars in Cancer Biology, 2015, 35, 180-190.	4.3	140
735	Implications of Akt2/ Twist crosstalk on breast cancer metastatic outcome. Drug Discovery Today, 2015, 20, 1152-1158.	3.2	32
736	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 255-265.	0.6	22
737	PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer: Targets and Therapy, 2015, 7, 111.	1.0	113
738	Phosphorylation of the translation initiation factor eIF2Î± at serine 51 determines the cell fate decisions of Akt in response to oxidative stress. Cell Death and Disease, 2015, 6, e1591-e1591.	2.7	91
739	Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinositide 3-kinase (PI3KÎ±). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3120-3124.	1.0	26
740	Novel therapeutic strategies for multiple myeloma. Experimental Hematology, 2015, 43, 732-741.	0.2	98
741	Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	91

#	ARTICLE	IF	CITATIONS
742	Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1407-1409.	0.8	10
743	The PI3K/AKT/mTOR interactive pathway. <i>Molecular BioSystems</i> , 2015, 11, 1946-1954.	2.9	379
744	Class IA Phosphatidylinositol 3-Kinase Isoform p110 β Mediates Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1434-1444.	1.1	13
745	Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2149-55.	3.3	8
746	Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2015, 96, 382-395.	2.6	33
747	Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials. <i>Tumor Biology</i> , 2015, 36, 643-654.	0.8	8
748	Knockdown of the AKT3 (PKB β), PI3KCA, and VEGFR2 genes by RNA interference suppresses glioblastoma multiforme T98G cells invasiveness in vitro. <i>Tumor Biology</i> , 2015, 36, 3263-3277.	0.8	13
749	The PI3K/AKT/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies. <i>Oral Diseases</i> , 2015, 21, 815-825.	1.5	132
750	Buparlisib in breast cancer. <i>Future Oncology</i> , 2015, 11, 1463-1470.	1.1	17
751	Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond. <i>Medicinal Research Reviews</i> , 2015, 35, 720-752.	5.0	22
752	Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 231-242.	1.1	35
753	Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. <i>Molecular and Cellular Biochemistry</i> , 2015, 406, 111-119.	1.4	79
754	Inhibition of PI3K β Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 48-58.	1.9	75
755	New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 1-14.	0.7	43
756	Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1730-1735.	1.0	14
757	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015, 17, 279-288.	2.3	56
758	Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. <i>Drug Discovery Today</i> , 2015, 20, 988-994.	3.2	43
759	The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 931-940.	1.9	45

#	ARTICLE	IF	CITATIONS
760	Dietary walnut suppression of colorectal cancer in mice: Mediation by miRNA patterns and fatty acid incorporation. <i>Journal of Nutritional Biochemistry</i> , 2015, 26, 776-783.	1.9	74
761	Phase I Trial of the Pan-PI3K Inhibitor Pifaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	3.2	51
762	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	3.2	101
763	Disabling mitochondrial reprogramming in cancer. <i>Pharmacological Research</i> , 2015, 102, 42-45.	3.1	3
764	PI3K α mTORC2 but not PI3K α mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma. <i>Cancer Research</i> , 2015, 75, 4617-4628.	0.4	75
765	Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1190-1194.	1.3	25
766	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2519-2526.	1.9	30
767	Status of the Parkinson α ™s disease gene family expression in non-small-cell lung cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 238.	0.8	25
769	Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 18327-18335.	4.0	16
770	Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. <i>Genomics Data</i> , 2015, 5, 272-274.	1.3	6
771	The Startling Properties of Fibroblast Growth Factor 2: How to Exit Mammalian Cells without a Signal Peptide at Hand. <i>Journal of Biological Chemistry</i> , 2015, 290, 27015-27020.	1.6	47
772	Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2441-2451.	1.9	62
773	Determination of GDC α 0980 (apitolisib), a small molecule dual phosphatidylinositide 3 α kinase/mammalian target of rapamycin inhibitor in dog plasma by LC α MS/MS to support a GLP toxicology study. <i>Biomedical Chromatography</i> , 2015, 29, 1274-1279.	0.8	3
774	Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3K α and PI3K β for the treatment of cancers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5155-5162.	1.0	29
775	Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylamino-pyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6477-6485.	1.4	39
776	Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. <i>Leukemia</i> , 2015, 29, 2184-2191.	3.3	88
777	Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. <i>Cancer Biology and Therapy</i> , 2015, 16, 1341-1352.	1.5	16
778	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 602-609.	1.5	33

#	ARTICLE	IF	CITATIONS
779	Suppression of Nkx3.2 by phosphatidylinositol-3-kinase signaling regulates cartilage development by modulating chondrocyte hypertrophy. <i>Cellular Signalling</i> , 2015, 27, 2389-2400.	1.7	10
780	Akt Phosphorylates Wnt Coactivator and Chromatin Effector Pygo2 at Serine 48 to Antagonize Its Ubiquitin/Proteasome-mediated Degradation. <i>Journal of Biological Chemistry</i> , 2015, 290, 21553-21567.	1.6	10
781	Absorption, distribution, metabolism, and excretion of [¹⁴ C]BYL719 (alpelisib) in healthy male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 751-760.	1.1	29
782	Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion. <i>Cell Cycle</i> , 2015, 14, 3242-3247.	1.3	26
783	Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. <i>Future Oncology</i> , 2015, 11, 1687-1699.	1.1	46
784	Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7765-7776.	1.4	19
785	Exploring a Non-ATP Pocket for Potential Allosteric Modulation of PI3K β . <i>Journal of Physical Chemistry B</i> , 2015, 119, 1002-1016.	1.2	30
786	Discovery of (<i>R</i>)-8-(1-(3,5-Difluorophenylamino)ethyl)-<i>N</i>-<i>N</i>-dimethyl-2-morpholino-4-oxo-4<i>H</i>-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3K β and PI3K γ for the Treatment of PTEN-Deficient Cancers. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 943-962.	2.9	73
787	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. <i>Nature Reviews Cancer</i> , 2015, 15, 7-24.	12.8	1,083
788	5,3β-Dihydroxy-6,7,4β-trimethoxyflavone exerts its anticancer and antiangiogenesis effects through regulation of the Akt/mTOR signaling pathway in human lung cancer cells. <i>Chemico-Biological Interactions</i> , 2015, 225, 32-39.	1.7	21
789	The Antiparasitic Drug, Potassium Antimony Tartrate, Inhibits Tumor Angiogenesis and Tumor Growth in Non-small-Cell Lung Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 129-138.	1.3	22
790	Cancer Stem Cell-Like Phenotype and Survival Are Coordinately Regulated by Akt/FoxO/Bim Pathway. <i>Stem Cells</i> , 2015, 33, 646-660.	1.4	64
791	Treatment deéescalation in HPVépositive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. <i>International Journal of Cancer</i> , 2015, 136, 1494-1503.	2.3	199
792	The impact of tumor stroma on drug response in breast cancer. <i>Seminars in Cancer Biology</i> , 2015, 31, 3-15.	4.3	82
793	Unconventional Secretion of Fibroblast Growth Factor 2éA Novel Type of Protein Translocation across Membranes?. <i>Journal of Molecular Biology</i> , 2015, 427, 1202-1210.	2.0	56
794	The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 19-31.	1.4	37
795	Targeting the genetic alterations of the PI3KéAKTémTOR pathway: Its potential use in the treatment of bladder cancers. , 2015, 145, 1-18.		75
796	Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 146, 62-73.	1.2	82

#	ARTICLE	IF	CITATIONS
797	A Focus on Current Molecular Pathways in Head and Neck. <i>Oncomedicine</i> , 2016, 1, 28-34.	1.1	0
798	BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. <i>Oncotarget</i> , 2016, 7, 9188-9221.	0.8	59
799	Post-transplant Merkel Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2016, 96, 442-447.	0.6	19
800	Management of mammalian target of rapamycin inhibitor-associated noninfectious pneumonitis in advanced breast cancer: A nursing perspective. <i>Journal of Nursing Education and Practice</i> , 2016, 7, .	0.1	0
801	Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells. <i>Environmental Health Perspectives</i> , 2016, 124, 563-569.	2.8	50
802	Specific inhibition of p110 α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. <i>Oncotarget</i> , 2016, 7, 68546-68558.	0.8	8
803	The PI3K inhibitor tasisib overcomes letrozole resistance in a breast cancer model expressing aromatase. <i>Genes and Cancer</i> , 2016, 7, 73-85.	0.6	17
804	KIF2A Overexpression and Its Association with Clinicopathologic Characteristics and Poor Prognoses in Patients with Gastric Cancer. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	18
805	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. <i>International Journal of Biological Sciences</i> , 2016, 12, 1523-1532.	2.6	31
806	Centrosomal Protein of 55 Regulates Glucose Metabolism, Proliferation and Apoptosis of Glioma Cells via the Akt/mTOR Signaling Pathway. <i>Journal of Cancer</i> , 2016, 7, 1431-1440.	1.2	32
807	Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. <i>Cancer Management and Research</i> , 2016, 8, 21.	0.9	9
808	Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation. <i>Journal of Korean Medical Science</i> , 2016, 31, 360.	1.1	11
809	Identifying significant pathways of hepatitis B virus-related hepatocellular carcinoma based on crosstalk and network pathways. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	2
810	Nanoparticle and Targeted Systems for Colon Cancer Therapy. , 2016, , 695-713.		0
811	The PI3K/Akt Pathway in Tumors of Endocrine Tissues. <i>Frontiers in Endocrinology</i> , 2015, 6, 188.	1.5	104
812	The CLC-2 Chloride Channel Modulates ECM Synthesis, Differentiation, and Migration of Human Conjunctival Fibroblasts via the PI3K/Akt Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2016, 17, 910.	1.8	17
813	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. <i>PLoS Medicine</i> , 2016, 13, e1002136.	3.9	28
814	The Anticancer Properties of Herba Epimedii and Its Main Bioactive Components icariin and Icariside II. <i>Nutrients</i> , 2016, 8, 563.	1.7	50

#	ARTICLE	IF	CITATIONS
815	Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. Translational Oncogenomics, 2016, Suppl. 1, 33-49.	1.7	25
816	PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget, 2016, 7, 33440-33450.	0.8	400
817	Phase Ib trial of the <scp>PI</scp>3K</scp>/<scp>mTOR</scp> inhibitor voxtalisib (<scp>SAR</scp>245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B–cell malignancies. British Journal of Haematology, 2016, 175, 55-65.	1.2	12
818	PI3K target based novel cyano derivative of betulinic acid induces its signalling inhibition by down-regulation of pGSK3 ^β and cyclin D1 and potentially checks cancer cell proliferation. Molecular Carcinogenesis, 2016, 55, 964-976.	1.3	15
819	Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer. Medicine (United States), 2016, 95, e2803.	0.4	21
820	SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance. Cell Proliferation, 2016, 49, 195-206.	2.4	37
821	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. Cancer Drug Discovery and Development, 2016, , 109-124.	0.2	0
822	Discovery of a novel target for cancer: PRR14. Cell Death and Disease, 2016, 7, e2502-e2502.	2.7	6
823	Interplay between cell cycle and autophagy induced by boswellic acid analog. Scientific Reports, 2016, 6, 33146.	1.6	24
824	Progestins and carcinogenesis. Molecular Biology, 2016, 50, 7-21.	0.4	5
825	Unconventional Protein Secretion: Fibroblast Growth Factor 2 and Interleukin-1 ^β as Examples. , 2016, , 520-527.		1
826	The hVps34–<scp>SCK</scp> 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating <scp>mTORC</scp> 1 and tumour–growth. EMBO Journal, 2016, 35, 1902-1922.	3.5	77
827	Clinicopathological significance of caspase-3 and Ki-67 expression in canine mammary gland tumours. Acta Veterinaria Hungarica, 2016, 64, 78-89.	0.2	8
828	mTOR Signaling Confers Resistance to Targeted Cancer Drugs. Trends in Cancer, 2016, 2, 688-697.	3.8	65
829	A new role under sortilin's belt in cancer. Communicative and Integrative Biology, 2016, 9, e1130192.	0.6	26
830	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. European Journal of Medicinal Chemistry, 2016, 117, 47-58.	2.6	26
831	Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. Journal of Controlled Release, 2016, 232, 131-142.	4.8	83
832	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer and Metastasis Reviews, 2016, 35, 413-426.	2.7	44

#	ARTICLE	IF	CITATIONS
833	A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. <i>Journal of Proteomics</i> , 2016, 145, 91-102.	1.2	21
834	New halogenated constituents from <i>Mangifera zeylanica</i> Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells. <i>Journal of Ethnopharmacology</i> , 2016, 189, 165-174.	2.0	17
835	Validation and determination of taselisib, a \hat{I}^2 -sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 126, 117-123.	1.4	6
836	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5488-5504.	2.9	53
837	Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors. <i>Nuclear Medicine and Biology</i> , 2016, 43, 101-107.	0.3	6
838	IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis. <i>Endocrine-Related Cancer</i> , 2016, 23, 481-493.	1.6	25
839	Computational modeling in melanoma for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 609-621.	2.5	15
840	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1412-1424.	1.9	16
841	The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date. <i>Drugs</i> , 2016, 76, 639-646.	4.9	20
842	Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2016, 473, 1170-1176.	1.0	32
843	Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2897-2906.	1.4	8
844	The Anti-Oxidant and Antitumor Properties of Plant Polysaccharides. <i>The American Journal of Chinese Medicine</i> , 2016, 44, 463-488.	1.5	125
845	Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. <i>European Journal of Medicinal Chemistry</i> , 2016, 117, 283-291.	2.6	14
846	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. <i>Cancer Cell</i> , 2016, 29, 711-722.	7.7	242
847	Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 83-90.	1.1	5
848	Piperazine derivatives for therapeutic use: a patent review (2010-present). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 777-797.	2.4	140
849	Naringenin pre-treatment inhibits neuroapoptosis and ameliorates cognitive impairment in rats exposed to isoflurane anesthesia by regulating the PI3/Akt/PTEN signalling pathway and suppressing NF- κ B-mediated inflammation. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1271-1280.	1.8	58
850	Current Status of Clinical Genomics in Patients with Metastatic Breast Cancer. <i>Breast Diseases</i> , 2016, 27, 182-186.	0.0	0

#	ARTICLE	IF	CITATIONS
851	Role of Herpes simplex virus 1 VP11/12 tyrosine-based binding motifs for Src family kinases, p85, Grb2 and Shc in activation of the phosphoinositide 3-kinase-Akt pathway. <i>Virology</i> , 2016, 498, 31-35.	1.1	11
852	Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms. <i>Tumor Biology</i> , 2016, 37, 15411-15431.	0.8	27
853	Nutrient restriction of glucose or serum results in similar proteomic expression changes in 3D colon cancer cell cultures. <i>Nutrition Research</i> , 2016, 36, 1068-1080.	1.3	31
854	Molecular Genetics of Pancreatic Neoplasms. <i>Surgical Pathology Clinics</i> , 2016, 9, 685-703.	0.7	12
855	Mechanism analysis of colorectal cancer according to the microRNA expression profile. <i>Oncology Letters</i> , 2016, 12, 2329-2336.	0.8	16
856	Downregulation of RUVBL1 inhibits proliferation of lung adenocarcinoma cells by G1/S phase cell cycle arrest via multiple mechanisms. <i>Tumor Biology</i> , 2016, 37, 16015-16027.	0.8	18
858	Rosemary extract reduces Akt/mTOR/p70S6K activation and inhibits proliferation and survival of A549 human lung cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 725-732.	2.5	50
859	Better understanding of phosphoinositide 3-kinase (PI3K) pathways in vasculature: Towards precision therapy targeting angiogenesis and tumor blood supply. <i>Biochemistry (Moscow)</i> , 2016, 81, 691-699.	0.7	12
860	Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. <i>Oncology Reports</i> , 2016, 36, 1173-1179.	1.2	41
861	Therapeutic significance of quinolines: a patent review (2013-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1201-1221.	2.4	51
862	A phase I, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 316-323.	1.0	4
863	Synthesis, structures elucidation, DNA-PK, PI3K and antiplatelet activity of a series of novel 7- or 8-(N-substituted)-2-morpholino-quinazolines. <i>Medicinal Chemistry Research</i> , 2016, 25, 1695-1704.	1.1	1
864	Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells. <i>Cancer Science</i> , 2016, 107, 307-314.	1.7	20
865	p110 [±] and p110 ² isoforms of PI3K signaling: are they two sides of the same coin?. <i>FEBS Letters</i> , 2016, 590, 3071-3082.	1.3	20
866	Small Molecule Inhibitors Targeting Tec Kinase Block Unconventional Secretion of Fibroblast Growth Factor 2. <i>Journal of Biological Chemistry</i> , 2016, 291, 17787-17803.	1.6	32
867	MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3 ^β signaling pathway. <i>Gene</i> , 2016, 593, 84-90.	1.0	72
868	Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. <i>Experimental Cell Research</i> , 2016, 349, 320-327.	1.2	76
869	Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases. <i>Nature Cell Biology</i> , 2016, 18, 1324-1335.	4.6	109

#	ARTICLE	IF	CITATIONS
870	Promotion of mitotic catastrophe via activation of PTEN by paclitaxel with supplement of mulberry water extract in bladder cancer cells. <i>Scientific Reports</i> , 2016, 6, 20417.	1.6	27
871	Structural insight into inhibition of human Class II PI3K isoforms: homology modeling, binding site characterization, docking and molecular dynamics studies. <i>RSC Advances</i> , 2016, 6, 112455-112467.	1.7	3
872	Discovery of Chromeno[4,3- <i>c</i>]pyrazol-4(2 <i>H</i>)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3K. <i>Chemical and Pharmaceutical Bulletin</i> , 2016, 64, 1576-1581.	0.6	15
873	The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 97.	3.5	36
874	Addition of the p110 α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. <i>Tumor Biology</i> , 2016, 37, 14831-14839.	0.8	6
875	Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7268-7274.	2.9	35
876	Serum- and glucocorticoid-regulated protein kinase 3 overexpression promotes tumor development and aggression in breast cancer cells. <i>Oncology Letters</i> , 2016, 12, 437-444.	0.8	9
877	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <i>Gynecologic Oncology</i> , 2016, 142, 548-556.	0.6	80
878	6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K- α inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 731-743.	2.6	39
879	Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT/NF- κ B/CXCL5 signaling. <i>Scientific Reports</i> , 2016, 6, 37085.	1.6	29
880	Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signalling pathway. <i>Bioscience Reports</i> , 2016, 36, .	1.1	30
881	Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K. <i>International Journal of Oncology</i> , 2016, 49, 1148-1154.	1.4	6
882	Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. <i>Scientific Reports</i> , 2016, 6, 21557.	1.6	75
883	Concurrent PI3K and NF- κ B activation drives B-cell lymphomagenesis. <i>Leukemia</i> , 2016, 30, 2267-2270.	3.3	4
884	DNA Repair Pathways as a Potential Target for Radiosensitization. , 2016, , 253-287.		0
885	PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma. <i>Tumor Biology</i> , 2016, 37, 16227-16236.	0.8	49
886	Role of phosphatidylinositol-4,5-bisphosphate 3-kinase signaling in vesicular trafficking. <i>Life Sciences</i> , 2016, 167, 39-45.	2.0	17
887	The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3K β/γ inhibitor. <i>EJNMMI Research</i> , 2016, 6, 62.	1.1	13

#	ARTICLE	IF	CITATIONS
888	Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 267-273.	1.0	9
889	Analysis of PI3K pathway components in human cancers. <i>Oncology Letters</i> , 2016, 11, 2913-2918.	0.8	21
890	Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. <i>American Journal of Surgery</i> , 2016, 211, 755-760.	0.9	7
891	14-Deoxy-11,12-didehydroandrographolide induces DDIT3-dependent endoplasmic reticulum stress-mediated autophagy in T-47D breast carcinoma cells. <i>Toxicology and Applied Pharmacology</i> , 2016, 300, 55-69.	1.3	19
892	Î ² -2-himachalen-6-ol: A novel anticancer sesquiterpene unique to the Lebanese wild carrot. <i>Journal of Ethnopharmacology</i> , 2016, 190, 59-67.	2.0	13
893	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. <i>Journal of Translational Medicine</i> , 2016, 14, 67.	1.8	42
894	Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model. <i>Pharmaceutical Research</i> , 2016, 33, 2540-2551.	1.7	15
895	Ras Conformational Ensembles, Allostery, and Signaling. <i>Chemical Reviews</i> , 2016, 116, 6607-6665.	23.0	290
896	Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 905-926.	1.1	15
897	Targeting therapeutic liabilities engendered by <i>PIK3R1</i> mutations for cancer treatment. <i>Pharmacogenomics</i> , 2016, 17, 297-307.	0.6	36
898	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. <i>Molecular Pharmaceutics</i> , 2016, 13, 784-794.	2.3	29
899	Gastric cardia adenocarcinoma microRNA profiling in Chinese patients. <i>Tumor Biology</i> , 2016, 37, 9411-9422.	0.8	25
900	DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. <i>Tumor Biology</i> , 2016, 37, 9221-9232.	0.8	3
901	Biological and clinical significance of loss of heterozygosity at the INPP4B gene locus in Japanese breast cancer. <i>Breast</i> , 2016, 25, 62-68.	0.9	7
902	AKT and JNK Signaling Pathways Increase the Metastatic Potential of Colorectal Cancer Cells by Altering Transgelin Expression. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1091-1097.	1.1	20
903	Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K. <i>Cell Adhesion and Migration</i> , 2016, 10, 269-281.	1.1	35
904	Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	30
905	Targeting of proangiogenic signalling pathways in chronic inflammation. <i>Nature Reviews Rheumatology</i> , 2016, 12, 111-122.	3.5	93

#	ARTICLE	IF	CITATIONS
906	PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 13-26.	1.6	66
907	PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. <i>Oncogene</i> , 2016, 35, 2961-2970.	2.6	30
908	Hyperlipidemia, Disease Associations, and Top 10 Potential Drug Targets: A Network View. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 152-168.	1.0	16
909	Emerging therapeutic targets in metastatic progression: A focus on breast cancer. , 2016, 161, 79-96.		53
910	Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. <i>Biomedical Reports</i> , 2016, 4, 365-368.	0.9	30
911	Theoretical calculations, DNA interaction, topoisomerase I and phosphatidylinositol-3-kinase studies of water soluble mixed-ligand nickel(II) complexes. <i>Chemico-Biological Interactions</i> , 2016, 248, 21-35.	1.7	21
912	Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 298-346.	2.6	55
913	Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF β signaling. <i>Oncogene</i> , 2016, 35, 4641-4652.	2.6	65
914	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 18-22.	1.1	22
915	mTOR Inhibition Beyond Rapalogs. , 2016, , 251-275.		1
916	Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. <i>Tumor Biology</i> , 2016, 37, 7033-7045.	0.8	49
917	Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling. <i>Journal of Biological Chemistry</i> , 2016, 291, 5221-5233.	1.6	25
918	The Rational Design of Selective Benzoxazepin Inhibitors of the β -Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[<i>f</i>]imidazo[1,2- <i>d</i>][1,4]oxazepin-9-yl)oxy)propanoic acid (GDC-0326). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 985-1002.	2.9	87
919	Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells. <i>Tumor Biology</i> , 2016, 37, 7989-8005.	0.8	21
920	Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 644-654.	2.6	28
921	MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. <i>Tumor Biology</i> , 2016, 37, 8047-8055.	0.8	9
922	The Dynamics of Cell Motility. <i>Science Policy Reports</i> , 2016, , 89-110.	0.1	0
923	The best of both worlds – managing the cancer, saving the bone. <i>Nature Reviews Endocrinology</i> , 2016, 12, 29-42.	4.3	35

#	ARTICLE	IF	CITATIONS
924	The Role of Energy Balance in Cancer Prevention. , 2016, , 321-337.		0
925	MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. <i>Tumor Biology</i> , 2016, 37, 3939-3947.	0.8	41
926	Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2016, 23, R43-R69.	1.6	52
927	Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt. <i>Journal of Gastroenterology</i> , 2016, 51, 230-240.	2.3	38
928	Dysregulation of ErbB Receptor Trafficking and Signaling in Demyelinating Charcot-Marie-Tooth Disease. <i>Molecular Neurobiology</i> , 2017, 54, 87-100.	1.9	23
929	Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 436-446.	2.0	41
930	Discovery of a Phosphoinositide 3-Kinase (PI3K) \hat{I}^2/\hat{I}^1 Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K \hat{I}^2 Potency in a PI3K \hat{I}^1 -Selective Template by Targeting Nonconserved Asp856. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1555-1567.	2.9	27
931	Prostate cancer, PI3K, PTEN and prognosis. <i>Clinical Science</i> , 2017, 131, 197-210.	1.8	146
932	The IgM receptor Fc $\hat{I}^{1/4}$ R limits tonic BCR signaling by regulating expression of the IgM BCR. <i>Nature Immunology</i> , 2017, 18, 321-333.	7.0	69
933	Quercetin Attenuates Cell Survival, Inflammation, and Angiogenesis via Modulation of AKT Signaling in Murine T-Cell Lymphoma. <i>Nutrition and Cancer</i> , 2017, 69, 470-480.	0.9	37
934	Targeting protein kinase-b3 (akt3) signaling in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 273-290.	1.5	16
935	Enteric nervous system development: A crest cellâ€™s journey from neural tube to colon. <i>Seminars in Cell and Developmental Biology</i> , 2017, 66, 94-106.	2.3	163
936	Prostate Cancer Metastasis. , 2017, , 33-59.		2
937	Dihydromyricetin induces mitochondria-mediated apoptosis in HepG2 cells through down-regulation of the Akt/Bad pathway. <i>Nutrition Research</i> , 2017, 38, 27-33.	1.3	34
938	miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 2310-2320.	2.3	46
939	Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. <i>Metallomics</i> , 2017, 9, 471-481.	1.0	70
940	Protection against cerebral infarction by Withaferin A involves inhibition of neuronal apoptosis, activation of PI3K/Akt signaling pathway, and reduced intimal hyperplasia via inhibition of VSMC migration and matrix metalloproteinases. <i>Advances in Medical Sciences</i> , 2017, 62, 186-192.	0.9	25
941	Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2129-2139.	1.6	28

#	ARTICLE	IF	CITATIONS
942	Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). <i>Molecular Pharmacology</i> , 2017, 91, 499-517.	1.0	22
943	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	2.1	471
944	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498.	1.5	4
945	Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. <i>Oncologist</i> , 2017, 22, 377-e37.	1.9	25
946	Autophagy is the key process in the re-establishment of the epitheloid phenotype during mesenchymal-epithelial transition (MET). <i>Experimental Cell Research</i> , 2017, 352, 382-392.	1.2	8
947	Anti-tumor activity of PI3K- γ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 85, 149-158.	1.2	22
948	The crosstalk between long non-coding RNAs and PI3K in cancer. <i>Medical Oncology</i> , 2017, 34, 39.	1.2	20
949	MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. <i>Oncology Reports</i> , 2017, 37, 631-639.	1.2	33
950	Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 485, 54-61.	1.0	56
951	Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769431.	0.8	12
952	Iodine catalyzed three component synthesis of 1-((2-hydroxy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 Td (naphthalen-1-yl)(phenyl)(m anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2510-2514.	1.0	22
953	Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin's neuroprotective activity after focal cerebral ischemia in mice. <i>Redox Biology</i> , 2017, 12, 657-665.	3.9	91
954	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. <i>Scientific Reports</i> , 2017, 7, 46079.	1.6	23
955	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. <i>Endocrine-Related Cancer</i> , 2017, 24, R239-R259.	1.6	16
956	Dalbergia odorifera extract promotes angiogenesis through upregulation of VEGFRs and PI3K/MAPK signaling pathways. <i>Journal of Ethnopharmacology</i> , 2017, 204, 132-141.	2.0	21
957	An overview of quinoline as a privileged scaffold in cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 583-597.	2.5	164
958	Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4023-4035.	2.9	29
959	New insight for metformin against bladder cancer. <i>Genes and Environment</i> , 2017, 39, 13.	0.9	20

#	ARTICLE	IF	CITATIONS
960	ROS in Cancer: The Burning Question. Trends in Molecular Medicine, 2017, 23, 411-429.	3.5	398
961	Matrine promotes oligodendrocyte development in CNS autoimmunity through the PI3K/Akt signaling pathway. Life Sciences, 2017, 180, 36-41.	2.0	32
962	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 2017, 17, 211.	1.1	24
963	An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms. Journal of Cellular Biochemistry, 2017, 118, 4558-4567.	1.2	29
964	SHORT syndrome in a two-year-old girl – case report. Italian Journal of Pediatrics, 2017, 43, 44.	1.0	19
965	Discovery of a novel aminopyrazine series as selective PI3K inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3030-3035.	1.0	6
966	PI3K is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3964-E3973.	3.3	54
967	Neuroprotection by plumbagin involves BDNF-TrkB-PI3K/Akt and ERK1/2/JNK pathways in isoflurane-induced neonatal rats. Journal of Pharmacy and Pharmacology, 2017, 69, 896-906.	1.2	34
968	TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1. Oncogenesis, 2017, 6, e323-e323.	2.1	12
969	Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clinical Cancer Research, 2017, 23, 4919-4928.	3.2	74
970	Metformin and Prostate Cancer: a New Role for an Old Drug. Current Urology Reports, 2017, 18, 46.	1.0	77
971	Linoleic acid induces migration and invasion through FFAR4- and PI3K-/Akt-dependent pathway in MDA-MB-231 breast cancer cells. Medical Oncology, 2017, 34, 111.	1.2	29
972	Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. Human Cell, 2017, 30, 140-148.	1.2	3
973	Maximising the potential of AKT inhibitors as anti-cancer treatments. , 2017, 172, 101-115.		177
974	EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells. Cancer Letters, 2017, 403, 119-127.	3.2	14
975	Human papillomavirus-related oropharyngeal cancer. Annals of Oncology, 2017, 28, 2386-2398.	0.6	270
976	Multiple functions of insulin-degrading enzyme: a metabolic crosslight?. Critical Reviews in Biochemistry and Molecular Biology, 2017, 52, 554-582.	2.3	73
977	Laminin-111 and the Level of Nuclear Actin Regulate Epithelial Quiescence via Exportin-6. Cell Reports, 2017, 19, 2102-2115.	2.9	68

#	ARTICLE	IF	CITATIONS
978	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 5044-5054.	3.2	54
979	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 335-346.	1.4	39
980	Puquitinib, a novel orally available PI3K \hat{I} inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. <i>Cancer Science</i> , 2017, 108, 1476-1484.	1.7	23
981	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K \hat{I} Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 5015-5023.	3.2	65
982	HIF $\hat{1}$ regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2896-2908.	1.6	25
983	Stressor-driven extracellular acidosis as tumor inducer via aberrant enzyme activation: A review on the mechanisms and possible prophylaxis. <i>Gene</i> , 2017, 626, 209-214.	1.0	17
984	PI(3,4)P ₂ plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cells. <i>Cancer Science</i> , 2017, 108, 941-951.	1.7	27
985	Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins. <i>Oncology Letters</i> , 2017, 13, 4785-4793.	0.8	15
986	Anticancer effects of oleuropein. <i>BioFactors</i> , 2017, 43, 517-528.	2.6	76
987	Generation of tricyclic imidazo[1,2- a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2536-2543.	1.0	10
988	Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. <i>Oncology Reports</i> , 2017, 37, 2071-2078.	1.2	47
989	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 704-715.	7.7	127
990	Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. <i>Cell Death and Disease</i> , 2017, 8, e2701-e2701.	2.7	23
991	Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 148-156.	3.3	16
992	Molecular biomarkers for lung adenocarcinoma. <i>European Respiratory Journal</i> , 2017, 49, 1601734.	3.1	110
993	Lanatoside C, a cardiac glycoside, acts through protein kinase C \hat{I} to cause apoptosis of human hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2017, 7, 46134.	1.6	34
994	Duvelisib: a phosphoinositide-3 kinase \hat{I} \hat{I} $\hat{3}$ inhibitor for chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 625-632.	1.9	60
995	Dalbergioidin (DAL) protects MC3T3-E1 osteoblastic cells against H ₂ O ₂ -induced cell damage through activation of the PI3K/AKT/SMAD1 pathway. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 711-720.	1.4	7

#	ARTICLE	IF	CITATIONS
996	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	5.8	112
997	Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives. <i>Pure and Applied Chemistry</i> , 2017, 89, 1267-1281.	0.9	5
998	The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 123-131.	3.3	117
999	Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3K \hat{I} inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1972-1977.	1.0	21
1000	A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 89-98.	1.1	32
1001	Effect of small molecules on cell reprogramming. <i>Molecular BioSystems</i> , 2017, 13, 277-313.	2.9	19
1002	Valproic acid attenuates renal fibrosis through the induction of autophagy. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 771-780.	0.7	29
1003	Enzyme Tunnels and Gates As Relevant Targets in Drug Design. <i>Medicinal Research Reviews</i> , 2017, 37, 1095-1139.	5.0	65
1004	Re-calculating! Navigating through the osteosarcoma treatment roadblock. <i>Pharmacological Research</i> , 2017, 117, 54-64.	3.1	19
1005	Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 56, 700-707.	1.4	65
1006	Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1 \hat{I} pathway. <i>Cancer Letters</i> , 2017, 410, 82-91.	3.2	33
1007	Inhibiting PI3K \hat{I} with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 7584-7595.	3.2	24
1008	Phosphoinositide Diversity, Distribution, and Effector Function: Stepping Out of the Box. <i>BioEssays</i> , 2017, 39, 1700121.	1.2	50
1009	Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 721-733.	2.6	14
1010	Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/ \hat{I} 2-Catenin and PI3K/Akt Signaling. <i>Clinical Cancer Research</i> , 2017, 23, 7340-7350.	3.2	41
1011	Expression and Function of hsa-miR-6165 in Human Cell Lines and During the NT2 Cell Neural Differentiation Process. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 254-266.	1.1	10
1012	Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 142, 493-505.	2.6	30
1013	Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities. <i>Archiv Der Pharmazie</i> , 2017, 350, 1700242.	2.1	17

#	ARTICLE	IF	CITATIONS
1014	Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM). <i>Cancer Biomarkers</i> , 2017, 20, 581-588.	0.8	4
1015	Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors. <i>Annals of Oncology</i> , 2017, 28, 2882-2887.	0.6	9
1016	Lactoferrin induces tropoelastin expression by activating the lipoprotein receptor-related protein 1-mediated phosphatidylinositol 3-kinase/Akt pathway in human dermal fibroblasts. <i>Cell Biology International</i> , 2017, 41, 1325-1334.	1.4	9
1017	Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2017, 46, 158-181.	4.3	57
1018	The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes. <i>Oncogene</i> , 2017, 36, 6774-6783.	2.6	74
1019	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7524-7538.	2.9	109
1020	Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment. <i>Future Science OA</i> , 2017, 3, FSO204.	0.9	15
1021	Soft Substrates Containing Hyaluronan Mimic the Effects of Increased Stiffness on Morphology, Motility, and Proliferation of Glioma Cells. <i>Biomacromolecules</i> , 2017, 18, 3040-3051.	2.6	70
1022	Polo-like kinase 3, hypoxic responses, and tumorigenesis. <i>Cell Cycle</i> , 2017, 16, 2032-2036.	1.3	18
1023	Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961772535.	0.3	16
1024	Synthesis and preliminary in vivo evaluation of new [18F]fluoro-inositols as Positron Emission Tomography radiotracers. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5603-5612.	1.4	0
1025	Genistein: Its role in metabolic diseases and cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 13-22.	2.0	180
1026	Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5859-5874.	1.4	14
1027	An emerging case for membrane pore formation as a common mechanism for the unconventional secretion of FGF2 and IL-1 β . <i>Journal of Cell Science</i> , 2017, 130, 3197-3202.	1.2	39
1028	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 93-101.	3.4	191
1029	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. <i>Journal of Hepatology</i> , 2017, 67, 1194-1203.	1.8	77
1030	New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. <i>European Journal of Cancer</i> , 2017, 83, 56-70.	1.3	82
1031	Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 875-880.	1.3	28

#	ARTICLE	IF	CITATIONS
1032	Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K β inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 95-106.	2.6	38
1033	Apoptosis, Autophagy, and Unfolded Protein Response and Cerebellar Development. , 2017, , 153-178.		2
1034	Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BE2325 on human melanoma. <i>Cancer Letters</i> , 2017, 406, 1-11.	3.2	46
1035	The molecular mechanism underlying unconventional secretion of Fibroblast Growth Factor 2 from tumour cells. <i>Biology of the Cell</i> , 2017, 109, 375-380.	0.7	9
1036	ErbB2-positive mammary tumors can escape PI3K-p110 β loss through downregulation of the Pten tumor suppressor. <i>Oncogene</i> , 2017, 36, 6059-6066.	2.6	7
1037	Expression of α CPPE1 in human trophoblasts is associated with timing of term birth. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 968-981.	1.6	10
1039	Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells. <i>Cell Death Discovery</i> , 2017, 3, 17072.	2.0	35
1040	Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors. <i>RSC Advances</i> , 2017, 7, 52180-52186.	1.7	19
1041	Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3 β /ANG Signaling Pathway in Anaplastic Thyroid Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1471-1484.	1.1	61
1042	A Dual Macrophage Targeting Nanovector for Delivery of Oligodeoxynucleotides To Overcome Cancer-Associated Immunosuppression. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 42566-42576.	4.0	48
1043	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1095-1103.	0.8	99
1044	Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. <i>International Immunopharmacology</i> , 2017, 53, 149-157.	1.7	71
1045	Targeting PI3K/AKT/mTOR Pathway. , 2017, , 787-793.		0
1046	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	1.3	34
1047	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5981-5992.	3.2	107
1048	AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. <i>Oncology Letters</i> , 2017, 14, 981-986.	0.8	10
1050	Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 27.	3.5	101
1051	Identification of peptide-mediated interactions between human PTTC and SH3 domains in pALL gene expression profile. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 76, 11-16.	1.3	4

#	ARTICLE	IF	CITATIONS
1052	Kinase-driven metabolic signalling as a predictor of response to carboplatin and paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017, 117, 494-502.	2.9	10
1053	Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signaling pathway. <i>Journal of Molecular Medicine</i> , 2017, 95, 311-322.	1.7	44
1054	Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. <i>Journal of Radiation Research</i> , 2017, 58, 183-194.	0.8	9
1055	MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. <i>Gene</i> , 2017, 596, 110-118.	1.0	81
1056	Neuroprotection of Ro25-6981 Against Ischemia/Reperfusion-Induced Brain Injury via Inhibition of Autophagy. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 743-752.	1.7	27
1057	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 176-189.	2.2	44
1058	Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL. <i>Integrative Cancer Therapies</i> , 2017, 16, 526-539.	0.8	17
1059	Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway. <i>Pharmacology</i> , 2017, 99, 188-195.	0.9	34
1060	Pathology of Anal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 57-71.	0.6	45
1061	Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. <i>Journal of Drug Targeting</i> , 2017, 25, 189-201.	2.1	21
1062	NPPB modulates apoptosis, proliferation, migration and extracellular matrix synthesis of conjunctival fibroblasts by inhibiting PI3K/AKT signaling. <i>International Journal of Molecular Medicine</i> , 2017, 41, 1331-1338.	1.8	7
1063	Carcinoma associated fibroblasts derived from oral squamous cell carcinoma promote lymphangiogenesis via c-Met/PI3K/AKT in vitro. <i>Oncology Letters</i> , 2017, 15, 331-337.	0.8	16
1064	Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells. <i>Oncology Research</i> , 2017, 25, 1283-1295.	0.6	7
1065	Functional characterization of a novel somatic oncogenic mutation of PIK3CB. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17063.	7.1	28
1066	PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT). <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 91-93.	0.9	15
1067	Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5703-5710.	1.0	13
1068	GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers. <i>Journal of Korean Medical Science</i> , 2017, 32, 1784.	1.1	14
1069	Phytochemicals and PI3K Inhibitors in Cancer: An Insight. <i>Frontiers in Pharmacology</i> , 2017, 8, 916.	1.6	36

#	ARTICLE	IF	CITATIONS
1070	Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3. <i>Journal of Cancer</i> , 2017, 8, 3742-3754.	1.2	30
1071	Somatic Host Cell Alterations in HPV Carcinogenesis. <i>Viruses</i> , 2017, 9, 206.	1.5	55
1072	GGNBP2 Suppresses the Proliferation, Invasion, and Migration of Human Glioma Cells. <i>Oncology Research</i> , 2017, 25, 831-842.	0.6	13
1073	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
1074	FANCD2 and DNA Damage. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1804.	1.8	42
1075	A Review on the Medicinal Plant <i>Dalbergia odorifera</i> Species: Phytochemistry and Biological Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-27.	0.5	37
1076	De Novo PTEN Mutation in a Young Boy with Cutaneous Vasculitis. <i>Case Reports in Pediatrics</i> , 2017, 2017, 1-4.	0.2	12
1077	MELK is not necessary for the proliferation of basal-like breast cancer cells. <i>ELife</i> , 2017, 6, .	2.8	86
1078	Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 395-403.	0.9	19
1079	Î²-carotene at physiologically attainable concentration induces apoptosis and down-regulates cell survival and antioxidant markers in human breast cancer (MCF-7) cells. <i>Molecular and Cellular Biochemistry</i> , 2017, 436, 1-12.	1.4	62
1081	Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells. <i>International Journal of Oncology</i> , 2017, 51, 1320-1330.	1.4	5
1082	Silencing of type IÎ³ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion. <i>Oncology Reports</i> , 2017, 38, 253-262.	1.2	3
1083	Racial disparity in metabolic regulation of cancer. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 1221-1246.	3.0	5
1084	Recent Advances on Nucleotide Analogs and Mimetics. , 2017, , .		2
1085	Selective Kinase Inhibitors in Cancer. , 2017, , 39-75.		4
1086	Ghrelin and gastrointestinal stromal tumors. <i>World Journal of Gastroenterology</i> , 2017, 23, 1758.	1.4	15
1087	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	1.0	56
1088	Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. <i>Oncotarget</i> , 2017, 8, 38755-38766.	0.8	83

#	ARTICLE	IF	CITATIONS
1089	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
1090	Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer. <i>New Biotechnology</i> , 2018, 45, 28-35.	2.4	20
1091	Targeting the PI3K pathway in cancer: are we making headway?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 273-291.	12.5	762
1092	LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. <i>Cancer Letters</i> , 2018, 420, 38-48.	3.2	46
1093	Ethnic differences in TGF β -signaling pathway may contribute to prostate cancer health disparity. <i>Carcinogenesis</i> , 2018, 39, 546-555.	1.3	16
1094	Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 555-564.	0.6	0
1095	Curcumin analogue 1,5-bis(4-hydroxy-3-((4-methylpiperazin-1-yl)methyl)phenyl)penta-1,4-dien-3-one mediates growth arrest and apoptosis by targeting the PI3K/AKT/mTOR and PKC-theta signaling pathways in human breast carcinoma cells. <i>Bioorganic Chemistry</i> , 2018, 78, 46-57.	2.0	30
1096	Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3K δ) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2028-2040.	1.4	21
1100	Synthesis, characterization, and bioactivity of new bisamidrazone derivatives as possible anticancer agents. <i>Medicinal Chemistry Research</i> , 2018, 27, 1419-1431.	1.1	6
1101	Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. <i>Cancer Research</i> , 2018, 78, 2179-2190.	0.4	33
1102	Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. <i>Oncologist</i> , 2018, 23, 660-669.	1.9	16
1103	Electroacupuncture Mitigates Endothelial Dysfunction via Effects on the Pi3K/Akt Signalling Pathway in High Fat Diet-Induced Insulin-Resistant Rats. <i>Acupuncture in Medicine</i> , 2018, 36, 162-169.	0.4	9
1104	Phosphate toxicity and tumorigenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 303-309.	3.3	81
1105	PI3K-AKT-GSK3 β -CREB signaling pathway regulates anxiety-like behavior in rats following alcohol withdrawal. <i>Journal of Affective Disorders</i> , 2018, 235, 96-104.	2.0	29
1106	First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). <i>European Journal of Cancer</i> , 2018, 96, 6-16.	1.3	51
1107	Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. <i>Cell</i> , 2018, 173, 879-893.e13.	13.5	777
1108	Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. <i>Cancer Science</i> , 2018, 109, 1592-1601.	1.7	24
1109	Isolation and evaluation of phytoconstituents from red alga <i>Acanthophora spicifera</i> as potential apoptotic agents towards A549 and HeLa cancer cells lines. <i>Algal Research</i> , 2018, 32, 172-181.	2.4	11

#	ARTICLE	IF	CITATIONS
1110	Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches. <i>Future Medicinal Chemistry</i> , 2018, 10, 879-894.	1.1	5
1111	Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K/AKT inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1675-1685.	1.4	25
1112	Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3K/AKT. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 460-470.	2.6	16
1113	Association of urinary and plasma DNA in early breast cancer patients and its links to disease relapse. <i>Clinical and Translational Oncology</i> , 2018, 20, 1053-1060.	1.2	13
1114	LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle. <i>Oncogenesis</i> , 2018, 7, 3.	2.1	7
1115	Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling. <i>Clinical Science</i> , 2018, 132, 381-397.	1.8	17
1116	GSK-3 Inhibitors: A Double-Edged Sword? An Update on Tideglusib. <i>Drug Research</i> , 2018, 68, 436-443.	0.7	14
1117	Nuclear Phosphatidylinositol-Phosphate Type I Kinase β -Coupled Star-PAP Polyadenylation Regulates Cell Invasion. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	9
1118	Identification of Natural Products as Novel PI3K/AKT Inhibitors Through Pharmacophore-based Virtual Screening. <i>Bulletin of the Korean Chemical Society</i> , 2018, 39, 294-299.	1.0	1
1119	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 637-646.	1.4	5
1120	PI3K inhibition to overcome endocrine resistance in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 1-15.	1.9	38
1121	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
1122	Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. <i>Journal of Digestive Diseases</i> , 2018, 19, 74-83.	0.7	142
1123	Activation of AKT-mTOR Signaling Directs Tenogenesis of Mesenchymal Stem Cells. <i>Stem Cells</i> , 2018, 36, 527-539.	1.4	36
1124	BCScreen: A gene panel to test for breast carcinogenesis in chemical safety screening. <i>Computational Toxicology</i> , 2018, 5, 16-24.	1.8	10
1125	Graph-Theoretic Analysis of Monomethyl Phosphate Clustering in Ionic Solutions. <i>Journal of Physical Chemistry B</i> , 2018, 122, 1484-1494.	1.2	46
1126	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 379-389.	3.0	111
1127	Bayesian graphical models for computational network biology. <i>BMC Bioinformatics</i> , 2018, 19, 63.	1.2	13

#	ARTICLE	IF	CITATIONS
1128	AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity. <i>BMC Cancer</i> , 2018, 18, 249.	1.1	11
1129	A Phase I, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 873-883.	1.1	15
1130	Phthalimide conjugations for the degradation of oncogenic PI3K. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 237-247.	2.6	73
1131	Hederacolchiside A1 suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. <i>Chinese Herbal Medicines</i> , 2018, 10, 215-222.	1.2	3
1132	In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). <i>Neurogenetics</i> , 2018, 19, 77-91.	0.7	65
1133	Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 311-320.	0.2	35
1134	Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3K δ) inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 651-656.	2.5	7
1135	Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1104-1119.	2.0	15
1136	A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of vixtalib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 36-44.	1.2	10
1137	Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?. <i>Seminars in Cancer Biology</i> , 2018, 48, 70-77.	4.3	28
1138	Integrated In Silico In Vitro Identification and Characterization of the SH3-Mediated Interaction between Human PTTG and its Cognate Partners in Medulloblastoma. <i>Cell Biochemistry and Biophysics</i> , 2018, 76, 83-90.	0.9	1
1139	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	3.2	92
1140	Small Molecules Drive Big Improvements in Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 4412-4428.	7.2	116
1141	Kleine Moleküle, ganz groß: niedermolekulare immunonkologische Kombinationstherapien. <i>Angewandte Chemie</i> , 2018, 130, 4499-4516.	1.6	1
1142	First-in-human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	2.0	29
1143	PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium. <i>International Journal of Pharmaceutics</i> , 2018, 548, 747-758.	2.6	40
1144	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2018, 37, 377-388.	2.6	29
1145	Copy Number Abnormalities and Gene Fusions in Lung Cancer. , 2018, , 82-94.e4.		0

#	ARTICLE	IF	CITATIONS
1146	Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 563-587.	2.4	29
1147	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLX4723 on Mantle cell lymphoma. <i>International Journal of Cancer</i> , 2018, 142, 202-213.	2.3	21
1148	GOLM1 promotes prostate cancer progression through activating PI3K/AKT/mTOR signaling. <i>Prostate</i> , 2018, 78, 166-177.	1.2	60
1149	Re-evaluating the role of FOXOs in cancer. <i>Seminars in Cancer Biology</i> , 2018, 50, 90-100.	4.3	136
1150	A validated chiral LC method for the enantiomeric separation of AT13148 on polysaccharide-based chiral stationary phase. <i>Journal of the Iranian Chemical Society</i> , 2018, 15, 711-717.	1.2	0
1151	Selectively Targeting the Kinome-Conserved Lysine of PI3K γ as a General Approach to Covalent Kinase Inhibition. <i>Journal of the American Chemical Society</i> , 2018, 140, 932-939.	6.6	73
1152	Effects of PI3K and FSH on steroidogenesis, viability and embryo development of the cumulus-oocyte complex after <i>in vitro</i> culture. <i>Zygote</i> , 2018, 26, 50-61.	0.5	10
1153	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. <i>Oncogene</i> , 2018, 37, 341-351.	2.6	98
1154	Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. <i>Human Pathology</i> , 2018, 72, 107-116.	1.1	37
1155	A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight. <i>Integrative Cancer Therapies</i> , 2018, 17, 200-209.	0.8	33
1156	P85 regulates neuronal migration through affecting neuronal morphology during mouse corticogenesis. <i>Cell and Tissue Research</i> , 2018, 372, 23-31.	1.5	5
1157	Multinomial classification with class-conditional overlapping sparse feature groups. <i>Pattern Recognition Letters</i> , 2018, 101, 37-43.	2.6	5
1158	Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1339-1342.	0.8	11
1159	Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2389-2396.	1.8	23
1160	Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. <i>International Journal of Oncology</i> , 2018, 52, 828-840.	1.4	20
1161	Metformin induces apoptosis in mesenchymal stromal cells and dampens their therapeutic efficacy in infarcted myocardium. <i>Stem Cell Research and Therapy</i> , 2018, 9, 306.	2.4	18
1162	SAMHD1 inhibits epithelial cell transformation <i>in vitro</i> and affects leukemia development in xenograft mice. <i>Cell Cycle</i> , 2018, 17, 2564-2576.	1.3	4
1163	SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway. <i>Cancer Cell International</i> , 2018, 18, 183.	1.8	55

#	ARTICLE	IF	CITATIONS
1164	Molecular Action of Herbal Antioxidants in Regulation of Cancer Growth: Scope for Novel Anticancer Drugs. <i>Nutrition and Cancer</i> , 2018, 70, 1199-1209.	0.9	8
1165	Relevance of Rab Proteins for the Life Cycle of Hepatitis C Virus. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 166.	1.8	13
1166	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 35-53.	0.8	16
1167	Tanshinol inhibits the growth, migration and invasion of hepatocellular carcinoma cells via regulating the PI3K-AKT signaling pathway. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 87-99.	1.0	20
1168	Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal. <i>Cell Death and Disease</i> , 2018, 9, 1013.	2.7	15
1169	Insulin-Like Growth Factor I Regulation and Its Actions in Skeletal Muscle. , 2018, 9, 413-438.		26
1170	Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. <i>Head and Neck</i> , 2019, 41, 185-197.	0.9	37
1171	Natural forms of vitamin E and metabolites regulation of cancer cell death and underlying mechanisms. <i>IUBMB Life</i> , 2019, 71, 495-506.	1.5	46
1172	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
1173	A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer. <i>Biochemical Pharmacology</i> , 2018, 158, 84-94.	2.0	37
1174	Restoration of microRNA-130b expression suppresses osteosarcoma cell malignant behavior in vitro. <i>Oncology Letters</i> , 2018, 16, 97-104.	0.8	4
1175	Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 105, 1-12.	1.2	8
1176	BACE1 gene silencing alleviates isoflurane anesthesia-induced postoperative cognitive dysfunction in immature rats by activating the PI3K/Akt signaling pathway. <i>Molecular Medicine Reports</i> , 2018, 18, 4259-4270.	1.1	8
1177	Sodium tanshinone IIA sulfonate protects ARPE-19 cells against oxidative stress by inhibiting autophagy and apoptosis. <i>Scientific Reports</i> , 2018, 8, 15137.	1.6	36
1178	The Akt pathway in oncology therapy and beyond (Review). <i>International Journal of Oncology</i> , 2018, 53, 2319-2331.	1.4	156
1179	Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene. <i>Oncology Letters</i> , 2018, 16, 6071-6080.	0.8	14
1180	Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression. <i>Genes</i> , 2018, 9, 512.	1.0	4
1181	UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3921-3928.	0.8	6

#	ARTICLE	IF	CITATIONS
1182	Medicinal Plants Against Cancer. , 2018, , 139-196.		1
1183	Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells. <i>Oncology Reports</i> , 2018, 40, 3223-3234.	1.2	18
1184	Hierarchical HotNet: identifying hierarchies of altered subnetworks. <i>Bioinformatics</i> , 2018, 34, i972-i980.	1.8	102
1185	Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. <i>Development & Reproduction</i> , 2018, 22, 133-142.	0.1	5
1186	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. <i>Future Medicinal Chemistry</i> , 2018, 10, 2445-2455.	1.1	7
1187	Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway. <i>Marine Drugs</i> , 2018, 16, 325.	2.2	32
1188	Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency <i>in Vitro</i> . <i>Journal of Cancer</i> , 2018, 9, 890-900.	1.2	29
1189	Comparison of PI3K Pathway in HPV-associated Oropharyngeal Cancer With and Without Tobacco Exposure. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 283-289.	0.6	7
1190	The Telomerase and Alternative Lengthening of Telomeres Mechanisms Regulate Laryngeal Cancer Cell Apoptosis via the PI3K/Akt Pathway. <i>Orl</i> , 2018, 80, 227-237.	0.6	5
1191	Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4817-4827.	1.0	40
1192	Midazolam and Dexmedetomidine Affect Neuroglioma and Lung Carcinoma Cell Biology <i>in Vitro</i> and <i>in Vivo</i> . <i>Anesthesiology</i> , 2018, 129, 1000-1014.	1.3	65
1193	Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with oral cancer. <i>Oral Cancer</i> , 2018, 2, 83-89.	0.3	10
1194	Smoothed stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothed with implications in lymphoma biology. <i>Cancer Letters</i> , 2018, 436, 149-158.	3.2	10
1195	Investigation of Novel Regulation of N-myristoyltransferase by Mammalian Target of Rapamycin in Breast Cancer Cells. <i>Scientific Reports</i> , 2018, 8, 12969.	1.6	11
1196	Exploring major signaling cascades in melanomagenesis: a rationale route for targeted skin cancer therapy. <i>Bioscience Reports</i> , 2018, 38, .	1.1	28
1197	Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis. <i>Gene</i> , 2018, 669, 99-106.	1.0	18
1198	MiR-141-3p is upregulated in esophageal squamous cell carcinoma and targets pleckstrin homology domain leucine-rich repeat protein phosphatase-2, a negative regulator of the PI3K/AKT pathway. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 507-513.	1.0	28
1199	PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 9655-9662.	0.8	21

#	ARTICLE	IF	CITATIONS
1200	Acquired Resistance to Drugs Targeting Tyrosine Kinases. <i>Advances in Cancer Research</i> , 2018, 138, 71-98.	1.9	65
1201	Effects of NVP-BEZ235, a dual phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines. <i>Oncology Letters</i> , 2018, 15, 5311-5317.	0.8	7
1202	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. <i>Genes and Diseases</i> , 2018, 5, 77-106.	1.5	714
1203	IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. <i>Journal of Surgical Research</i> , 2018, 231, 116-125.	0.8	13
1204	The effect of P85 on neuronal proliferation and differentiation during development of mouse cerebral cortex. <i>Developmental Biology</i> , 2018, 441, 95-103.	0.9	8
1205	The Nogo receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7738-7746.	1.2	5
1206	Cancer Metabolism: Current Understanding and Therapies. <i>Chemical Reviews</i> , 2018, 118, 6893-6923.	23.0	161
1207	Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. <i>Advances in Clinical Chemistry</i> , 2018, 83, 53-72.	1.8	22
1208	SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42	2.8	53
1209	Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1. <i>Oncology Letters</i> , 2018, 15, 8687-8694.	0.8	8
1210	Deregulation of the Notch pathway as a common road in viral carcinogenesis. <i>Reviews in Medical Virology</i> , 2018, 28, e1988.	3.9	14
1211	Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 833-844.	0.4	1
1212	<i>Drosophila melanogaster</i> as a Model for Diabetes Type 2 Progression. <i>BioMed Research International</i> , 2018, 2018, 1-16.	0.9	41
1213	Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3K/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3992-4000.	1.4	10
1214	Oxidized fish oil injury stress in <i>Megalobrama amblycephala</i> : Evaluated by growth, intestinal physiology, and transcriptome-based PI3K-Akt/NF- κ B/TCR inflammatory signaling. <i>Fish and Shellfish Immunology</i> , 2018, 81, 446-455.	1.6	67
1215	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
1216	Emodin, Phycion, and Crude Extract of <i>Rhamnus sphaerosperma</i> var. <i>pubescens</i> Induce Mixed Cell Death, Increase in Oxidative Stress, DNA Damage, and Inhibition of AKT in Cervical and Oral Squamous Carcinoma Cell Lines. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-18.	1.9	25
1217	Overexpression of the Kininogen-1 inhibits proliferation and induces apoptosis of glioma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 180.	3.5	46

#	ARTICLE	IF	CITATIONS
1218	Modeling of PH Domains and Phosphoinositides Interactions and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1111, 19-32.	0.8	14
1219	Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. <i>Medical Oncology</i> , 2018, 35, 122.	1.2	22
1220	Semen Cassiae Extract Improves Glucose Metabolism by Promoting GLUT4 Translocation in the Skeletal Muscle of Diabetic Rats. <i>Frontiers in Pharmacology</i> , 2018, 9, 235.	1.6	13
1221	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. <i>Frontiers in Physiology</i> , 2018, 9, 335.	1.3	66
1222	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , 2018, 10, 23.	1.7	108
1223	Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy. <i>Theranostics</i> , 2018, 8, 2217-2228.	4.6	48
1224	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
1225	CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4221-4232.	1.0	19
1226	Calmodulin (CaM) Activates PI3K by Targeting the CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85. <i>Journal of Physical Chemistry B</i> , 2018, 122, 11137-11146.	1.2	15
1227	Pathobiology of Acute Lymphoblastic Leukemia. , 2018, , 1005-1019.e11.		1
1228	Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. <i>Cell Death and Disease</i> , 2018, 9, 817.	2.7	58
1229	Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF- κ B signaling. <i>Cell Death and Disease</i> , 2018, 9, 809.	2.7	26
1230	Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 2713-2722.	1.2	33
1231	A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer. <i>Theranostics</i> , 2018, 8, 78-91.	4.6	38
1232	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 89.	1.3	64
1233	WIP-YAP/TAZ as A New Pro-Oncogenic Pathway in Glioma. <i>Cancers</i> , 2018, 10, 191.	1.7	17
1234	SPC24 Regulates breast cancer progression by PI3K/AKT signaling. <i>Gene</i> , 2018, 675, 272-277.	1.0	20
1235	Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 556.	1.8	17

#	ARTICLE	IF	CITATIONS
1236	Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases. <i>Molecules</i> , 2018, 23, 512.	1.7	80
1237	Elucidation of Mechanisms of Anticancer Plant Compounds Against the Tumor Cells. , 2018, , 99-130.		2
1238	<i>Leishmania</i> parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in <i>Leishmania</i> infections. <i>Cellular Microbiology</i> , 2018, 20, e12889.	1.1	18
1239	Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal. <i>Biomedicines</i> , 2018, 6, 29.	1.4	38
1240	Design, Synthesis and Biological Evaluation of Novel Phenylsulfonyleurea Derivatives as PI3K/mTOR Dual Inhibitors. <i>Molecules</i> , 2018, 23, 1553.	1.7	8
1241	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 7497-7505.	0.8	50
1242	Concurrent interactome and metabolome analysis reveals role of AKT1 in central carbon metabolism. <i>BMC Research Notes</i> , 2018, 11, 270.	0.6	6
1243	Molecular Characterization of Colorectal Signet-Ring Cell Carcinoma Using Whole-Exome and RNA Sequencing. <i>Translational Oncology</i> , 2018, 11, 836-844.	1.7	14
1244	Eukaryotic cell survival mechanisms: Disease relevance and therapeutic intervention. <i>Life Sciences</i> , 2018, 205, 73-90.	2.0	19
1245	Current and Investigational Agents Targeting the Phosphoinositide 3-kinase Pathway. <i>Pharmacotherapy</i> , 2018, 38, 1058-1067.	1.2	8
1246	Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 809-821.	1.0	36
1247	Knockdown of TMPRSS3 inhibits gastric cancer cell proliferation, invasion and EMT via regulation of the ERK1/2 and PI3K/Akt pathways. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 841-848.	2.5	20
1248	Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 395-408.	1.0	21
1249	Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2764-2769.	1.0	15
1250	Involvement of Akt in mitomycin C and its analog triggered cytotoxicity in MCF-7 and K562 cancer cells. <i>Chemical Biology and Drug Design</i> , 2018, 92, 2022-2034.	1.5	5
1251	Clonal variation in productivity and proteolytic clipping of an Fc-fusion protein in CHO cells: Proteomic analysis suggests a role for defective protein folding and the UPR. <i>Journal of Biotechnology</i> , 2018, 281, 21-30.	1.9	10
1252	Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NF- κ B. <i>Behavioural Brain Research</i> , 2018, 351, 4-16.	1.2	27
1253	Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 103, 1272-1278.	2.5	38

#	ARTICLE	IF	CITATIONS
1254	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 285-298.	1.1	37
1255	Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6087-6109.	2.9	30
1256	Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3K $\hat{\imath}$ inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3982-3991.	1.4	4
1257	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	1.2	7
1258	Molecular dynamics insights for PI3K $\hat{\imath}$ inhibition & structure guided identification of novel PI3K $\hat{\imath}$ inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 2404-2414.	2.0	4
1259	Carvacrol induces mitochondria $\hat{\imath}$ mediated apoptosis via disruption of calcium homeostasis in human choriocarcinoma cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 1803-1815.	2.0	28
1260	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R83-R103.	1.1	9
1261	Activation of WNT/ $\hat{\imath}$ catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring <i>PIK3CA</i> mutations. <i>International Journal of Cancer</i> , 2019, 144, 389-401.	2.3	48
1262	Formononetin: A Review of Its Anticancer Potentials and Mechanisms. <i>Frontiers in Pharmacology</i> , 2019, 10, 820.	1.6	174
1264	Infection with genotoxin $\hat{\imath}$ producing <i>Salmonella enterica</i> synergises with loss of the tumour suppressor <i>APC</i> in promoting genomic instability via the PI3K pathway in colonic epithelial cells. <i>Cellular Microbiology</i> , 2019, 21, e13099.	1.1	26
1265	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives bearing sulfonylpiperazine as antitumor inhibitors targeting PI3K $\hat{\imath}$. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111630.	2.6	8
1266	Steroid receptor coactivator 3 inhibits hepatitis B virus gene expression through activating Akt signaling to prevent HNF4 $\hat{\imath}$ nuclear translocation. <i>Cell and Bioscience</i> , 2019, 9, 64.	2.1	5
1267	Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3K $\hat{\imath}$ inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115035.	1.4	9
1268	An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer. <i>Journal of Applied Genetics</i> , 2019, 60, 335-346.	1.0	25
1269	Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7264-7288.	2.9	23
1270	Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3383.	1.8	26
1271	Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 72-85.	2.6	18
1272	Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6972-6984.	2.9	17

#	ARTICLE	IF	CITATIONS
1273	Discovery of a novel phosphoinositide 3-kinase gamma (PI3K $\hat{\gamma}$) inhibitor against hematologic malignancies and theoretical studies on its PI3K $\hat{\gamma}$ -specific binding mechanisms. RSC Advances, 2019, 9, 20207-20215.	1.7	15
1274	PI3K-AKT-mTOR and NF $\hat{\kappa}$ B Pathways in Ovarian Cancer: Implications for Targeted Therapeutics. Cancers, 2019, 11, 949.	1.7	109
1275	Single nucleotide polymorphism of PIK3CA and its interaction with the environment are risk factors for Chinese Han ovarian cancer. Pathology Research and Practice, 2019, 215, 152520.	1.0	7
1276	Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management. International Journal of Molecular Sciences, 2019, 20, 3525.	1.8	19
1277	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS Journal, 2019, 286, 3510-3539.	2.2	33
1278	Theoretical studies on the selectivity mechanisms of PI3K $\hat{\gamma}$ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation. Journal of Molecular Modeling, 2019, 25, 242.	0.8	22
1279	Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2019, 62, 8873-8879.	2.9	19
1280	Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. Oncogene, 2019, 38, 6491-6506.	2.6	20
1281	Targeting cellular cholesterol for anticancer therapy. FEBS Journal, 2019, 286, 4192-4208.	2.2	39
1282	Myosin 1b Regulates Nuclear AKT Activation by Preventing Localization of PTEN in the Nucleus. IScience, 2019, 19, 39-53.	1.9	10
1283	Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. Cancers, 2019, 11, 1058.	1.7	32
1284	Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches. PLoS ONE, 2019, 14, e0219180.	1.1	27
1285	p110 $\hat{\delta}$ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 14724-14733.	3.3	22
1286	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in <i>KRAS</i> -Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
1287	The role of $\hat{\epsilon}$ cell protein tyrosine phosphatase in epithelial carcinogenesis. Molecular Carcinogenesis, 2019, 58, 1640-1647.	1.3	7
1288	Augmented therapeutic efficacy of 5-fluorouracil in conjunction with lantibiotic nisin against skin cancer. Biochemical and Biophysical Research Communications, 2019, 520, 551-559.	1.0	23
1289	Extracranial arteriovenous malformations: from bedside to bench. Mutagenesis, 2019, 34, 299-306.	1.0	13
1290	Design, Synthesis, Molecular Docking, ADMET Studies, and Biological Evaluation of Isoxazoline and Pyrazoline Incorporating 1,2,3-Triazole Benzene Sulfonamides. Russian Journal of Bioorganic Chemistry, 2019, 45, 381-390.	0.3	9

#	ARTICLE	IF	CITATIONS
1291	The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. <i>Biomolecules</i> , 2019, 9, 713.	1.8	17
1292	On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective. <i>Biomolecules</i> , 2019, 9, 690.	1.8	78
1293	ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin. <i>Cell Death and Disease</i> , 2019, 10, 809.	2.7	72
1294	<p>Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF- κ B Signalling Pathway</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3539-3550.	2.0	7
1295	Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization. <i>Cancers</i> , 2019, 11, 1599.	1.7	112
1296	Comparative proteomics analysis reveals the difference during antler regeneration stage between red deer and sika deer. <i>PeerJ</i> , 2019, 7, e7299.	0.9	9
1297	Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives containing piperazine as inhibitors of PI3K. <i>Bioorganic Chemistry</i> , 2019, 92, 103238.	2.0	7
1298	Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis. <i>World Journal of Gastroenterology</i> , 2019, 25, 3408-3425.	1.4	28
1299	Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes. <i>Scientific Reports</i> , 2019, 9, 13225.	1.6	3
1300	Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents. <i>Bioorganic Chemistry</i> , 2019, 93, 103283.	2.0	19
1301	Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109478.	2.5	20
1302	Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2699-2711.	1.2	15
1303	β -Caryophyllene promotes oxidative stress and apoptosis in KB cells through activation of mitochondrial-mediated pathway – An <i>in-vitro</i> and <i>in-silico</i> study. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 148-162.	1.0	16
1304	Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 1053-1062.	1.0	14
1305	mTOR Inhibitors in Advanced Biliary Tract Cancers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 500.	1.8	23
1306	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 41.	3.5	57
1307	Progesterone Treatment Attenuates Glycolytic Metabolism and Induces Senescence in Glioblastoma. <i>Scientific Reports</i> , 2019, 9, 988.	1.6	23
1308	HCMV modulation of cellular PI3K/AKT/mTOR signaling: New opportunities for therapeutic intervention?. <i>Antiviral Research</i> , 2019, 163, 82-90.	1.9	29

#	ARTICLE	IF	CITATIONS
1309	Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 412.	1.8	58
1310	Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. <i>Chemico-Biological Interactions</i> , 2019, 302, 101-107.	1.7	11
1311	Phase I study of alpelisib (BYL719), an Î±-specific PI3K inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2019, 110, 1021-1031.	1.7	40
1312	MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 20.	2.2	52
1313	Synthesis and Evaluation of Imidazo[1,2- <i>a</i>]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3-Kinase Inhibitors. <i>Chemistry - an Asian Journal</i> , 2019, 14, 1249-1261.	1.7	9
1314	Development of new agents for peripheral T-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 197-209.	1.4	26
1315	Chitooligosaccharide Biguanide Repairs Islet Î²-Cell Dysfunction by Activating the IRS-2/PI3K/Akt Signaling Pathway in Type 2 Diabetic Rats. <i>Advanced Therapeutics</i> , 2019, 2, 1800136.	1.6	6
1316	Virtual Screening Guided Design, Synthesis and Bioactivity Study of Benzisoselenazolones (BISAs) on Inhibition of c-Met and Its Downstream Signalling Pathways. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2489.	1.8	6
1317	Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. <i>Pharmaceuticals</i> , 2019, 12, 69.	1.7	53
1318	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6992-7014.	2.9	58
1319	Functions of Nuclear Polyphosphoinositides. <i>Handbook of Experimental Pharmacology</i> , 2019, 259, 163-181.	0.9	1
1320	Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis. <i>Biochemical Pharmacology</i> , 2019, 168, 1-13.	2.0	14
1321	Serine Protease from <i>Nereis virens</i> Inhibits H1299 Lung Cancer Cell Proliferation via the PI3K/AKT/mTOR Pathway. <i>Marine Drugs</i> , 2019, 17, 366.	2.2	12
1322	Vitamin D, cancer, and dysregulated phosphate metabolism. <i>Endocrine</i> , 2019, 65, 238-243.	1.1	22
1323	Gentisyl Alcohol Inhibits Proliferation and Induces Apoptosis via Mitochondrial Dysfunction and Regulation of MAPK and PI3K/AKT Pathways in Epithelial Ovarian Cancer Cells. <i>Marine Drugs</i> , 2019, 17, 331.	2.2	15
1325	AKT and ERK dual inhibitors: The way forward?. <i>Cancer Letters</i> , 2019, 459, 30-40.	3.2	144
1326	Role of leptin as a biomarker for early detection of renal cell carcinoma? No evidence from a systematic review and meta-analysis. <i>Medical Hypotheses</i> , 2019, 129, 109239.	0.8	4
1327	Target identification, screening and in vivo evaluation of pyrrolone-fused benzosuberene compounds against human epilepsy using Zebrafish model of pentylene tetrazol-induced seizures. <i>Scientific Reports</i> , 2019, 9, 7904.	1.6	58

#	ARTICLE	IF	CITATIONS
1328	Correlation between renin-angiotensin system (RAS) related genes, type 2 diabetes, and cancer: Insights from metanalysis of transcriptomics data. <i>Molecular and Cellular Endocrinology</i> , 2019, 493, 110455.	1.6	6
1329	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 114930.	1.4	11
1330	Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3K/± Inhibitor. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1013-1018.	0.6	3
1331	Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 667-686.	2.6	9
1332	Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 337-343.	1.1	5
1333	bFGF overexpression adipose derived mesenchymal stem cells improved the survival of pulmonary arterial endothelial cells via PI3k/Akt signaling pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 113, 87-94.	1.2	10
1334	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. <i>Molecular Carcinogenesis</i> , 2019, 58, 1602-1611.	1.3	5
1335	Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol-2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1831-1835.	1.0	9
1336	The significance of gene mutations across eight major cancer types. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 88-99.	2.4	15
1337	Type IÎ³ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. <i>EBioMedicine</i> , 2019, 44, 375-386.	2.7	19
1338	Inferring disease and pathway associations of long non-coding RNAs using heterogeneous information network model. <i>Journal of Bioinformatics and Computational Biology</i> , 2019, 17, 1950020.	0.3	1
1339	Targeting Delivery of Oligodeoxynucleotides to Macrophages by Mannosylated Cationic Albumin for Immune Stimulation in Cancer Treatment. <i>Molecular Pharmaceutics</i> , 2019, 16, 2616-2625.	2.3	14
1340	Modulating autophagy as a therapeutic strategy for the treatment of paediatric high-grade glioma. <i>Brain Pathology</i> , 2019, 29, 707-725.	2.1	12
1341	IGF1R as druggable target mediating PI3K-Î³ inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 534-547.	0.6	51
1342	TRPM7, Magnesium, and Signaling. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1877.	1.8	99
1343	Synthesized Ceramide Induces Growth of Dermal Papilla Cells with Potential Contribution to Hair Growth. <i>Annals of Dermatology</i> , 2019, 31, 164.	0.3	6
1344	Cancer Genetic Network Inference Using Gaussian Graphical Models. <i>Bioinformatics and Biology Insights</i> , 2019, 13, 117793221983940.	1.0	33
1345	Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1605-1608.	1.0	15

#	ARTICLE	IF	CITATIONS
1346	Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives containing sulfonamido as potential PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2261-2267.	1.4	8
1347	Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2729-2740.	1.4	5
1348	Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 70.	1.8	97
1349	Alzheimer's Disease and Cancer: When Two Monsters Cannot Be Together. <i>Frontiers in Neuroscience</i> , 2019, 13, 155.	1.4	64
1350	Impact of p85 Alterations in Cancer. <i>Biomolecules</i> , 2019, 9, 29.	1.8	17
1351	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3689-3701.	3.2	81
1352	The relation between PI3K/AKT signalling pathway and cancer. <i>Gene</i> , 2019, 698, 120-128.	1.0	331
1353	Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1347.	3.4	56
1354	Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. <i>Cancer Letters</i> , 2019, 451, 11-22.	3.2	28
1355	The mechanism of PI3K activation at the atomic level. <i>Chemical Science</i> , 2019, 10, 3671-3680.	3.7	75
1357	A Bayesian Random Partition Model For Sequential Refinement and Coagulation. <i>Biometrics</i> , 2019, 75, 988-999.	0.8	3
1358	PNUTS mediates ionizing radiation-induced CNE-2 nasopharyngeal carcinoma cell migration, invasion, and epithelial-mesenchymal transition via the PI3K/AKT signaling pathway. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1205-1214.	1.0	7
1359	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3996-4013.	3.2	77
1360	ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2019, 17, 3371-3381.	0.8	8
1361	Leptin-induced signaling pathways in cancer cell migration and invasion. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 243-260.	2.1	63
1362	Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential. <i>Pure and Applied Chemistry</i> , 2019, 91, 1085-1105.	0.9	7
1363	Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. <i>Phytotherapy Research</i> , 2019, 33, 1683-1688.	2.8	20
1364	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. <i>Seminars in Cancer Biology</i> , 2019, 59, 3-22.	4.3	29

#	ARTICLE	IF	CITATIONS
1365	Emerging role of PI3K/AKT in tumor-related epigenetic regulation. <i>Seminars in Cancer Biology</i> , 2019, 59, 112-124.	4.3	113
1366	Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1159-1194.	1.4	64
1367	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
1368	Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations. <i>Bioorganic Chemistry</i> , 2019, 86, 410-419.	2.0	18
1369	Mechanism of bioactive polysaccharide from <i>Lachnum</i> sp. acts synergistically with 5-fluorouracil against human hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 15548-15562.	2.0	14
1370	MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. <i>Cell Death and Disease</i> , 2019, 10, 153.	2.7	36
1371	Dysregulated Phosphate Metabolism, Periodontal Disease, and Cancer: Possible Global Health Implications. <i>Dentistry Journal</i> , 2019, 7, 18.	0.9	7
1372	Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1529-1545.	1.4	12
1373	The Flavone Baicalein and Its Use in Gastrointestinal Disease. , 2019, , 145-155.		1
1374	PI3K is a Versatile Transducer for GPCR, RTK, and Small GTPase Signaling. <i>Endocrinology</i> , 2019, 160, 536-555.	1.4	35
1375	Targeting PI3K in cancer: mechanisms and advances in clinical trials. <i>Molecular Cancer</i> , 2019, 18, 26.	7.9	940
1376	NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation. <i>Journal of Cellular Physiology</i> , 2019, 234, 15963-15976.	2.0	18
1377	CTHRC1 facilitates bladder cancer cell proliferation and invasion through regulating the PI3K/Akt signaling pathway. <i>Archives of Medical Science</i> , 2019, 18, 183-194.	0.4	2
1378	Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24583-24592.	3.3	34
1379	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. <i>Oncology Reviews</i> , 2019, 13, 455.	0.8	12
1380	PROTACs: great opportunities for academia and industry. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 64.	7.1	367
1381	A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 900-908.	0.7	2
1382	Overview of the relevance of PI3K pathway in HR-positive breast cancer. <i>Annals of Oncology</i> , 2019, 30, x3-x11.	0.6	92

#	ARTICLE	IF	CITATIONS
1383	PIPKI β Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	26
1384	The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells. <i>Frontiers in Pharmacology</i> , 2019, 10, 1311.	1.6	26
1385	Recent discovery of phosphoinositide 3-kinase β inhibitors for the treatment of immune diseases and cancers. <i>Future Medicinal Chemistry</i> , 2019, 11, 2151-2169.	1.1	13
1386	Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis. <i>Medicine (United States)</i> , 2019, 98, e17803.	0.4	9
1387	HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer. <i>Cancer Letters</i> , 2019, 444, 94-104.	3.2	16
1388	A Linkage Between Thyroid and Breast Cancer: A Common Etiology?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 643-649.	1.1	62
1389	Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct C-H Arylation toward Dihydrobenzothienooxepines. <i>Journal of Organic Chemistry</i> , 2019, 84, 4796-4802.	1.7	10
1390	Activation of the Omega-3 Fatty Acid Receptor GPR120 Protects against Focal Cerebral Ischemic Injury by Preventing Inflammation and Apoptosis in Mice. <i>Journal of Immunology</i> , 2019, 202, 747-759.	0.4	44
1391	The cell biology behind the oncogenic PIP3 lipids. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	18
1392	Minocycline attenuates ethanol-induced cell death and microglial activation in the developing spinal cord. <i>Alcohol</i> , 2019, 79, 25-35.	0.8	14
1393	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. <i>Gut</i> , 2019, 68, 742-758.	6.1	68
1394	Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2019, 55, 36-44.	0.7	5
1395	Herbal medicine in oral lichen planus. <i>Phytotherapy Research</i> , 2019, 33, 288-293.	2.8	19
1396	Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. <i>Bioorganic Chemistry</i> , 2019, 82, 340-359.	2.0	33
1397	Dopamine: Functions, Signaling, and Association with Neurological Diseases. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 31-59.	1.7	537
1398	The human oncogene SCL/TAL1 interrupting locus (STIL) promotes tumor growth through MAPK/ERK, PI3K/Akt and AMPK pathways in prostate cancer. <i>Gene</i> , 2019, 686, 220-227.	1.0	18
1399	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. <i>Genes</i> , 2019, 10, 25.	1.0	111
1400	Role of PI3K/Akt on migration and invasion of MCF10A cells treated with extracellular vesicles from MDA-MB-231 cells stimulated with linoleic acid. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 235-244.	1.8	13

#	ARTICLE	IF	CITATIONS
1401	Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors. <i>Chemical Biology and Drug Design</i> , 2019, 94, 2013-2022.	1.5	3
1402	Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K inhibition through the transcriptional regulation of ER. <i>Cancer Letters</i> , 2019, 440-441, 54-63.	3.2	25
1403	p110 ^α and p110 ^β isoforms of PI3K are involved in protection against H ₂ O ₂ induced oxidative stress in cancer cells. <i>Breast Cancer</i> , 2019, 26, 378-385.	1.3	1
1404	Virtual screening of naphthoquinone analogs for potent inhibitors against the cancer signaling PI3K/AKT/mTOR pathway. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1328-1339.	1.2	32
1405	Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. <i>Seminars in Cancer Biology</i> , 2019, 56, 128-134.	4.3	26
1406	System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]isoquinoline Derivative as Anticancerous Drug Candidate Against it. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 125-134.	2.2	7
1407	Membrane-initiated nuclear trafficking of the glucocorticoid receptor in hypothalamic neurons. <i>Steroids</i> , 2019, 142, 55-64.	0.8	27
1408	Effect of resistance training with <i>Spirulina platensis</i> on PI3K/Akt/mTOR/p70S6k signaling pathway in cardiac muscle. <i>Science and Sports</i> , 2020, 35, 91-98.	0.2	2
1409	Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. <i>Oncogene</i> , 2020, 39, 987-1003.	2.6	24
1410	PDK1 Regulates Transition Period of Apical Progenitors to Basal Progenitors by Controlling Asymmetric Cell Division. <i>Cerebral Cortex</i> , 2020, 30, 406-420.	1.6	8
1411	Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. <i>Medicinal Research Reviews</i> , 2020, 40, 709-752.	5.0	138
1412	Design, synthesis and evaluation of wound healing activity for Δ^2 -steroids derivatives as potent Na ⁺ /K ⁺ -ATPase inhibitors. <i>Bioorganic Chemistry</i> , 2020, 98, 103150.	2.0	4
1413	Gene mutation and surgical technique: Suggestion or more?. <i>Surgical Oncology</i> , 2020, 33, 210-215.	0.8	10
1414	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. <i>Oncogene</i> , 2020, 39, 50-63.	2.6	43
1415	CA8 promotes RCC proliferation and migration though its expression level is lower in tumor compared to adjacent normal tissue. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109578.	2.5	15
1416	MicroRNAs: pivotal regulators in acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 399-412.	0.8	14
1417	Astilbin protects chicken peripheral blood lymphocytes from cadmium-induced necroptosis via oxidative stress and the PI3K/Akt pathway. <i>Ecotoxicology and Environmental Safety</i> , 2020, 190, 110064.	2.9	60
1418	Phosphoprotein Biosensors for Monitoring Pathological Protein Structural Changes. <i>Trends in Biotechnology</i> , 2020, 38, 519-531.	4.9	8

#	ARTICLE	IF	CITATIONS
1419	From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer. <i>Nutrition Research</i> , 2020, 74, 23-36.	1.3	23
1420	Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 575-587.	1.7	323
1421	A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. <i>Nutrition</i> , 2020, 72, 110659.	1.1	31
1422	Therapeutic potential of targeting mitochondrial dynamics in cancer. <i>Biochemical Pharmacology</i> , 2020, 182, 114282.	2.0	78
1423	Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus. <i>Nature Medicine</i> , 2020, 26, 1754-1765.	15.2	84
1424	Prospects of tangeretin as a modulator of cancer targets/pathways. <i>Pharmacological Research</i> , 2020, 161, 105202.	3.1	36
1425	TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K \hat{I} inhibition in head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 217.	3.5	10
1426	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <i>Blood Advances</i> , 2020, 4, 5093-5106.	2.5	4
1427	AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation. <i>Nature Communications</i> , 2020, 11, 5127.	5.8	71
1428	Molecular Target Therapy against Neuroblastoma. , 2020, , .		0
1429	Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5040.	1.8	28
1430	Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 456-467.	3.6	26
1431	Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112637.	2.6	29
1432	A small library of chalcones induce liver cancer cell death through Akt phosphorylation inhibition. <i>Scientific Reports</i> , 2020, 10, 11814.	1.6	7
1433	Avenanthramide C Prevents Neuronal Apoptosis via PI3K/Akt/GSK3 \hat{I} Signaling Pathway Following Middle Cerebral Artery Occlusion. <i>Brain Sciences</i> , 2020, 10, 878.	1.1	14
1434	Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents. <i>Molecules</i> , 2020, 25, 5348.	1.7	8
1435	Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells. <i>Molecules</i> , 2020, 25, 5299.	1.7	13
1436	miR-29 Sustains B Cell Survival and Controls Terminal Differentiation via Regulation of PI3K Signaling. <i>Cell Reports</i> , 2020, 33, 108436.	2.9	18

#	ARTICLE	IF	CITATIONS
1437	Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 372.	1.2	5
1438	Calcitriol Suppresses HIF-1 and HIF-2 Transcriptional Activity by Reducing HIF-1/2 \pm Protein Levels via a VDR-Independent Mechanism. <i>Cells</i> , 2020, 9, 2440.	1.8	14
1439	Natural Products from Endophytic Fungi Associated with Rubiaceae Species. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 1000.	1.5	17
1440	PDK1/mTOR Signaling in Myeloid Cells Differentially Regulates the Early and Late Stages of Sepsis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-9.	1.4	1
1441	Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6937-6955.	1.0	21
1442	Degradation of <i>Sargassum crassifolium</i> Fucoidan by Ascorbic Acid and Hydrogen Peroxide, and Compositional, Structural, and In Vitro Anti-Lung Cancer Analyses of the Degradation Products. <i>Marine Drugs</i> , 2020, 18, 334.	2.2	13
1443	PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. <i>Cancer Management and Research</i> , 2020, Volume 12, 6123-6135.	0.9	25
1444	Preliminary study of mechanisms of intestinal inflammation induced by plant proteins in juvenile hybrid groupers (<i>Epinephelus fuscoguttatus</i> × <i>E. lanceolatus</i>). <i>Fish and Shellfish Immunology</i> , 2020, 106, 341-356.	1.6	36
1445	Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3K β Kinase Using Computational Methods. <i>Anticancer Research</i> , 2020, 40, 4547-4556.	0.5	12
1446	Di-2-pyridylketone-N1-substituted thiosemicarbazone derivatives of copper(II): Biosafe antimicrobial potential and high anticancer activity against immortalized L6 rat skeletal muscle cells. <i>Journal of Inorganic Biochemistry</i> , 2020, 212, 111205.	1.5	9
1447	Research advances on selective phosphatidylinositol 3 kinase γ (PI3K γ) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127457.	1.0	9
1448	Testing considerations for phosphatidylinositol 3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 6463-6472.	1.3	9
1449	In Vitro Evaluation of the Neuroprotective Effect of <i>Panax notoginseng</i> Saponins by Activating the EGFR/PI3K/AKT Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-11.	0.5	8
1450	Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aryl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition. <i>Bioorganic Chemistry</i> , 2020, 104, 104197.	2.0	12
1451	Rosemary (<i>Rosmarinus officinalis</i> L.) extract inhibits prostate cancer cell proliferation and survival by targeting Akt and mTOR. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110717.	2.5	15
1452	Direct stimulation of ERBB2 highlights a novel cytoskeletal signaling pathway driven by the receptor Thr701 phosphorylation. <i>Scientific Reports</i> , 2020, 10, 16906.	1.6	3
1453	Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission. <i>BMC Gastroenterology</i> , 2020, 20, 290.	0.8	4
1454	Elaborating piperazinyl-fuopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3K α) inhibitors to combat pancreatic cancer. <i>RSC Advances</i> , 2020, 10, 32103-32112.	1.7	6

#	ARTICLE	IF	CITATIONS
1455	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1475.	1.3	11
1456	Lipid rafts as potential mechanistic targets underlying the pleiotropic actions of polyphenols. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, , 1-14.	5.4	9
1457	Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways. <i>Molecules</i> , 2020, 25, 4279.	1.7	34
1458	<p>Integrative Analysis of the IQ Motif-Containing GTPase-Activating Protein Family Indicates That the IQGAP3-PIK3C2B Axis Promotes Invasion in Colon Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8299-8311.	1.0	10
1459	Cellular and molecular events of inflammation induced transdifferentiation (EMT) and regeneration (MET) in mesenteric mesothelial cells. <i>Inflammation Research</i> , 2020, 69, 1173-1179.	1.6	10
1460	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2934.	1.0	57
1461	Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2278-2287.	1.9	10
1462	GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation. <i>Carcinogenesis</i> , 2020, 41, 1660-1670.	1.3	8
1463	5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i>-Mutant Colorectal Cancers. <i>Cancer Research</i> , 2020, 80, 4815-4827.	0.4	49
1464	ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-Î¸B signaling pathway. <i>BMC Cancer</i> , 2020, 20, 853.	1.1	14
1465	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564601.	1.8	315
1466	Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway. <i>Journal of Cancer</i> , 2020, 11, 5568-5577.	1.2	12
1467	A bibliometric analysis of highly cited Phosphoinositide 3-Kinase (PI3K) research papers. <i>Collnet Journal of Scientometrics and Information Management</i> , 2020, 14, 37-54.	0.4	0
1468	Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review. <i>Pharmacological Research</i> , 2021, 171, 105264.	3.1	114
1469	Identification of Novel Thiazolo[5,4-b]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors. <i>Molecules</i> , 2020, 25, 4630.	1.7	8
1470	Small moleculesâ€™ Giant leaps for immuno-oncology. <i>Progress in Medicinal Chemistry</i> , 2020, 59, 1-62.	4.1	2
1471	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	1.7	26
1472	The algal polysaccharide ulvan suppresses growth of hepatoma cells. <i>Food Frontiers</i> , 2020, 1, 83-101.	3.7	32

#	ARTICLE	IF	CITATIONS
1473	Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 ⁺ T cells. <i>European Journal of Immunology</i> , 2020, 50, 1386-1399.	1.6	38
1474	Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3285.	1.8	120
1475	Skp2 in the ubiquitin-proteasome system: A comprehensive review. <i>Medicinal Research Reviews</i> , 2020, 40, 1920-1949.	5.0	64
1476	Roles of PI3K pan-inhibitors and PI3K-Î inhibitors in allergic lung inflammation: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 7608.	1.6	17
1477	NLRC3 inhibits PDGF α -induced PSMCs proliferation via PI3K-mTOR pathway. <i>Journal of Cellular Physiology</i> , 2020, 235, 9557-9567.	2.0	14
1478	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. <i>Scientific Reports</i> , 2020, 10, 8867.	1.6	13
1479	An investigation of the metabolic activity, isozyme contribution, species differences and potential drug-drug interactions of PI-103, and the identification of efflux transporters for PI-103-O-glucuronide in HeLa1A9 cells. <i>RSC Advances</i> , 2020, 10, 9610-9622.	1.7	6
1480	Silencing of S-phase kinase-associated protein 2 enhances radiosensitivity of esophageal cancer cells through inhibition of PI3K/AKT signaling pathway. <i>Genomics</i> , 2020, 112, 3504-3510.	1.3	6
1481	Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. <i>Life Sciences</i> , 2020, 255, 117816.	2.0	18
1482	Construction of a 13-microRNA-based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 1151-1163.	1.8	8
1483	Development of Artificial Cell Models Using Microfluidic Technology and Synthetic Biology. <i>Micromachines</i> , 2020, 11, 559.	1.4	27
1484	Research advances on neurite outgrowth inhibitor B receptor. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7697-7705.	1.6	13
1485	The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. <i>Toxicology and Applied Pharmacology</i> , 2020, 401, 115091.	1.3	6
1486	Molecular recognition of a host protein by NS1 of pandemic and seasonal influenza A viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6550-6558.	3.3	13
1487	MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma. <i>Molecular Metabolism</i> , 2020, 34, 136-145.	3.0	18
1488	Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	125
1489	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4256-4292.	2.9	59
1490	The FOXO TM s Advantages of Being a Family: Considerations on Function and Evolution. <i>Cells</i> , 2020, 9, 787.	1.8	38

#	ARTICLE	IF	CITATIONS
1491	Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. <i>Frontiers in Oncology</i> , 2020, 10, 1012.	1.3	24
1492	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66
1493	Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade. <i>Clinical Cancer Research</i> , 2020, 26, 5019-5035.	3.2	61
1494	Anticancer fungal natural products: Mechanisms of action and biosynthesis. <i>European Journal of Medicinal Chemistry</i> , 2020, 202, 112502.	2.6	25
1495	Hematopoietic stem cell transplant effects on the kidney: Endothelial view. <i>Journal of Onco-Nephrology</i> , 2020, 4, 28-36.	0.3	0
1496	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-16.	0.6	33
1497	Glucose Transporter-1 Cooperating with AKT Signaling Promote Gastric Cancer Progression. <i>Cancer Management and Research</i> , 2020, Volume 12, 4151-4160.	0.9	16
1498	The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4507.	1.8	289
1499	p-TSA.H ₂ O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer. <i>Bioorganic Chemistry</i> , 2020, 102, 104046.	2.0	17
1500	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
1501	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1060.	1.8	27
1502	The role of ubiquitination in tumorigenesis and targeted drug discovery. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 11.	7.1	338
1503	Metformin and statins: a possible role in high-risk prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 163-167.	0.3	4
1504	Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review. <i>Seminars in Cancer Biology</i> , 2022, 80, 276-305.	4.3	53
1505	Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 377-386.	0.6	173
1506	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.	3.3	27
1507	Comparative Analysis and Molecular Evolution of Class I PI3K Regulatory Subunit p85 β Reveal the Structural Similarity Between nSH2 and cSH2 Domains. <i>International Journal of Peptide Research and Therapeutics</i> , 2020, 26, 2555-2569.	0.9	0
1508	Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. <i>Clinical Breast Cancer</i> , 2020, 20, e439-e449.	1.1	10

#	ARTICLE	IF	CITATIONS
1509	PI3K mediates tumor necrosis factor induced-necroptosis through initiating RIP1-RIP3-MLKL signaling pathway activation. <i>Cytokine</i> , 2020, 129, 155046.	1.4	29
1510	Targeting AKT/PKB to improve treatment outcomes for solid tumors. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2020, 819-820, 111690.	0.4	42
1511	Synthesis and biological activity of new 2,4,6-trisubstituted triazines as potential phosphoinositide 3-kinase inhibitors. <i>Journal of Chemical Research</i> , 2020, 44, 393-402.	0.6	1
1512	Targeting effector pathways in RAC1 ^{P29S} -driven malignant melanoma. <i>Small GTPases</i> , 2021, 12, 273-281.	0.7	12
1513	Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function. <i>Viruses</i> , 2020, 12, 110.	1.5	38
1514	Structural and functional characterization of <i>Solanum lycopersicum</i> phosphatidylinositol 3-kinase C2 domain. <i>Plant Physiology and Biochemistry</i> , 2020, 148, 180-192.	2.8	4
1515	Microglia Mediated Neuroinflammation: Focus on PI3K Modulation. <i>Biomolecules</i> , 2020, 10, 137.	1.8	94
1516	Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR). <i>Bioorganic Chemistry</i> , 2020, 96, 103578.	2.0	105
1517	Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy. <i>Journal of Lipid Research</i> , 2020, 61, 611-635.	2.0	150
1518	miR-548x and miR-4698 controlled cell proliferation by affecting the PI3K/AKT signaling pathway in Glioblastoma cell lines. <i>Scientific Reports</i> , 2020, 10, 1558.	1.6	21
1519	Endogenous thrombopoietin promotes non-small cell lung carcinoma cell proliferation and migration by regulating EGFR signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6644-6657.	1.6	11
1520	Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 122, 983.	1.2	5
1521	Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators. <i>Frontiers in Pharmacology</i> , 2020, 11, 547.	1.6	25
1522	Monomeric Targeted Protein Degraders. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11330-11361.	2.9	48
1523	Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabiatic acid as PI3K \pm inhibitors. <i>Bioorganic Chemistry</i> , 2020, 100, 103845.	2.0	20
1524	The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology. <i>Journal of Molecular Medicine</i> , 2020, 98, 495-512.	1.7	12
1525	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 233-248.	1.1	19
1526	Modulation of the PI3K/mTOR pathways. , 2020, , 89-105.		0

#	ARTICLE	IF	CITATIONS
1527	Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127194.	1.0	12
1528	DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. <i>Cancer Letters</i> , 2020, 483, 87-97.	3.2	31
1529	Extracellular Matrix Derived from High Metastatic Human Breast Cancer Triggers Epithelial-Mesenchymal Transition in Epithelial Breast Cancer Cells through $\alpha_2\beta_3$ Integrin. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2995.	1.8	16
1530	Synthetic Approaches to New Drugs Approved during 2018. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10652-10704.	2.9	33
1531	Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K α inhibitors with potent antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 197, 112309.	2.6	8
1532	SNX-2112, an Hsp90 inhibitor, suppresses cervical cancer cells proliferation, migration, and invasion by inhibiting the Akt/mTOR signaling pathway. <i>Medicinal Chemistry Research</i> , 2020, 29, 942-953.	1.1	1
1533	Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation. <i>Oncogene</i> , 2020, 39, 4241-4256.	2.6	8
1534	N ⁶ -methyladenosine mRNA methylation of <i>PIK3CB</i> regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. <i>Gut</i> , 2020, 69, 2180-2192.	6.1	52
1535	Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses. <i>Cells</i> , 2020, 9, 830.	1.8	23
1536	CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1 β . <i>International Journal of Molecular Sciences</i> , 2020, 21, 2429.	1.8	28
1537	9-Methyl- β -carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. <i>Journal of Neural Transmission</i> , 2020, 127, 999-1012.	1.4	5
1538	Integrative Analysis of Gene Expression and Regulatory Network Interaction Data Reveals the Protein Kinase C Family of Serine/Threonine Receptors as a Significant Druggable Target for Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 466-480.	1.1	7
1539	Phosphate imbalance conducting by BPs-based cancer-targeting phosphate anions carrier induces necrosis. <i>Chinese Chemical Letters</i> , 2021, 32, 1550-1554.	4.8	7
1540	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112904.	2.6	45
1541	PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241.	3.1	23
1542	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol 3-kinase (PI3K): Current and Future Prospects. <i>ChemMedChem</i> , 2021, 16, 448-457.	1.6	16
1543	Structure-based design, synthesis, biological evaluation, and molecular docking of novel 10-methoxy dibenzo[b,h][1,6]naphthyridinecarboxamides. <i>Medicinal Chemistry Research</i> , 2021, 30, 133-141.	1.1	1
1544	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115890.	1.4	12

#	ARTICLE	IF	CITATIONS
1545	Integrated Analysis of an lncRNA-Associated ceRNA Network Reveals Potential Biomarkers for Hepatocellular Carcinoma. <i>Journal of Computational Biology</i> , 2021, 28, 330-344.	0.8	5
1546	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
1547	The role and therapeutic implications of PI3K signaling pathway in cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 39-41.	0.8	6
1548	Non-mitotic functions of polo-like kinases in cancer cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188467.	3.3	45
1549	Development of a practical synthesis to PI3K β -selective inhibitor GDC-0326. <i>Tetrahedron</i> , 2021, 79, 131840.	1.0	4
1550	Mutant Allele Imbalance in Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 221-234.	2.3	2
1551	DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E598-E608.	1.8	81
1552	Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113109.	2.6	8
1553	Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma. <i>Molecular Oncology</i> , 2021, 15, 987-1004.	2.1	15
1554	Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells. <i>Cytotechnology</i> , 2021, 73, 49-61.	0.7	13
1555	Quercetin induces autophagy in myelodysplastic bone marrow including hematopoietic stem/progenitor compartment. <i>Environmental Toxicology</i> , 2021, 36, 149-167.	2.1	8
1556	Landscape of clinically actionable mutations in breast cancer â€”A cohort studyâ€™. <i>Translational Oncology</i> , 2021, 14, 100877.	1.7	4
1557	Validated HPLCâ€”UV method for simultaneous quantification of phosphatidylinositol 3â€”kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats. <i>Biomedical Chromatography</i> , 2021, 35, e5015.	0.8	9
1558	Wikstromol from <i>Wikstroemia indica</i> induces apoptosis and suppresses migration of MDA-MB-231 cells via inhibiting PI3K/Akt pathway. <i>Journal of Natural Medicines</i> , 2021, 75, 178-185.	1.1	7
1559	Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 525-533.	0.4	4
1560	Cytotoxicity of oleanane type triterpene from leaf extract of <i>Pterospermum acerifolium</i> (in vitro) and theoretical investigation of inhibitory signaling pathway. <i>Chinese Herbal Medicines</i> , 2021, 13, 124-130.	1.2	3
1561	Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. , 2021, 4, 573-595.		17
1562	β -Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3 β /E-cadherin pathway. <i>Bioengineered</i> , 2021, 12, 5688-5704.	1.4	16

#	ARTICLE	IF	CITATIONS
1563	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. <i>Frontiers in Immunology</i> , 2020, 11, 595818.	2.2	13
1564	Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. <i>Medical Oncology</i> , 2021, 38, 10.	1.2	34
1565	Comparative hematopoiesis and signal transduction in model organisms. <i>Journal of Cellular Physiology</i> , 2021, 236, 5592-5619.	2.0	6
1566	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(âˆ-) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 277-287.	1.1	5
1567	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
1568	Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 691-703.	1.9	18
1569	Medicinal attributes of pyridine scaffold as anticancer targeting agents. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	34
1570	RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 120-138.	1.4	3
1571	Upregulation of phosphatidylinositol glycan anchor biosynthesis class C is associated with unfavorable survival prognosis in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 21, 237.	0.8	3
1572	Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-19.	0.0	0
1573	Common Motifs in KEGG Cancer Pathways. <i>Transactions on Computational Science and Computational Intelligence</i> , 2021, , 775-785.	0.3	0
1574	Characterization of Signalling Pathways That Link Apoptosis and Autophagy to Cell Death Induced by Estrone Analogues Which Reversibly Depolymerize Microtubules. <i>Molecules</i> , 2021, 26, 706.	1.7	5
1575	Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 32, 115997.	1.4	25
1576	Targeting SHIP1 and SHIP2 in Cancer. <i>Cancers</i> , 2021, 13, 890.	1.7	15
1577	Biological Role of AKT and Regulation of AKT Signaling Pathway by Thymoquinone: Perspectives in Cancer Therapeutics. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 288-301.	1.1	12
1578	ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells. <i>Cancer Cell International</i> , 2021, 21, 108.	1.8	10
1579	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451.	3.2	13
1580	Validated LC-MS/MS Method for Simultaneous Quantitation of Three PI3K Inhibitors, Copanlisib, Duvelisib and Idelalisib in Mouse Plasma: Application to a Pharmacokinetic Study in Mice. <i>Analytical Chemistry Letters</i> , 2021, 11, 140-152.	0.4	4

#	ARTICLE	IF	CITATIONS
1581	Posttranslational modifications as therapeutic targets for intestinal disorders. <i>Pharmacological Research</i> , 2021, 165, 105412.	3.1	11
1582	Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer. <i>Purinergic Signalling</i> , 2021, 17, 215-227.	1.1	28
1583	Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 1205.	1.7	25
1584	Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3K \pm). <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 716-724.	0.9	1
1585	Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. <i>Cancers</i> , 2021, 13, 1280.	1.7	14
1586	Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol. <i>Frontiers in Oncology</i> , 2021, 11, 617937.	1.3	25
1587	Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. <i>Npj Breast Cancer</i> , 2021, 7, 24.	2.3	5
1588	Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3K γ with marketed Idelalisib. <i>Chemical Biology and Drug Design</i> , 2021, 97, 1158-1169.	1.5	11
1589	Design, synthesis, anticancer activity, and in silico studies of novel imidazo[1,2-a]pyridine based 1,2,3-triazole derivatives. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 1311-1320.	1.4	12
1590	The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 595675.	1.3	4
1591	Construction of a microRNA-mRNA Regulatory Network in De Novo Cytogenetically Normal Acute Myeloid Leukemia Patients. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 199-210.	0.3	4
1592	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
1594	Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. <i>Targeted Oncology</i> , 2021, 16, 295-308.	1.7	14
1595	miR-486-5p: A Prognostic Biomarker for Chronic Myeloid Leukemia. <i>ACS Omega</i> , 2021, 6, 7711-7718.	1.6	14
1596	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 628690.	1.6	165
1597	How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 605-619.	1.1	23
1598	Cell signaling pathways as molecular targets to eliminate AML stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103277.	2.0	20
1599	HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU. <i>Bioscience Reports</i> , 2021, 41, .	1.1	7

#	ARTICLE	IF	CITATIONS
1600	Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 641937.	2.2	5
1601	FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. <i>Oncogene</i> , 2021, 40, 3072-3086.	2.6	18
1602	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <i>Medicinal Research Reviews</i> , 2022, 42, 112-155.	5.0	24
1603	Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103284.	2.0	12
1604	Progesterone Modulates Mitochondrial Functions in Human Glioblastoma Cells. <i>Molecular Neurobiology</i> , 2021, 58, 3805-3816.	1.9	3
1605	Insulin Signaling in Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 672519.	2.2	19
1606	Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells. <i>BMC Cancer</i> , 2021, 21, 433.	1.1	6
1607	Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 825-838.	0.9	15
1608	Purpurin, a anthraquinone induces ROS-mediated A549 lung cancer cell apoptosis via inhibition of PI3K/AKT and proliferation. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 1101-1108.	1.2	16
1609	The FGF-AKT pathway is necessary for cardiomyocyte survival for heart regeneration in zebrafish. <i>Developmental Biology</i> , 2021, 472, 30-37.	0.9	15
1610	New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation. <i>Acta Pharmaceutica</i> , 2021, 71, 545-565.	0.9	1
1611	mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme. <i>Molecular Biology Reports</i> , 2021, 48, 4813-4835.	1.0	15
1612	Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 877-892.	2.4	27
1613	Umbralisib, a Dual PI3K/CK1 μ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
1614	The Mechanisms of HBV-Induced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 435-450.	1.8	83
1615	Transcriptome analysis reveals possible antitumor mechanism of Chlorella exopolysaccharide. <i>Gene</i> , 2021, 779, 145494.	1.0	5
1616	Obesity and aging: Molecular mechanisms and therapeutic approaches. <i>Ageing Research Reviews</i> , 2021, 67, 101268.	5.0	68
1617	Computational study on subfamilies of piperidine derivatives: QSAR modelling, model external verification, the inter-subset similarity determination, and structure-based drug designing. <i>SAR and QSAR in Environmental Research</i> , 2021, 32, 433-462.	1.0	4

#	ARTICLE	IF	CITATIONS
1618	SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF- κ B and ERK Signaling. <i>Biomolecules and Therapeutics</i> , 2021, 29, 331-341.	1.1	5
1619	Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. <i>Pharmaceutics</i> , 2021, 13, 723.	2.0	63
1620	Comprehensive Analysis and Identification of Key Driver Genes for Distinguishing Between Esophageal Adenocarcinoma and Squamous Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 676156.	1.8	8
1621	KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway. <i>Cell Death and Disease</i> , 2021, 12, 556.	2.7	6
1622	Kinase Inhibitors as Underexplored Antiviral Agents. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 935-954.	2.9	30
1623	Current Evidence of the Role of the Myokine Irisin in Cancer. <i>Cancers</i> , 2021, 13, 2628.	1.7	16
1624	An updated patent review of Akt inhibitors (2016-present). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 837-849.	2.4	8
1625	Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic. <i>Phytomedicine Plus</i> , 2021, 1, 100027.	0.9	23
1626	Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies. <i>Biomarker Research</i> , 2021, 9, 34.	2.8	10
1627	Cell specific tumor suppressor effect of Hsa-miR-1226-3p through downregulation of HER2, PIK3R2, and AKT1 genes. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105965.	1.2	10
1628	Thidiazuron suppresses breast cancer via targeting miR-132 and dysregulation of the PI3K/Akt signaling pathway mediated by the miR-202-5p/PTEN axis. <i>Biochemistry and Cell Biology</i> , 2021, 99, 374-384.	0.9	8
1629	Current Understandings of Core Pathways for the Activation of Mammalian Primordial Follicles. <i>Cells</i> , 2021, 10, 1491.	1.8	20
1630	Natural-Derived Molecules as a Potential Adjuvant in Chemotherapy: Normal Cell Protectors and Cancer Cell Sensitizers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 836-850.	0.9	7
1631	Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. <i>Seminars in Cancer Biology</i> , 2022, 85, 69-94.	4.3	140
1633	Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway. <i>Hereditas</i> , 2021, 158, 18.	0.5	5
1634	Differential expression of mTOR related molecules in the placenta from gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR) and preeclampsia patients. <i>Reproductive Biology</i> , 2021, 21, 100503.	0.9	26
1635	Emerging Role and Clinicopathological Significance of AEG-1 in Different Cancer Types: A Concise Review. <i>Cells</i> , 2021, 10, 1497.	1.8	12
1636	Targeting Protein Kinases Degradation by PROTACs. <i>Frontiers in Chemistry</i> , 2021, 9, 679120.	1.8	28

#	ARTICLE	IF	CITATIONS
1637	Cardiac Safety of Kinase Inhibitors â€œ Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 639824.	1.1	4
1638	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. <i>Current Problems in Cancer</i> , 2022, 46, 100776.	1.0	7
1639	Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15.	0.5	7
1640	miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710337.	1.3	3
1641	A review of mechanisms of disease across PI3CA-related disorders with vascular manifestations. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 306.	1.2	62
1642	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3453.	1.7	6
1643	Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1641-1648.	1.2	9
1644	Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways. <i>Journal of Nutritional Biochemistry</i> , 2021, 93, 108634.	1.9	65
1645	Luteolin attenuates cognitive dysfunction induced by chronic cerebral hypoperfusion through the modulation of the PI3K/Akt pathway in rats. <i>Journal of Veterinary Research (Poland)</i> , 2021, 65, 341-349.	0.3	5
1646	Î²A3/A1-crystallin regulates apical polarity and EGFR endocytosis in retinal pigmented epithelial cells. <i>Communications Biology</i> , 2021, 4, 850.	2.0	13
1647	Possible Biochemical Processes Underlying the Positive Health Effects of Plant-Based Dietsâ€”A Narrative Review. <i>Nutrients</i> , 2021, 13, 2593.	1.7	13
1648	Overview of the molecular mechanisms of migration and invasion in glioblastoma multiforme. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 669-677.	0.6	2
1649	CCAT1/FABP5 promotes tumour progression through mediating fatty acid metabolism and stabilizing PI3K/AKT/mTOR signalling in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9199-9213.	1.6	28
1650	Pharmacological and cell-specific genetic PI3KÎ± inhibition worsens cardiac remodeling after myocardial infarction. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 157, 17-30.	0.9	9
1651	Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. <i>Pharmaceutics</i> , 2021, 13, 1195.	2.0	32
1652	Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse. <i>Leukemia and Lymphoma</i> , 2021, 62, 2690-2702.	0.6	2
1653	Interplay between p300 and HDAC1 regulate acetylation and stability of Api5 to regulate cell proliferation. <i>Scientific Reports</i> , 2021, 11, 16427.	1.6	6
1654	Mild chronic hypoxia-induced HIF-2Î± interacts with c-MYC through competition with HIF-1Î± to induce hepatocellular carcinoma cell proliferation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1151-1166.	2.1	9

#	ARTICLE	IF	CITATIONS
1655	Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3K β . ACS Chemical Biology, 2021, 16, 1644-1653.	1.6	2
1656	Inhibition of phosphatidylinositol 3-kinase (PI3K) enzyme and human skin carcinoma cell growth by Combretum apiculatum Sond.. South African Journal of Botany, 2021, 140, 95-102.	1.2	2
1657	Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase β . Journal of Medicinal Chemistry, 2021, 64, 12304-12321.	2.9	4
1658	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications, 2021, 12, 5053.	5.8	14
1659	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2021, 233, 272-284e13.	0.2	18
1660	Trigoxypin L Induces Apoptosis of Human Retinoblastoma Y79 Cells via PI3K/AKT/NF- κ B Pathway. International Journal of Pharmacology, 2021, 17, 420-427.	0.1	1
1661	Purple Sweet Potato Phytochemicals: Potential Chemo-preventive and Anticancer Activities. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 288-298.	0.1	1
1662	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. Frontiers in Oncology, 2021, 11, 697967.	1.3	11
1663	Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. Pharmaceutics, 2021, 13, 1509.	2.0	2
1664	Molecular Mechanism Exploration of Potent Fluorinated PI3K Inhibitors with a Triazine Scaffold: Unveiling the Unusual Synergistic Effect of Pyridine-to-Pyrimidine Ring Interconversion and CF ₃ Defluorination. Journal of Physical Chemistry B, 2021, 125, 10072-10084.	1.2	3
1665	Obesity and Inflammation: Colorectal Cancer Engines. Current Molecular Pharmacology, 2022, 15, 620-646.	0.7	14
1666	Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway. Scientific Reports, 2021, 11, 19268.	1.6	7
1667	Aberrant activation of the Hedgehog signalling pathway in squamous cell carcinoma of the vulva as a potential target for cancer therapy. Scientific Reports, 2021, 11, 17665.	1.6	1
1668	Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents. Frontiers in Pharmacology, 2021, 12, 738235.	1.6	13
1669	Shogaol potentiates sevoflurane mediated neuroprotection against ischemia/reperfusion-induced brain injury via regulating apoptotic proteins and PI3K/Akt/mTOR/s6K signalling and HIF-1 α /HO-1 expression. Saudi Journal of Biological Sciences, 2021, 28, 5002-5010.	1.8	9
1670	Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3K β -specific inhibitors for the treatment of hematologic malignancies. Bioorganic and Medicinal Chemistry, 2021, 45, 116312.	1.4	4
1671	Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 1416-1424.	0.6	7
1672	Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway. Science China Life Sciences, 2021, 64, 1814-1828.	2.3	6

#	ARTICLE	IF	CITATIONS
1673	Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 721-738.	2.7	11
1674	Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 48, 128271.	1.0	9
1675	Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 518, 82-93.	3.2	16
1676	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. <i>Frontiers in Pharmacology</i> , 2021, 12, 741697.	1.6	7
1677	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. <i>ESMO Open</i> , 2021, 6, 100230.	2.0	15
1678	Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3K $\hat{\kappa}$ inhibitor: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113661.	2.6	10
1679	A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1163, 122508.	1.2	11
1680	Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e304-e311.	0.3	3
1681	Bromamine T (BAT) Exerts Stronger Anti-Cancer Properties than Taurine (Tau). <i>Cancers</i> , 2021, 13, 182.	1.7	7
1682	C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors. <i>Current Cancer Drug Targets</i> , 2021, 21, 2-20.	0.8	15
1683	Occurrence of Morpholine in Central Nervous System Drug Discovery. <i>ACS Chemical Neuroscience</i> , 2021, 12, 378-390.	1.7	30
1684	Advancements in the preparation methods of artificial cell membranes with lipids. <i>Materials Chemistry Frontiers</i> , 2021, 5, 5233-5246.	3.2	18
1685	Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure. <i>Pathogens</i> , 2021, 10, 44.	1.2	11
1686	Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance. <i>Frontiers in Oral Health</i> , 2020, 1, 603160.	1.2	32
1687	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
1688	The PI3K Pathway in Colorectal Cancers. , 2013, , 157-199.		1
1689	Biology and Treatment of Basal-Like Breast Cancer. , 2013, , 91-109.		2
1690	HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. <i>Cancer Treatment and Research</i> , 2019, 177, 131-181.	0.2	6

#	ARTICLE	IF	CITATIONS
1691	Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 319-331.	0.8	54
1692	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. <i>Cancer Treatment and Research</i> , 2020, 180, 173-195.	0.2	48
1693	<i>Skin Neuroendocrine Neoplasms.</i> , 2021, , 335-356.		1
1694	PI3K Isoform-Selective Inhibitors in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1255, 165-173.	0.8	7
1695	New Emerging Molecules in Cancer Research Which Hold Promise in Current Era. , 2019, , 539-583.		1
1696	A multiscale biophysical model for the recruitment of actin nucleating proteins at the membrane interface. <i>Soft Matter</i> , 2020, 16, 4941-4954.	1.2	7
1697	Cardiovascular toxicity of PI3K inhibitors. <i>Clinical Science</i> , 2020, 134, 2595-2622.	1.8	11
1698	Cancer immune resistance: can theories converge?. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 411-419.	1.1	13
1699	NF- κ B signaling and crosstalk during carcinogenesis. <i>4open</i> , 2019, 2, 13.	0.1	16
1700	Brusatol reverses lipopolysaccharide-induced epithelial-mesenchymal transformation and induces apoptosis through PI3K/Akt/NF- κ B pathway in human gastric cancer SGC-7901 cells. <i>Anti-Cancer Drugs</i> , 2021, 32, 394-404.	0.7	12
1701	A PI3K inhibitor-induced growth inhibition of cancer cells is linked to MEK-ERK pathway. <i>Anti-Cancer Drugs</i> , 2021, 32, 517-525.	0.7	4
1702	Progesterone Induces NF- κ B DNA Binding Activity through a PI3K/Akt-Dependent Pathway in MCF-7 Breast Cancer Cells. <i>Cancer Research Journal</i> , 2014, 2, 63.	0.0	3
1703	Cell Migration Induced by Native Type IV Collagen Requires PI3K/Akt2 and EGFR Activity in MDA-MB-231 Breast Cancer Cells. <i>Cancer Research Journal</i> , 2015, 3, 52.	0.0	1
1704	PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. <i>Journal of Clinical Investigation</i> , 2010, 120, 2655-2658.	3.9	31
1705	Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. <i>Journal of Clinical Investigation</i> , 2011, 121, 1231-1241.	3.9	362
1706	Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. <i>Journal of Clinical Investigation</i> , 2013, 123, 5269-5283.	3.9	143
1707	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2551-2563.	3.9	108
1708	Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy. <i>Future Journal of Pharmaceutical Sciences</i> , 2020, 6, .	1.1	14

#	ARTICLE	IF	CITATIONS
1709	Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway. <i>Medical Science Monitor</i> , 2016, 22, 4644-4650.	0.5	26
1710	The Effects of Hesperidin on Neuronal Apoptosis and Cognitive Impairment in the Sevoflurane Anesthetized Rat are Mediated Through the PI3/Akt/PTE η and Nuclear Factor- κ B (NF- κ B) Signaling Pathways. <i>Medical Science Monitor</i> , 2020, 26, e920522.	0.5	10
1711	Recent advances in understanding and managing T-cell lymphoma. <i>F1000Research</i> , 2017, 6, 2123.	0.8	4
1712	NAVIGaTing the Micronome â€œ Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs. <i>PLoS ONE</i> , 2011, 6, e17429.	1.1	207
1713	Genomewide Analysis of Inherited Variation Associated with Phosphorylation of PI3K/AKT/mTOR Signaling Proteins. <i>PLoS ONE</i> , 2011, 6, e24873.	1.1	7
1714	The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer. <i>PLoS ONE</i> , 2011, 6, e25132.	1.1	117
1715	Extract of <i>Pleurotus pulmonarius</i> Suppresses Liver Cancer Development and Progression through Inhibition of VEGF-Induced PI3K/AKT Signaling Pathway. <i>PLoS ONE</i> , 2012, 7, e34406.	1.1	53
1716	FKBP5 as a Selection Biomarker for Gemcitabine and Akt Inhibitors in Treatment of Pancreatic Cancer. <i>PLoS ONE</i> , 2012, 7, e36252.	1.1	48
1717	Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection. <i>PLoS ONE</i> , 2012, 7, e46518.	1.1	42
1718	Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2013, 8, e80070.	1.1	59
1719	Epigenetic Inactivation of Inositol polyphosphate 4-phosphatase B (INPP4B), a Regulator of PI3K/AKT Signaling Pathway in EBV-Associated Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105163.	1.1	28
1720	Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206. <i>PLoS ONE</i> , 2014, 9, e109705.	1.1	45
1721	The Phosphoinositide 3-Kinase p110 α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. <i>PLoS ONE</i> , 2015, 10, e0123958.	1.1	24
1722	VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo. <i>PLoS ONE</i> , 2015, 10, e0132655.	1.1	15
1723	Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0136155.	1.1	39
1724	Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. <i>PLoS ONE</i> , 2016, 11, e0153155.	1.1	114
1725	Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells. <i>PLoS ONE</i> , 2016, 11, e0154745.	1.1	42
1726	PI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide. <i>PLoS ONE</i> , 2016, 11, e0160686.	1.1	43

#	ARTICLE	IF	CITATIONS
1727	Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study. <i>PLoS ONE</i> , 2016, 11, e0162133.	1.1	17
1728	PI3 Kinase in Cancer: From Biology to Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , e93-e98.	1.8	4
1729	Genomic Landscape of Squamous Cell Carcinoma of the Lung. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 348-353.	1.8	6
1730	New insights into 4E-BP1-regulated translation in cancer progression and metastasis. <i>Cancer Cell & Microenvironment</i> , 2014, 1, .	0.8	12
1731	Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells. <i>Advanced Pharmaceutical Bulletin</i> , 2019, 9, 470-480.	0.6	18
1732	The role of mTOR pathway as target for treatment in adrenocortical cancer. <i>Endocrine Connections</i> , 2019, 8, R144-R156.	0.8	12
1733	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R109-R130.	1.6	24
1734	Novel cancer therapies and their association with diabetes. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R187-R199.	1.1	20
1735	MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 β signaling impedes castration-resistant prostate cancer growth. <i>Aging</i> , 2019, 11, 10644-10663.	1.4	8
1736	Metabolomic profiling of dried blood spots reveals gender-specific discriminant models for the diagnosis of small cell lung cancer. <i>Aging</i> , 2020, 12, 978-995.	1.4	5
1737	Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection. <i>Oncoscience</i> , 2016, 3, 220-241.	0.9	34
1738	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , 2010, 1, 89-103.	0.8	227
1739	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. <i>Oncotarget</i> , 2013, 4, 1496-1506.	0.8	47
1740	Recent development of ATP-competitive small molecule phosphatidylinositol-3-kinase inhibitors as anticancer agents. <i>Oncotarget</i> , 2017, 8, 7181-7200.	0.8	40
1741	E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3K β silencing. <i>Oncotarget</i> , 2016, 7, 84054-84071.	0.8	10
1742	The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. <i>Oncotarget</i> , 2017, 8, 2083-2095.	0.8	16
1743	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. <i>Oncotarget</i> , 2017, 8, 7964-7976.	0.8	16
1744	Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 22203-22217.	0.8	81

#	ARTICLE	IF	CITATIONS
1745	Akt/mTOR mediated induction of bystander effect signaling in a nucleus independent manner in irradiated human lung adenocarcinoma epithelial cells. <i>Oncotarget</i> , 2017, 8, 18010-18020.	0.8	12
1746	Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. <i>Oncotarget</i> , 2017, 8, 55582-55592.	0.8	9
1747	EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 48820-48831.	0.8	72
1748	Erythropoietin drives breast cancer progression by activation of its receptor EPOR. <i>Oncotarget</i> , 2017, 8, 38251-38263.	0.8	24
1749	A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 3836-3848.	0.8	13
1750	EGFR-induced phosphorylation of type β^3 phosphatidylinositol phosphate kinase promotes pancreatic cancer progression. <i>Oncotarget</i> , 2017, 8, 42621-42637.	0.8	8
1751	FKBP51 decreases cell proliferation and increases progesterin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. <i>Oncotarget</i> , 2017, 8, 80405-80415.	0.8	8
1752	Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 3662-3672.	0.8	40
1753	Targeting FANCD2 for therapy sensitization. <i>Oncotarget</i> , 2014, 5, 3426-3427.	0.8	5
1754	Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway. <i>Oncotarget</i> , 2017, 8, 78530-78544.	0.8	17
1755	Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. <i>Oncotarget</i> , 2017, 8, 92926-92942.	0.8	6
1756	AKT regulates NPM dependent ARF localization and p53mut stability in tumors. <i>Oncotarget</i> , 2014, 5, 6142-6167.	0.8	30
1757	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , 2014, 5, 6788-6800.	0.8	32
1758	Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 112893-112906.	0.8	29
1759	HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy. <i>Oncotarget</i> , 2014, 5, 10180-10197.	0.8	5
1760	A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. <i>Oncotarget</i> , 2018, 9, 31709-31718.	0.8	32
1761	Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. <i>Oncotarget</i> , 2014, 5, 11576-11587.	0.8	67
1762	Combination of resveratrol and 5-fluorouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. <i>Oncotarget</i> , 2018, 9, 32943-32957.	0.8	59

#	ARTICLE	IF	CITATIONS
1763	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. <i>Oncotarget</i> , 2019, 10, 6526-6535.	0.8	15
1764	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011, 2, 510-517.	0.8	85
1765	Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors. <i>Oncotarget</i> , 2015, 6, 5134-5146.	0.8	30
1766	Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. <i>Oncotarget</i> , 2015, 6, 4051-4065.	0.8	26
1767	Evi1 forms a bridge between the epigenetic machinery and signaling pathways. <i>Oncotarget</i> , 2011, 2, 575-586.	0.8	32
1768	Novel oral histone deacetylase inhibitor, MPTOE028, displays potent growth-inhibitory activity against human B-cell lymphoma <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 4976-4991.	0.8	14
1769	The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. <i>Oncotarget</i> , 2015, 6, 11061-11073.	0.8	33
1770	PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. <i>Oncotarget</i> , 2015, 6, 14385-14398.	0.8	36
1771	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 35542-35555.	0.8	60
1772	miRNA interventions serve as "magic bullets"™ in the reversal of glioblastoma hallmarks. <i>Oncotarget</i> , 2015, 6, 38628-38642.	0.8	38
1773	DAB2IP in cancer. <i>Oncotarget</i> , 2016, 7, 3766-3776.	0.8	50
1774	Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion. <i>Oncotarget</i> , 2016, 7, 17854-17869.	0.8	47
1775	Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13153-13166.	0.8	66
1776	Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. <i>Oncotarget</i> , 2016, 7, 22128-22139.	0.8	21
1777	Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway. <i>Oncotarget</i> , 2017, 8, 10891-10904.	0.8	48
1778	CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. <i>Oncotarget</i> , 2016, 7, 27787-27801.	0.8	47
1779	Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. <i>Oncotarget</i> , 2016, 7, 29780-29793.	0.8	64
1780	IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma. <i>Oncotarget</i> , 2016, 7, 52900-52911.	0.8	34

#	ARTICLE	IF	CITATIONS
1781	High throughput chemical library screening identifies a novel p110- β inhibitor that potentiates the anti-myeloma effect of bortezomib. <i>Oncotarget</i> , 2016, 7, 38523-38538.	0.8	4
1782	The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. <i>Cancer Biology and Medicine</i> , 2019, 16, 688-699.	1.4	65
1783	Translational research in radiation-induced DNA damage signaling and repair. <i>Translational Cancer Research</i> , 2017, 6, S875-S891.	0.4	40
1784	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. <i>Journal of Experimental Pharmacology</i> , 2011, 3, 21.	1.5	4
1785	Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2014, 21, 3173-3187.	1.2	39
1786	Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using "In silico Pharmacology"™. <i>Current Protein and Peptide Science</i> , 2014, 15, 561-571.	0.7	19
1787	Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 2047-2059.	1.1	13
1788	Molecular Mechanisms of the Action of Myricetin in Cancer. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 123-133.	1.1	24
1789	Anticancer Agents Based on Vulnerable Components in a Signalling Pathway. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 886-907.	1.1	13
1790	Genetic Predisposition to Parkinson's Disease and Cancer. <i>Current Cancer Drug Targets</i> , 2014, 14, 310-321.	0.8	6
1791	New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2745-2766.	1.0	67
1792	The Use of Conformational Restriction in Medicinal Chemistry. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1712-1733.	1.0	26
1793	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2128-2142.	1.0	9
1794	Isoform-Selective PI3K Inhibitors for Various Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1074-1092.	1.0	20
1795	An Overview of Privileged Scaffold: Quinolines and Isoquinolines in Medicinal Chemistry as Anticancer Agents. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2599-2633.	1.0	28
1796	Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents. <i>Medicinal Chemistry</i> , 2019, 15, 417-429.	0.7	8
1797	Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1575-1581.	0.9	48
1798	Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1552-1564.	0.9	25

#	ARTICLE	IF	CITATIONS
1799	Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 263-276.	0.9	20
1800	New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2156-2176.	0.9	4
1801	Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 6185-6194.	0.5	17
1802	Association Between the PIK3CA Ile391Met Polymorphism and the Risk of Breast Cancer in an Iranian Population. <i>Journal of Applied Biotechnology Reports</i> , 2018, 5, 8-12.	0.9	2
1803	The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc&/i> analyses from the phase III MURANO study. <i>Haematologica</i> , 2022, 107, 134-142.	1.7	11
1804	N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents. <i>Molecules</i> , 2021, 26, 73.	1.7	11
1805	Embryonic liver fordin is involved in glucose glycolysis of hepatic stellate cell by regulating PI3K/Akt signaling. <i>World Journal of Gastroenterology</i> , 2016, 22, 8519.	1.4	13
1806	Inhibitory effect of oxymatrine on hepatocyte apoptosis <i>via</i> TLR4/PI3K/Akt/GSK-3 β signaling pathway. <i>World Journal of Gastroenterology</i> , 2017, 23, 3839.	1.4	25
1807	Large intestine embryogenesis: Molecular pathways and related disorders (Review). <i>International Journal of Molecular Medicine</i> , 2020, 46, 27-57.	1.8	11
1808	Simultaneous inhibition of atypical protein kinase ϵ and mTOR impedes bladder cancer cell progression. <i>International Journal of Oncology</i> , 2020, 56, 1373-1386.	1.4	8
1809	Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis. <i>Oncology Letters</i> , 2020, 19, 2963-2970.	0.8	8
1810	Molecular characteristics of uveal melanoma and intraocular tumors. <i>Oncology Letters</i> , 2021, 21, 9.	0.8	3
1811	PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells. <i>Oncology Reports</i> , 2020, 43, 773-782.	1.2	8
1812	Pneumonitis After Precision Oncology Therapies: A Concise Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 26-37.	0.6	5
1813	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane ϵ -Based Neoadjuvant Chemotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 689-696.	1.3	29
1814	Molecular predictive markers in tumors of the gastrointestinal tract. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 772.	0.8	6
1815	Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 248.	0.9	48
1816	Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer. <i>BMB Reports</i> , 2011, 44, 765-771.	1.1	15

#	ARTICLE	IF	CITATIONS
1817	The role of the microenvironment in tumor immune surveillance. <i>Bioinformatics</i> , 2011, 5, 285-290.	0.2	15
1818	PIK3CA and AKT Gene Polymorphisms in Susceptibility to Osteosarcoma in a Chinese Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5117-5122.	0.5	28
1819	The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6463-6475.	0.5	38
1820	Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2645-2651.	0.5	14
1821	Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1596-1596.	0.7	9
1822	RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. <i>Cell Reports</i> , 2021, 37, 109854.	2.9	17
1823	Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11088.	1.8	65
1824	The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?. <i>Frontiers in Oncology</i> , 2021, 11, 745187.	1.3	33
1825	The structural basis of PTEN regulation by multi-site phosphorylation. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 858-868.	3.6	20
1827	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. <i>Genes</i> , 2021, 12, 1593.	1.0	2
1829	Potential lncRNA Biomarkers for HBV-Related Hepatocellular Carcinoma Diagnosis Revealed by Analysis on Coexpression Network. <i>BioMed Research International</i> , 2021, 2021, 1-15.	0.9	8
1830	3D-QSAR and molecular docking studies of 4-methyl quinazoline derivatives as PI3K inhibitors. <i>Journal of the Indian Chemical Society</i> , 2021, 98, 100183.	1.3	3
1831	Phospho-PKCs in Abeta1-42-Specific Human T Cells from Alzheimer's Disease Patients. , 0, , .		0
1832	Polyomaviruses and Cancer. , 2012, , 337-375.		1
1835	Dynamic Simulations of Pathways Downstream of TGF β 2, Wnt and EGF-Family Growth Factors, in Colorectal Cancer, including Mutations and Treatments with Onco-Protein Inhibitors. <i>SIMAI Springer Series</i> , 2012, , 127-142.	0.4	0
1836	Phosphoinositide 3-Kinase. , 2012, , 1392-1400.		0
1837	Iris Nertschinskia Ethanol Extract Differentially Induces Cytotoxicity in Human Breast Cancer Cells Depending on AKT1/2 Activity. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 6511-6516.	0.5	4
1838	Neuregulin1 Improved Cardiac Function in Doxorubicin-Treated Mice with Cardiomyocyte-Specific over expression of a Dominant-Negative PI3Kp110 Δ . <i>Journal of Cardiovascular Diseases & Diagnosis</i> , 2013, 01, .	0.0	0

#	ARTICLE	IF	CITATIONS
1839	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
1840	Robustness Analysis of the PI3K/AKT Cell Signaling Module. Journal of Medical and Bioengineering, 2013, 2, 93-97.	0.5	3
1841	Emerging Targeted Agents for HER2-Positive Breast Cancer. , 2013, , 75-96.		0
1842	Molecular Pathology and Diagnostics of Gynecologic Malignancies. , 2014, , 365-395.		0
1843	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 81-114.		0
1844	Obesity research: Status quo and future outlooks. World Journal of Translational Medicine, 2014, 3, 119.	3.5	0
1846	Novel Targets for Future Medical Treatments. , 2015, , 145-162.		0
1847	Critical Roles of the AKT Substrate Girdin in Disease Initiation and Progression. , 2015, , 233-250.		0
1849	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.2	0
1850	Emerging targeted agents for HER2-positive breast cancer. , 2016, , 87-110.		0
1851	Small-Molecule Inhibitors in Glioblastoma: Key Pathways and Resistance Mechanisms. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 145-174.	0.1	0
1852	The Role of mTOR Inhibitors in Neuroendocrine Tumors. , 2016, , 93-112.		0
1853	Crosstalk Mechanisms Following Targeted Therapy in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2016, 59, 181.	0.0	0
1854	THE ROLE OF PHOSPHATIDYLINOSITOL-3-KINASE IN CARCINOGENESIS. Voprosy Onkologii, 2017, 63, 545-556.	0.1	1
1856	Rene policistico autosomico dominante: nuovi aspetti terapeutici. Giornale Di Clinica Nefrologica E Dialisi, 2010, 22, 59-64.	0.0	0
1857	Kinase Inhibitors in Large Cell Lymphoma. Technik Im Fokus, 2019, , 297-305.	0.2	0
1858	Biology of Pancreas and Possible Diseases. , 2019, , 1-25.		0
1862	CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK. Current Cancer Drug Targets, 2019, 19, 655-665.	0.8	6

#	ARTICLE	IF	CITATIONS
1864	Interaction of YAP1 and mTOR promotes bladder cancer progression. <i>International Journal of Oncology</i> , 2020, 56, 232-242.	1.4	12
1865	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
1866	Connecting Pathway Errors in the Insulin Signaling Cascade: The Molecular Link to Inflammation, Obesity, Cancer, and Alzheimer's Disease. <i>Engineering Materials</i> , 2020, , 223-258.	0.3	1
1867	Isolation and characterization of cytotoxic withanolides from the calyx of <i>Physalis alkekengi</i> L. var <i>franchetii</i> . <i>Bioorganic Chemistry</i> , 2020, 96, 103614.	2.0	13
1868	Ascofuranone inhibits epidermal growth factor-induced cell migration by blocking epithelial-mesenchymal transition in lung cancer cells. <i>European Journal of Pharmacology</i> , 2020, 880, 173199.	1.7	3
1869	Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 121-127.	0.6	1
1870	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5471.	1.7	18
1871	The role of PI3' lipid signalling in melanoma initiation, progression and maintenance. <i>Experimental Dermatology</i> , 2022, 31, 43-56.	1.4	7
1873	Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms. , 0, , .		0
1874	MicroRNA-128 Confers Anti-Endothelial Adhesion and Anti-Migration Properties to Counteract Highly Metastatic Cervical Cancer Cells' Migration in a Parallel-Plate Flow Chamber. <i>International Journal of Molecular Sciences</i> , 2021, 22, 215.	1.8	11
1875	Mechanistic insights into lysine-targeting covalent inhibition through a theoretical study of ester aminolysis. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 9996-10004.	1.5	1
1876	CBX2 Induces Glioma Cell Proliferation and Invasion Through the Akt/PI3K Pathway. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110458.	0.8	12
1877	Plantamajoside represses the growth and metastasis of malignant melanoma. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2296-2302.	0.8	10
1878	Modelling of Protein Complexes Involved in Signalling Pathway for Non-small Cell Lung Cancer. , 2020, , 3-28.		0
1879	The AKT antagonist AZD5363 suppresses features associated with cancer progression in human larynx cancer cells. <i>The European Research Journal</i> , 0, , .	0.1	0
1880	Barriers to achieving a cure in lymphoma. , 2021, 4, 965-983.		0
1881	Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. <i>Toxins</i> , 2021, 13, 785.	1.5	5
1882	The role of PIK3CA mutations in the development of breast cancer (a literature review). <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2020, .	0.0	0

#	ARTICLE	IF	CITATIONS
1884	Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application. <i>Current Organic Chemistry</i> , 2020, 24, 1555-1581.	0.9	2
1885	Current and Future molecular mechanism in Inflammation and Arthritis. <i>Journal of Pharmacopuncture</i> , 2020, 23, 54-61.	0.4	2
1886	Autophagy regulation in cancer development and therapy. <i>American Journal of Cancer Research</i> , 2011, 1, 362-372.	1.4	36
1887	Modeling follicular thyroid cancer for future therapies. <i>American Journal of Cancer Research</i> , 2012, 2, 130-40.	1.4	1
1888	A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 471-93.	0.0	18
1889	PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8295-303.	0.5	18
1890	Human activated macrophages and hypoxia: a comprehensive review of the literature. <i>Iranian Journal of Basic Medical Sciences</i> , 2014, 17, 820-30.	1.0	2
1891	Lipid Signaling in Tumorigenesis. <i>Molecular and Cellular Pharmacology</i> , 2014, 6, 1-9.	1.7	5
1892	p38 MAPK and PI3K/AKT Signalling Cascades in Parkinson's Disease. <i>International Journal of Molecular and Cellular Medicine</i> , 2015, 4, 67-86.	1.1	117
1893	Dihydropyridine kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 4356-66.	0.5	8
1894	The use of dynamic nuclear polarization (¹³ C)-pyruvate MRS in cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 548-60.	1.0	32
1898	Relationship Between PIK3CA Amplification and P110 α and CD34 Tissue Expression as Angiogenesis Markers in Iranian Women with Sporadic Breast Cancer. <i>Iranian Journal of Pathology</i> , 2018, 13, 447-453.	0.2	3
1899	mutations contribute to fulvestrant resistance in ER-positive breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6055-6065.	0.0	7
1901	Clinical Profile of Overgrowth Syndromes Consistent with PROS (-Related Overgrowth Syndromes)-A Case Series. <i>Indian Dermatology Online Journal</i> , 2020, 11, 738-746.	0.2	2
1902	Proteomics and its applications in breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 4006-4049.	1.4	0
1903	Identification of stage-specific differentially expressed genes and SNPs in gastric cancer employing RNA-Seq based transcriptome profiling. <i>Genomics</i> , 2022, 114, 61-71.	1.3	2
1904	Oncogenic KRAS: Signaling and Drug Resistance. <i>Cancers</i> , 2021, 13, 5599.	1.7	25
1905	Evodiamine Inhibits Gastric Cancer Cell Proliferation via PTEN-Mediated EGF/PI3K Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-15.	0.5	5

#	ARTICLE	IF	CITATIONS
1906	Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 6123-6133.	0.5	5
1907	The evaluation of PIK3CA gene variation and serum PI3K level in breast cancer risk and prognosis in Turkish population. <i>Biyokimya Dergisi</i> , 2021, .	0.1	1
1908	Modulating CRISPR/Cas9 genome-editing activity by small molecules. <i>Drug Discovery Today</i> , 2022, 27, 951-966.	3.2	12
1909	Clinical profile of overgrowth syndromes consistent with PROS (PIK3CA-related overgrowth) Tj ETQq1 1 0.784314 ggBT /Overlock 10 TF	0.2	5
1910	Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114055.	2.6	12
1911	Contradictory Effect of Notch1 and Notch2 on Phosphatase and Tensin Homolog and its Influence on Glioblastoma Angiogenesis. <i>Galen</i> , 0, 10, e2091.	0.6	0
1912	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 441-456.	1.0	3
1913	Exosome application in tumorigenesis: diagnosis and treatment of melanoma. <i>Medical Oncology</i> , 2022, 39, 19.	1.2	7
1915	Involvement of FoxO1, Sp1, and Nrf2 in Upregulation of Negative Regulator of ROS by 15d-PGJ2 Attenuates H2O2-Induced IL-6 Expression in Rat Brain Astrocytes. <i>Neurotoxicity Research</i> , 2022, 40, 154-172.	1.3	2
1916	A supramolecular host for phosphatidylglycerol (PG) lipids with antibacterial activity. <i>Organic and Biomolecular Chemistry</i> , 2021, , .	1.5	4
1917	Delineation of gastric tumors with activated ERK/MAPK signaling cascades for the development of targeted therapeutics. <i>Experimental Cell Research</i> , 2022, 410, 112956.	1.2	2
1918	AMPK increases expression of ATM through transcriptional factor Sp1 and induces radioresistance under severe hypoxia in glioblastoma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2022, 590, 82-88.	1.0	11
1919	Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation. <i>Genes</i> , 2022, 13, 219.	1.0	7
1920	Pathogenic signaling in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 27-40.	0.8	6
1921	Blocking PI3K p110 ^{Î²} Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 673-685.	1.5	6
1922	Mesenchyme homeobox 2 has a cancer-inhibiting function in breast carcinoma via affection of the PI3K/AKT/mTOR and ERK1/2 pathways. <i>Biochemical and Biophysical Research Communications</i> , 2022, 593, 20-27.	1.0	4
1923	Optochemical Control of mTOR Signaling and mTOR-Dependent Autophagy. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 149-155.	2.5	2
1924	Serum metabolic profiles and metal levels of patients with multiple sclerosis and patients with neuromyelitis optica spectrum disorders - NMR spectroscopy and ICP-MS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103672.	0.9	2

#	ARTICLE	IF	CITATIONS
1925	Minireview: Parabens Exposure and Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1873.	1.2	35
1926	Overview on Biological Activities of Thiazole Derivatives. <i>Materials Horizons</i> , 2022, , 101-134.	0.3	2
1927	Characterization, management, and risk factors of hyperglycemia during <sc>PI3K</sc> or <sc>AKT</sc> inhibitor treatment. <i>Cancer Medicine</i> , 2022, 11, 1796-1804.	1.3	8
1928	Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq [®] , Cancer Hotspot Panel v.2.0. <i>Biomedical Reports</i> , 2022, 16, 26.	0.9	5
1929	Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand. <i>Journal of Pathology and Translational Medicine</i> , 2022, , .	0.4	1
1930	Carboxyl-Functionalized Carbon Nanotubes Loaded with Cisplatin Promote the Inhibition of PI3K/Akt Pathway and Suppress the Migration of Breast Cancer Cells. <i>Pharmaceutics</i> , 2022, 14, 469.	2.0	8
1931	Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer. <i>Genes and Diseases</i> , 2022, 9, 868-888.	1.5	1
1932	2-Methoxy-1,4-naphthoquinone (MNQ) regulates cancer key genes of MAPK, PI3K, and NF- κ B pathways in Raji cells. <i>Genomics and Informatics</i> , 2022, 20, e7.	0.4	0
1933	Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC). <i>Cancers</i> , 2022, 14, 1753.	1.7	7
1934	Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2022, 22, 320.	1.1	3
1935	A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 825-831.	1.1	4
1936	A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/ β -Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response. <i>Current Oncology</i> , 2022, 29, 2326-2349.	0.9	6
1938	Viral α -specific cytotoxic T α cell responses in HLA α -sensitized kidney transplant patients maintained on everolimus and low α -dose tacrolimus. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	1
1939	PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. , 2022, 10, e003402.		21
1940	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β / γ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	3.2	11
1941	Advances in indole-containing alkaloids as potential anticancer agents by regulating autophagy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112827.	2.5	21
1942	MicroRNAs in Pancreatic Cancer and Chemoresistance. <i>Pancreas</i> , 2021, 50, 1334-1342.	0.5	1
1943	Imperatorin induces autophagy and G0/G1 phase arrest via PTEN-PI3K-AKT-mTOR/p21 signaling pathway in human osteosarcoma cells in vitro and in vivo. <i>Cancer Cell International</i> , 2021, 21, 689.	1.8	14

#	ARTICLE	IF	CITATIONS
1944	Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
1945	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. <i>Journal of Hematology and Oncology</i> , 2021, 14, 206.	6.9	24
1946	Smoothed (SMO) regulates insulin-like growth factor 1 receptor (IGF1R) levels and protein kinase B (AKT) localization and signaling. <i>Laboratory Investigation</i> , 2022, 102, 401-410.	1.7	6
1947	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1781-1804.	5.7	27
1948	Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. <i>Neuro-Oncology Advances</i> , 0, .	0.4	3
1949	Competition for shared downstream signaling molecules establishes indirect negative feedback between EGFR and EphA2. <i>Biophysical Journal</i> , 2022, 121, 1897-1908.	0.2	3
1950	The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4295.	1.8	5
1951	The science of Hirschsprung disease: What we know and where we are headed. <i>Seminars in Pediatric Surgery</i> , 2022, 31, 151157.	0.5	26
1952	Therapeutic approaches for the treatment of head and neck squamous cell carcinoma—An update on clinical trials. <i>Translational Oncology</i> , 2022, 21, 101426.	1.7	33
1959	Design, synthesis, and cytotoxic activities of isaindigotone derivatives as potential anti-gastric cancer agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1212-1226.	2.5	8
1960	Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210903.	0.8	5
1964	Cathepsin B: structure, function, tumorigenesis, and prognostic value in hepatocellular carcinoma. , 2022, , 341-350.		0
1965	Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. <i>Molecules</i> , 2022, 27, 2742.	1.7	3
1966	A spectrum of overgrowth syndromes associated with the π PIK3CA mutation. Literature review. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2022, 9, 29-44.	0.1	2
1967	ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 391-404.	0.3	4
1968	MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 147.	7.1	14
1969	Network Pharmacology-Based Prediction and Verification of Ginsenoside Rh2-Induced Apoptosis of A549 Cells via the PI3K/Akt Pathway. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	4
1970	Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury—A systematic review. <i>Phytomedicine</i> , 2022, 101, 154123.	2.3	15

#	ARTICLE	IF	CITATIONS
1971	The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer. Journal of Obstetrics, Gynecology and Cancer Research, 2022, 7, 258-271.	0.0	0
1973	Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway. International Journal of Biological Sciences, 2022, 18, 3714-3730.	2.6	10
1974	Akt inhibitors in cancer therapy. , 2022, , 239-260.		1
1975	Long non-coding RNA HOTAIR induces the PI3K/AKT/mTOR signaling pathway in breast cancer cells. Revista Da Associação Médica Brasileira, 2022, 68, 456-462.	0.3	6
1976	PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Molecular Cancer, 2022, 21, .	7.9	12
1977	Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3K γ Inhibitors for the Treatment of B-Cell Malignancies. Journal of Medicinal Chemistry, 2022, 65, 8011-8028.	2.9	7
1978	A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer. Molecules, 2022, 27, 3412.	1.7	7
1979	Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer. Molecules, 2022, 27, 3492.	1.7	10
1980	Design, Synthesis, and Biological Examination of <i>N</i> -Phenyl-6-fluoro-4-hydroxy-2-quinolone-3-carboxamides as Anticancer Agents. ChemistrySelect, 2022, 7, .		4
1981	Republication: Targeting PI3K γ Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours. Anticancer Research, 2022, 42, 3217-3230.	0.5	2
1982	Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone. International Journal of Molecular Sciences, 2022, 23, 6311.	1.8	3
1983	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. Oral Oncology, 2022, 131, 105939.	0.8	5
1985	NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model. Current Bioinformatics, 2022, 17, 835-847.	0.7	2
1986	Synthesis of dihydrofuran-3-one and 9,10-phenanthrenequinone hybrid molecules and biological evaluation against colon cancer cells as selective Akt kinase inhibitors. Molecular Diversity, 2023, 27, 845-855.	2.1	2
1987	Evaluation of doxorubicin in three-dimensional culture of breast cancer cells and the response in PI3K/AKT/PTEN signaling pathways: a pilot study. Women and Health, 0, , 1-9.	0.4	0
1988	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2022, 176, 103749.	2.0	37
1989	Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. Journal of Medicinal Chemistry, 2022, 65, 8144-8168.	2.9	7
1990	Alpelisib therapy: from theory to practice. Meditsinskiy Sovet, 2022, , 57-64.	0.1	0

#	ARTICLE	IF	CITATIONS
1991	A Review of Oral Lichen Planus and its Management with Herbal Treatment. <i>Pakistan Biomedical Journal</i> , 0, , 29-32.	0.0	0
1992	Discovering Tuberosin and Villosol as Potent and Selective Inhibitors of AKT1 for Therapeutic Targeting of Oral Squamous Cell Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 1083.	1.1	3
1994	The <sc>PI3K</sc>/<sc>AKT</sc> signalling pathway in inflammation, cell death and glial scar formation after traumatic spinal cord injury: Mechanisms and therapeutic opportunities. <i>Cell Proliferation</i> , 2022, 55, .	2.4	53
1995	Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. <i>Reproduction and Fertility</i> , 2022, 3, R147-R162.	0.6	14
1996	Carvacrol as a Prospective Regulator of Cancer Targets/Signalling Pathways. <i>Current Molecular Pharmacology</i> , 2023, 16, .	0.7	5
1997	Renoprotective Effect of <i>Pediococcus acidilactici</i> GKA4 on Cisplatin-Induced Acute Kidney Injury by Mitigating Inflammation and Oxidative Stress and Regulating the MAPK, AMPK/SIRT1/NF- κ B, and PI3K/AKT Pathways. <i>Nutrients</i> , 2022, 14, 2877.	1.7	10
1998	Evodiamine as the Active Compound of <i>Evodia fructus</i> to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF- κ B Signaling Pathway. <i>Disease Markers</i> , 2022, 2022, 1-20.	0.6	4
1999	LncRNA LINC00460 facilitates the proliferation and metastasis of renal cell carcinoma via PI3K/AKT signaling pathway. <i>Journal of Cancer</i> , 2022, 13, 2844-2854.	1.2	3
2000	Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3K γ Inhibitors: Part II—Benzimidazole Derivatives. <i>Pharmaceuticals</i> , 2022, 15, 927.	1.7	5
2001	The importance of natural chalcones in ischemic organ damage: Comprehensive and bioinformatic analysis review. <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	1
2002	Molecular mechanisms and physiological functions of autophagy in kidney diseases. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2003	AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	3
2004	The Effects of Deoxyelephantopin on the Akt/mTOR/P70S6K Signaling Pathway in MCF-7 Breast Carcinoma Cells <i>In Vitro</i> . <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 0, , 0976500X2211140.	0.2	0
2005	Novel Derivatives of 4,6-Dihydroxy-2-Quinolone-3-Carboxamides as Potential PI3K γ Inhibitors. <i>ChemistrySelect</i> , 2022, 7, .	0.7	3
2006	Resistance to prostate cancer treatments. <i>IUBMB Life</i> , 2023, 75, 390-410.	1.5	4
2007	IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
2008	Transcriptomic Profiling Analysis of Castration-Resistant Prostate Cancer Cell Lines Treated with Chronic Intermittent Hypoxia. <i>Cancers</i> , 2022, 14, 3959.	1.7	0
2009	Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 266-276.	1.5	14

#	ARTICLE	IF	CITATIONS
2011	The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway. <i>Toxicology and Applied Pharmacology</i> , 2022, 454, 116232.	1.3	0
2012	Pyridine ring as an important scaffold in anticancer drugs. , 2023, , 375-410.		1
2013	Structure elucidation, immunomodulatory activity, antitumor activity and its molecular mechanism of a novel polysaccharide from <i>Boletus reticulatus</i> Schaeff. <i>Food Science and Human Wellness</i> , 2023, 12, 647-661.	2.2	10
2014	Signaling pathways in metabolic dysregulation in solid tumors. , 2022, , 119-140.		0
2015	Role of Tyrosine Kinase Receptors in Growth Factor Mediated Signal Transduction, with Specific Reference to MAPK/Ras and p13k-Akt Containing Pathways in Oncogenesis: A Qualitative Database Review. <i>American Journal of Molecular Biology</i> , 2022, 12, 135-146.	0.1	0
2016	Bioanalysis of alpelisib using liquid chromatography-tandem mass spectrometry and application to pharmacokinetic study. <i>Journal of Analytical Science and Technology</i> , 2022, 13, .	1.0	2
2017	Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
2018	Molecular Mechanism of Tanshinone against Prostate Cancer. <i>Molecules</i> , 2022, 27, 5594.	1.7	5
2019	Cancer Metabolism and Ischemia-Reperfusion Injury: Two Sides of the Same Coin. <i>Journal of Clinical Medicine</i> , 2022, 11, 5096.	1.0	3
2020	Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10502.	1.8	16
2021	EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). <i>Future Oncology</i> , 2022, 18, 3481-3492.	1.1	8
2022	Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
2023	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, .	1.4	3
2024	A neural stem cell paradigm of pediatric hydrocephalus. <i>Cerebral Cortex</i> , 2023, 33, 4262-4279.	1.6	13
2025	The endoplasmic reticulum stress response in prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 708-726.	1.9	14
2026	Systemic explanation of <i>Glycyrrhiza glabra</i> 's analyzed compounds and anti-cancer mechanism based on network pharmacology in oral cancer. <i>Journal of Oral Biosciences</i> , 2022, 64, 452-460.	0.8	1
2027	In-silico molecular modelling, MM/GBSA binding free energy and molecular dynamics simulation study of novel pyrido fused imidazo[4,5-c]quinolines as potential anti-tumor agents. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	27
2028	Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 14237-14260.	2.9	7

#	ARTICLE	IF	CITATIONS
2029	Akt: a key transducer in cancer. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	21
2030	The orchestrated signaling by PI3K \pm and PTEN at the membrane interface. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5607-5621.	1.9	4
2031	The Cross-Talk between Epigenetic Gene Regulation and Signaling Pathways Regulates Cancer Pathogenesis. <i>Sub-Cellular Biochemistry</i> , 2022, , 427-472.	1.0	1
2032	Synthesis, Characterization, and Anticancer Activity of Novel Imidazo[1,2-a]pyridine Linked 1,2,3-Triazole Derivatives. <i>Russian Journal of General Chemistry</i> , 2022, 92, 1775-1784.	0.3	2
2033	Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach. <i>Molecular Diversity</i> , 0, , .	2.1	1
2034	Immune Pathway and Gene Database (IMPAGT) Revealed the Immune Dysregulation Dynamics and Overactivation of the PI3K/Akt Pathway in Tumor Buddings of Cervical Cancer. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5139-5152.	1.0	4
2035	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
2036	The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
2037	Computational Design of Phosphatidylinositol 3-Kinase Inhibitors. <i>Assay and Drug Development Technologies</i> , 2022, 20, 317-337.	0.6	6
2038	Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions. <i>Cancers</i> , 2022, 14, 5117.	1.7	1
2039	Prevalencia de la mutaci3n de PIK3CA en c3ncer de mama en la Argentina y su asociaci3n con variables cl3nico-patol3gicas. , 2022, 26, .		0
2040	Targeting Host Tyrosine Kinase Receptor EPHA2 Signaling Affects Uropathogen Infection in Human Bladder Epithelial Cells. <i>Pathogens</i> , 2022, 11, 1176.	1.2	2
2041	Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3K \pm selective inhibitors. <i>Bioorganic Chemistry</i> , 2023, 130, 106211.	2.0	6
2042	Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients. <i>Heliyon</i> , 2022, , e11396.	1.4	0
2043	Omics analyses of a somatic <i>Trp53^{R245W/+}</i> breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
2044	Dysregulation of gene expression of PTEN and AKT signaling pathway in patients of ovarian cancer: A pilot study. <i>Journal of King Saud University - Science</i> , 2023, 35, 102378.	1.6	2
2045	Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	31
2046	Exploring the macromolecules for secretory pathway in cancer disease. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 55-83.	1.0	5

#	ARTICLE	IF	CITATIONS
2047	Synthesis, Characterization, and Anticancer Activity of Novel Imidazo[1,2-a]pyridine Linked 1,2,3-Triazole Derivatives. Russian Journal of General Chemistry, 2022, 92, 2082-2091.	0.3	0
2048	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers, 2022, 14, 5520.	1.7	10
2049	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117.	1.8	7
2050	Circular RNAs in cholangiocarcinoma. Cancer Letters, 2023, 553, 215980.	3.2	11
2051	Onkodiabetol—gja III.. Orvosi Hetilap, 2022, 163, 1614-1628.	0.1	0
2052	Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19. Phytomedicine, 2023, 109, 154549.	2.3	5
2053	Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer and Prostatic Diseases, 2023, 26, 188-193.	2.0	2
2054	Systemic Therapy for Hereditary Breast Cancers. Hematology/Oncology Clinics of North America, 2023, 37, 203-224.	0.9	1
2055	Novel Targets and Therapies in T Cell Lymphoma. European Medical Journal Oncology, 0, , 79-90.	0.0	0
2056	Inhibition of GSK3 β Promotes Proliferation and Suppresses Apoptosis of Porcine Muscle Satellite Cells. Animals, 2022, 12, 3328.	1.0	1
2057	The Neuroprotective Potentiality of Flavonoids on Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 14835.	1.8	30
2058	The multifaced role and therapeutic regulation of autophagy in ovarian cancer. Clinical and Translational Oncology, 2023, 25, 1207-1217.	1.2	1
2059	The botanical drug PBI-05204, a supercritical CO ₂ extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. Frontiers in Pharmacology, 0, 13, .	1.6	0
2060	Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways. Molecules, 2022, 27, 8864.	1.7	18
2061	N1-Benzyl Tryptamine Pan-SHIP1/2 Inhibitors: Synthesis and Preliminary Biological Evaluation as Anti-Tumor Agents. Molecules, 2022, 27, 8451.	1.7	2
2062	Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Molecular Biomedicine, 2022, 3, .	1.7	29
2063	Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degradar of Mutant PI3K δ . Journal of Medicinal Chemistry, 2022, 65, 16589-16621.	2.9	23
2064	Regulation of Kinase Signaling Pathways by β 6-Integrins and Plectin in Prostate Cancer. Cancers, 2023, 15, 149.	1.7	3

#	ARTICLE	IF	CITATIONS
2065	Targeted therapy for head and neck cancer: signaling pathways and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
2066	Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	3
2067	Nutrition and Diet: A Double-Edged Sword in Development and Treatment of Brain Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 153-180.	0.8	0
2068	PI3K/“AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. <i>Biomolecules</i> , 2023, 13, 93.	1.8	16
2069	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18
2070	Triazole-fused pyrimidines in target-based anticancer drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115101.	2.6	13
2071	Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	0
2072	Inhibition of PI3 kinase isoform p110 α suppresses neuroblastoma growth and induces the reduction of Anaplastic Lymphoma Kinase. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	1
2073	Targeted Therapies in Gallbladder Cancer: Current Status and Future Perspectives. , 2023, , 291-316.		1
2074	Cancer: A Complex Problem Requiring Interdisciplinary Research. , 2023, , 1-45.		0
2075	Apoptosis, Autophagy, and Unfolded Protein Response and Cerebellar Development. <i>Contemporary Clinical Neuroscience</i> , 2023, , 221-253.	0.3	0
2076	Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. <i>Chinese Medicine</i> , 2023, 18, .	1.6	7
2077	Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
2079	Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2080	The spectrum of cell death in sarcoma. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114683.	2.5	0
2081	1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines. <i>Current Organic Chemistry</i> , 2023, 26, 2188-2202.	0.9	1
2082	Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations. <i>Journal of Personalized Medicine</i> , 2023, 13, 673.	1.1	3
2083	2-Aminobenzothiazoles in anticancer drug design and discovery. <i>Bioorganic Chemistry</i> , 2023, 135, 106477.	2.0	9

#	ARTICLE	IF	CITATIONS
2084	Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review. <i>Toxicology in Vitro</i> , 2023, 88, 105558.	1.1	0
2085	Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3K \hat{I} inhibitors for hematological cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 82, 129152.	1.0	3
2086	Unveiling New Druggable Pockets in Influenza Non-Structural Protein 1: NS1 \hat{I} Host Interactions as Antiviral Targets for Flu. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2977.	1.8	0
2087	Crebanine induces ROS-dependent apoptosis in human hepatocellular carcinoma cells via the AKT/FoxO3a signaling pathway. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
2088	Usnic acid as potential inhibitors of BCL2 and P13K protein through network pharmacology-based analysis, molecular docking and molecular dynamic simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13632-13645.	2.0	3
2089	mTOR pathway candidate genes and obesity interaction on breast cancer risk in black women from the Women \hat{I} s Circle of Health Study. <i>Cancer Causes and Control</i> , 2023, 34, 431-447.	0.8	2
2090	Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology. <i>Non-coding RNA</i> , 2023, 9, 16.	1.3	3
2091	GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4203.	1.8	1
2092	PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2093	Anticancer Potential of Compounds Bearing Thiazolidin-4-one Scaffold: Comprehensive Review. <i>Pharmacophore</i> , 2023, 14, 56-70.	0.2	3
2094	mTOR pathway candidate genes and physical activity interaction on breast cancer risk in black women from the women \hat{I} s circle of health study. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
2095	Monensin, an Antibiotic Isolated from <i>Streptomyces Cinnamomensis</i> , Regulates Human Neuroblastoma Cell Proliferation via the PI3K/AKT Signaling Pathway and Acts Synergistically with Rapamycin. <i>Antibiotics</i> , 2023, 12, 546.	1.5	3
2096	Fenugreek (<i>Trigonella foenum-graecum</i> L.) modulates energy metabolism and anti-inflammatory response in obesity via combinatorial analysis. <i>Natural Products Journal</i> , 2023, 13, .	0.1	0
2097	Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents. <i>Molecules</i> , 2023, 28, 2587.	1.7	6
2098	Role of Trichocytic Keratins in Anti \hat{I} Neuroinflammatory Effects After Spinal Cord Injury. <i>Advanced Functional Materials</i> , 2023, 33, .	7.8	6
2099	Potential Phytochemicals for Prevention of Familial Breast Cancer with BRCA Mutations. <i>Current Drug Targets</i> , 2023, 24, 521-531.	1.0	2
2100	Recent advances in the role of endogenous hydrogen sulphide in cancer cells. <i>Cell Proliferation</i> , 2023, 56, .	2.4	3
2101	An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6031.	1.8	1

#	ARTICLE	IF	CITATIONS
2102	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. <i>British Journal of Cancer</i> , 2023, 128, 2150-2162.	2.9	18
2103	HSP70 Family in Cancer: Signaling Mechanisms and Therapeutic Advances. <i>Biomolecules</i> , 2023, 13, 601.	1.8	8
2104	ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines. <i>Cells</i> , 2023, 12, 1056.	1.8	3
2105	Novel Sulfonamide-Triazine Hybrid Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents. <i>ACS Omega</i> , 2023, 8, 14247-14263.	1.6	8
2106	Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6945.	1.8	7
2107	Clustering analysis and prognostic model based on PI3K/AKT-related genes in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2120	Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways. <i>Metabolic Brain Disease</i> , 2023, 38, 1471-1499.	1.4	3
2154	Current trends and future prospects of molecular targeted therapy in head and neck squamous carcinoma. , 2023, , 165-182.		0
2155	An Update on Potential Molecular Biomarkers of Dietary Phytochemicals Targeting Lung Cancer Interception and Prevention. <i>Pharmaceutical Research</i> , 2023, 40, 2699-2714.	1.7	1
2170	CCL2-CCR2 Signaling Axis in Cancer. , 2023, , 241-270.		0
2173	The polypharmacology of natural products in drug discovery and development. <i>Annual Reports in Medicinal Chemistry</i> , 2023, , 55-100.	0.5	2
2193	The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia. <i>Annals of Hematology</i> , 0, , .	0.8	1
2195	Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors. <i>International Review of Cell and Molecular Biology</i> , 2024, , .	1.6	0